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1. INTRODUCTION  
1.1. The structure of the skin 
The skin is a multifunctional organ which protects the body from pathogens and 
components from the environment, including the protection against external physical, 
chemical, and biologic attacks, the control of thermoregulation and water homostasis 
of the body. It is continuous with mucous membranes and basically consists of the 
epidermis, dermis, and subcutaneous tissue which constitutes the three main layers 
of the skin1,2 (Figure 1). 
The epidermis, which is the outer layer of the skin, contains squamous and 
stratified epithelium and mainly consists of keratinocytes2. According to keratinocyte 
position and morphology, the epidermis can be divided into four layers including the 
cornified or horny cell layer (stratum corneum), the granular cell layer (stratum 
granulosum), the squamous cell layer (stratum spinosum), and the basal cell layer 
(stratum germinativum)2–4. The dermis as middle layer of the skin, is an integrated 
system of fibrous, filamentous, and connective tissues as well as nerve and vascular 
networks2,5. The outer zone, the papillary stratum is a thin layer below the epidermis 
and the basement membrane and is composed of epidermally derived macrophages, 
fibroblasts, and mast cells2,5. The inner zone of the dermis, the reticular stratum, is 
rich in elastic fibers and collagen2. The primary materials of the dermal matrix are 
collagens which are the stress-resistant component of the skin and considered as a 
fibrous family of proteins with genetically distinct types2. The major collagens of the 
dermis are type I, IV and VII collagens which can be found in the basement 
membrane zone (BMZ)2. Collagen type VII (COLVII) is the major structural 
component of anchoring fibrils produced by keratinocytes2,3. The dermis and 
epidermis interact with each other in shaping a dermal-epidermal junction (DEJ) 
which maintains the structure of both tissues2.  
The interface between the epidermis and dermis (DEJ) is characterized by mainly 
basal keratinocytes2,6. Basal cell plasma membrane, lamina lucida, lamina densa, 
and  the sub-lamina densa fibrous part are the most important component of the 
BMZ7. The basal cell plasma membrane is constituted of the keratinocyte and 
attachment molecules or hemidesmosomes7. The lamina lucida includes mainly 
laminin, whereas the lamina densa, as the central part of the basal membrane is 
composed of collagen IV8. Type VII collagen forms the anchoring fibrils of the fibrillar 
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zone which is a connection between the lamina densa and the anchoring plaques of 
the papillary dermis9,10. The DEJ provides the integrity of the skin by attaching the 
dermis to epidermis and also support the epidermis11. The basement membrane is 
connected to the underlying connective tissue and provides the stability of the skin 
structure. Therefore, in addition to the desmosomes as cell-cell junctions in the 
epidermis and also numerous fibers and hemidesmosomes anchoring fibrils as cell-
matrix contacts in the dermis, the basement membrane is an essential component for 
the integrity of the skin.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Schematic cross-section of the skin and panniculus (Ref.
12
, modified). The three 
main layers of the skin epidermis, dermis and hypodermis as well as hair follicles, glands, blood 
vessels and nerves in the dermal layer are shown. The basement membrane is located as a thin layer 
between the epidermis and dermis. 
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1.2. Autoimmune bullous diseases 
The immune system consists of specific organs, tissues, cells and molecules, 
which protect the body against pathogenic organisms or substances. This system is 
categorized into two major sections, the ‘innate’ immunity and the ‘adaptive’ 
immunity13. The innate immune system is a fast acting mechanism which includes, 
beside others, the complement pathway, antimicrobial peptides, and phagocytes. 
The main components of the innate immune system are anatomic, humoral 
(complement system), and cellular barriers (neutrophils, dendritic cells, 
macrophages, and etc.)13. The innate immune response is activated immediately 
after infection and controls rapidly the replication of the infecting pathogen. By 
contrast, the adaptive immune system is considered as a second line defense 
mechanism which secures host survival if invading pathogens succeed in escaping 
innate host defense. The term ‘adaptive’ refers to the ability of the system for shaping 
the response to adapt to the microbial challenge; it is also called ‘acquired’ or 
‘specific immunity’. This immune system consists of antibodies and lymphocytes, 
specifically attackting the invading pathogens and retains a “memory” of them for 
speeding up future responses. The adaptive system requires some time to develop 
its response and react slower than the innate system13. 
To protect the body effectively against disease, the immune system must 
recognize and respond to invading microbial pathogens (non-self). Furthermore, to 
avoid the unwanted reactions against to the healthy self components, the immune 
system must identify and ignore host structures, a phenomenon called ‘self-
tolerance’. Self tolerance is controlled by various immune tolerance mechanisms. 
However, genetic and enviromental factors can break self-tolerance which can result 
in autoimmunity and consequent autoimmune disease (AID)14. Several AIDs15 have 
been identified so far with systemic or local manifestations which can affect different 
regions of the body, including skin.  
Autoimmunity may be a concequence of a loss of central as well as peripheral 
tolerance. A loss of central tolerance can be due to an immune dysregulation in the 
thymus including abnormal negative selection in neonatal thymus, involving 
autoimmune regulator proteins, regulatory T cells, and antigen expression by 
medullar thymic epithelial cells. Loss of immune tolerance outside the thymus can be 
related to different immune dysregulations involving regulatory T cells, regulatory B 
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cells, memory T cells, MHC class II, antigen-presenting cells, and cytokines16,17. 
However, this type of tolerance disruption can develop only in genetically susceptible 
individuals18–21. 
Autoimmune bullous diseases (AIBDs) represent a rare and heterogeneous group 
of skin and mucous membrane disorders characterized by various diverging clinical 
manifestations with some overlapping features, and by their potential lethality22. 
AIBDs are believed to be aberrant immunological reactions to self-antigens which are 
related to pathogenic autoantibodies against different adhesion and structural 
molecules of the epidermis and dermal-epidermal BMZ23,24. The integrity of the 
epidermis is maintained by a strong cell adhesion between keratinocytes at the 
epidermal BMZ25–28. Desmosomes and hemidesmosomes are two major cell 
adhesion structures which are relevant for adhesion between keratinocytes as well 
as between the epidermis and dermis28. In the epidermal BMZ, many molecules 
located in the uppermost dermis are important for the integrity of the skin. While 
BP230 is found in the intracellular attachment plaques in hemidesmosomes, BP180 
is involved in the connection between keratinocytes and extracellular matrices at the 
epidermal BMZ28. Laminin, type IV collagen and COLVII are among the most 
important extracellular matrix (ECM) proteins within the BMZ28. Pathogenic genetic 
mutations within genes encoding those molecules lead to inherited skin blistering 
diseases, demonstrating their essential role in maintaining the normal structure of the 
skin27. 
Depending on the site of autoantibodies binding, AIBDs have been defined as 
pemphigus, pemphigoids, dermatitis herpetiformis, and epidermolysis bullosa 
acquisita (EBA)29–31. The presence of autoantibodies is associated with a loss of skin 
adhesion which is clinically characterized by the formation of blisters or erosions31. 
Patients with AIBDs have reactive autoantibodies to the skin adhesion and structural 
proteins, which induce separation between epidermal keratinocytes or at the BMZ32. 
Based on clinical, histopathological and immunological features, AIBDs are classified 
to those with loss of adhesion within the epidermis like pemphigus, and those with 
blister within or underneath the BMZ, such as pemphigoids and EBA which termed 
subepidermal AIBD29–31. This thesis focuses on two AIBDs, EBA and bullous 
pemphigoid (BP). 
  INTRODUCTION 5 
Autoantibodies are hallmarks of AIDs and are used as specific markers for 
disease diagnoses28. Although in many autoimmune disorders, especially in several 
rheumatic diseases, the relevant autoantigens are not clear, the pathogenic role of 
autoantibodies in most AIBDs has been clearly demonstrated in several disease 
models28,33,34. Furthermore, it has been shown in human disease as well as animal 
models that each AIBD results in blisters by a different pathway28. Therefore, 
different inflammatory processes are involved in the development of skin lesions in 
various subepidermal AIBDs28. 
Patients suffering from AIBDs are routinely treated with systemic corticosteroids 
alone or in combination with other immunosuppressive drugs which are effective 
therapeuticals28,35. However, treatment with these drugs is frequently associated with 
various serious side effects such as hypertension, systemic infections, osteoporosis, 
diabetes mellitus, obesity, etc. which are significantly associated with increased 
mortality of patients28,36,37. Therefore, more medical efforts are needed for more 
secure and effective therapeutic approaches for AIBDs. 
 
1.2.1. Bullous Pemphigoid 
1.2.1.1. Definition, prevalence, and symptoms 
Bullous Pemphigoid (BP), a chronic blistering skin eruption, was first described in 
1953 as a subepidermal bullous dermatosis seen in the elderly38. As the most 
common autoimmune subepidermal skin blistering disease39,40, BP is characterized 
immunohistologically by DEJ separation, infiltration of inflammatory cells in the upper 
dermis, and presence of autoantibodies against hemidesmosomal proteins BP180 
(also called BPAG2 or COLVII) and BP230 (BPAG1)39,41. These autoantibodies and 
complement components deposit along the BMZ and are pathogenic by triggering an 
inflammatory cascade that leads to tissue damage and subepidermal blister 
formation42–44. The DEJ separation is accompanied by an extensive inflammatory 
mononuclear and eosinophilic cellular infiltrate and destruction of ECM 
components45,46. BP patients suffer from the lesions that predominantly affect the 
inner parts of the limbs and the trunk, while mucous membranes, and face and neck 
regions are usually not affected47.  
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1.2.1.2. Autoantigens BP230 and BP180 in BP 
As aforementioned, patients suffering from BP display circulating autoantibodies 
targeting two major hemidesmosomal proteins BP230 and BP180 (COLVII). These 
proteins contain structural components of hemidesmosomes promoting the adhesion 
of basal keratinocytes cytoskeleton to the underlying BMZ and structures within the 
papillary dermis48 (Figure 2). Keratin intermediate filaments are connected to 
hemidesmosomal proteins such as α6β4 integrins and BP180. The intracellular 
fragments of these proteins are attached to the BP230 and plectin, two elements of 
hemidesmosomal plaque, and their extracellular domains extend into the BMZ48. 
BP230 contribute in the correlation of hemidesmosomes with keratin intermediate 
filaments and contains a central coil-coiled domain region flanked by two globular 
end domains41,48–50 (Figure 2A, B). By contrast, BP180 is a transmembrane 
glycoprotein with its amino-terminal located in the hemidesmosomal plaque and its 
carboxy-terminal projecting into the basal lamina48,51. The extracellular portion of 
BP180 is composed of 15 interrupted collagen domains separated by noncollagen 
sequences and form a collagen-like trimeric structure48,52,53. The largest 
noncollagenous NC16A domain of BP180 in the N-terminal region localizes within the 
lamina lucida under the hemidesmosome and the C-terminal part is conneted to the 
anchoring filaments at the interface between the lamina lucida and the lamina 
densa48,54,55 (Figure 2A). Although the extracellular region of NC16A domain is the 
immunodominant part in BP56, IgG antibodies against epitopes outside the NC16A 
domain are also elevated in most patients57–59. Reactivity of antibodies against the C-
terminal epitopes could be associated with mucosal involvement and severe skin 
disease, whereas the intracellular domain is targeted at an early clinical stage58,60,61. 
In addition to IgG reactivity, IgA and IgE anti-BP180 antibodies are present in serum 
samples of most patients62–65. Thus, transmembrane BP180 antigen is the target for 
pathogenic autoantibodies in BP48. 
 
1.2.1.3. Diagnosis and therapeutic approaches for the treatment of BP 
Beside a significant impact on the quality of life related to severity of the skin 
blisters and lesions, BP patients have a considerable increased mortality rate which 
could be between 20% and 40% in the first year37,66–68. Diagnosis of the disease is 
usually based on a combination of criteria, including positive immunopathological 
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findings and typical clinical features69,70. Direct immunofluorescence microscopy can 
be used for detecting IgG or complement component 3 (C3) deposition at the DEJ68. 
Serum antibodies against BP180 NC16A and BP230 are detectable with 
commercially enzyme linked immunosorbent assay (ELISA) systems68,71–74. 
Autoantibodies can be detected in serum samples from all patients by using different 
recombinant fragments of BP180 and BP23059,68. Subepidermal separation and 
inflammatory infiltration (lymphocytes, neutrophils, and eosinophils) are typical 
histopathological features of lesional biopsy68. Localized and mild form of the disease 
are mostly treated with topical corticosteroids alone while patients with moderate and 
wide spread disease receive topical corticosteroids or oral prednisolone at 0.5 mg 
per kg per day36,68. Other drugs such as azathioprine, chlorambucil, dapsone, 
methotrexate, mycophenolic acid, and tetracyclines can also have a therapeutical 
effects68. In resistant cases, high-dose intravenous immunoglobulin (IVIG), 
plasmapheresis, immunoadsorption, or rituximab can be combined68. 
 
 
 
 
 
 
 
 
 
 
Figure 2  Schematic structure of skin molecules and clinical features in BP (Ref.
48,68
, 
modified). (A) Schematic representation of the DEJ. Keratin filaments are connected to the 
hemidesmosomal plaque containing plectin and BP230 which BP230 interact with the cytoplasmatic 
domain of the transmembrane components BP180 and α6β4 integrin. The extracellular domains of 
these transmembrane structures link the basal cells to the underlying basement membrane by binding 
 
A B 
C 
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to laminins, which associates with COLVII, the major component of anchoring fibrils of the upper 
dermis. (B) Schematic organization of BP230 and BP180. BP230 is predicted to consist of a central 
coil-coiled region flanked by two globular end domains, while BP180 has a type II orientation with an 
extracellular COOH-terminal portion consisting of 15 interrupted collagen domains. The 16th 
noncollagenous domain localizes next to the cell membrane and harbors the major epitopes targeted 
by autoantibodies from BP patients. TM, transmembrane domain. (C) Clinical and immunopathological 
characteristics of BP. Tense blisters and erosions on back and right arm and eczematous lesions, 
erosions, and crusts on left arm and flank of patients with BP. 
 
1.2.2. Epidermolysis bullosa acquisita 
1.2.2.1. Definition, prevalence, and symptoms 
The term "epidermolysis bullosa acquisita" (EBA) was first described as a 
characteristic diagnosis of an acquired bullous disease with clinical manifestations 
similar to inherited epidermolysis bullosa dystrophica75. EBA is a rare disease, with 
an estimated prevalence of 0.2-0.5 new cases/million per year76–79. It is a chronic 
blistering disease of skin and mucous membranes characterized by subepidermal 
blisters and tissue-bound and circulating autoantibodies to the DEJ80. EBA is an 
organ-specific AID with generally well-characterized clinical, histo- and 
immunopathological features80,81. In general, IgG and complement deposition are 
located at the DEJ of EBA patient skin. According to the clinical presentation, EBA is 
a heterogenous disease and its clinical spectrum is still being defined81. However, 
two main categories have been distinguished that include the noninflammatory 
(classical or mechanobullous) and the inflammatory form79. The non-inflammatory 
form of EBA presents as a mechanobullous features with skin fragility, blisters, 
erosions, and milia formation79. Blisters, erosions, and scars occur over the back of 
the hands, knuckles, elbows, knees, sacral area, and toes81. The inflammatory form 
of EBA is marked by bullous eruption involving the trunk, extremities and skin folds 
usually accompanied by pruritus81. Skin fragility is not eminent in this form and 
scarring and milia formation are rare81. However, EBA patients may present an 
inflammatory phenotype which have overlap with non-inflammatory features82,83. 
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1.2.2.2. Autoantigens collagen type VII in EBA 
COLVII is the main constituent of anchoring fibrils at the DEJ9. It is an ECM 
protein and is one major target of autoantibodies in AIBDs29. COLVII consists of three 
identical α chains where each chain is composed of a central collagenous region of 
145 kDa, flanked by a 145 kDa (NC1) and 34 kDa (NC2) non-collagenous domain at 
the amino and carboxy-terminal84,85. Inherited or targeted disruptions in COLVII gene 
which result in subepidermal blisters indicate the essential role of this protein in 
maintaining cell-matrix adhesion in the skin86–89. Pathogenesis of EBA involves the 
production of autoantibodies directed against the 145-kDa non-collagenous amino-
terminal (NC-1) domain of COLVII, a major component of anchoring fibrils in the BMZ 
of skin and mucosa80. Antibodies bind most likely at the DEJ which induces a 
cascade of proinflammatory pathways including the activation of the complement 
system and Fc receptors90. Inflammatory cells such as neutrophils release different 
mediators including cytokines, proteases (Elastase, matrix metalloproteinase-9 
(MMP-9)), and reactive oxygen species (ROS) which could be responsible for 
amplification of local inflammation and finally tissue damage90 (Figure 3). 
 
1.2.2.3. Diagnosis and therapeutic approaches for the treatment of EBA 
EBA is generally diagnosed by clinical presentation and detection of circulating as 
well as tissue-bound antibodies directed against COLVII79. In unclear cases of 
disease, additional tests such analysis by transmission electron microscopy or 
antigen mapping could be performed79. Clinical presentation includes hematoxylin 
and eosin (H&E) staining and direct immunofluorescence microscopy of lesional 
skin79. IgG and/or IgA deposition at basement membrane could be observed in 
almost all EBA patient and is detectable in at least 93% of all cases79. Circulating 
anti-COLVII IgG can also be detected by different ELISA systems that provides 
additional information79,91–93. Detection of autoantibodies directed against COLVII can 
also be specifically performed by immunofluorescence microscopy93 or by Western 
blotting94.  
Concerning to the treatment of EBA, controlled clinical studies are missing due to 
the low prevalence of the disease. Thus, current recommendations for treatment are 
only based on the clinical expertise by clinicians specialized in AIBD79,95,96. Moreover, 
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the disease severity as well as clinical phenotype has to be considered for treatment 
of EBA79. Various therapeutic procedures have identified by increased understanding 
of EBA pathogenesis. The use of systemic corticosteroids is the most common 
pharmaceutical treatment of EBA patients97 which has also been approved in 
experimentally induced EBA98. Due to several side effects, different treatment 
procedures should be considered before systemic corticosteroid treatment is used79. 
Methotrexate99, azathioprine99, cyclosporine95,100–102 and colchicine103–109, IVIG110,111, 
rituximab112–114, dapsone103, and cyclophosphamide115 are several alternative drugs 
for EBA treatment with high efficacy. Currently, colchicine due to beneficial effects 
and fewer adverse events is highly recommended as first line treatment for EBA 
treatment79. 
 
 
 
 
 
 
 
 
 
 
Figure 3  Schematic figure of the pathological mechanisms in EBA (Ref.
90,116
, modified). The 
pathogenesis of EBA is characterized by three phases, loss of tolerance, production of autoantibodies, 
and tissue damage. Disruption of tolerance to structural proteins of the skin initiates the pathogenesis 
of EBA. In the next step, the interaction of T and B lymphocytes leads to the production of 
autoantibodies targeting COLVII in the skin. Finally, binding the autoantibodies to their targets activate 
an inflammatory cascade including activation of complement and recruitment of leucocytes. Activated 
neutrophils release toxic mediators as well as proteases which cause blister formation and tissue 
damage. 
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1.2.3. Experimental models of EBA and BP 
Animal models are essential tools to understand the causes and pathogenic 
mechanisms of diseases and are required to develop new treatments for AIDs. From 
a technical point of view, animal models are helpful instruments to study EBA and BP 
pathogenesis as they enable an identification of pathological processes including 
cellular and molecular pathways, disease-relevant genetic as well as environmental 
factors. Several experimental systems such as in vivo and ex vivo models are 
currently available to study the pathogenesis of EBA and BP. Antibody transfer 
models using rabbit or human IgGs against COLVII and type XVII collagen 
(COLXVII) have been established in mice for both diseases43,117–119. Moreover, both, 
autoimmune response against COLVII and the active subepidermal blistering disease 
can be reproduced by immunizing mice with autologous COLVII120. 
To reproduce the blistering phenotype, purified IgG antibodies against murine 
COLVII are injected repeatedly into mice90,117–119. Moreover, antibody transfer from 
EBA patients or from rabbits immunized against murine117 or human118 COLVII119  
results in a blister formation in mice. Several inbred mouse strains including 
C57BL/6, BALB/c, and nude mice as well as mice of the SKH-1 outbred stock are 
susceptible to blister development by the transfer of antibodies against COLVII90,117–
119. Total IgG (20 to 500 µg/g body weight/injection) induces blistering in mice 2-4 
days after the first administration which depends on their reactivity to the DEJ90. 
Disease severity increases during the observation period and a full disease 
phenotype is usually observed 5-6 days after the first administration90. The onset and 
severity of the disease are related to the dose of IgG injected and the levels of 
COLVII-specific antibodies in the serum of mice117. In mouse models of BP, 
administration of anti-murine BP180 IgG induces subepidermal blister formation with 
a correlation between severity of the disease and the levels of anti-BP180 antibodies 
in the serum of mice43,121. 
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1.3. Neutrophils in autoimmune skin diseases 
Neutrophil granulocytes (also called polymorphonuclear leukocytes or PMNs) are 
the most abundant type of leukocytes in humans and essential for the innate immune 
response against invading pathogens122. Neutrophils are able to kill microorganisms 
immediately without dependency on previous exposure to the pathogen13. These 
cells are highly motile and form a first line of defense against invaders123. Beside 
their protective function in clearing extracellular pathogens, neutrophils have to be 
considered also as tissue distructing cells124,125. In AIBDs, neutrophils can be 
considered as an important component of effector and regulatory pathways124. In the 
concept of effector function, they play a significant role as executors of tissue 
damage, e.g. by the release of serine proteases126. On the other hand, neutrophils 
are regulators in inflammation which communicate with other immune cells by cell-
cell contacts or secretion of mediators124.  
 
1.3.1. Neutrophils as executors of tissue damage 
Neutrophils are equipped with granules which contain toxic materials against 
pathogens, but also to promote damage in the host127. Four different granule 
compartments (primary/azurophilic, secondary/specific, tertiary/gelatinase granules, 
and secretory vesicles) are recognized in neutrophils and classified according to their 
content of antimicrobial enzymes and peptides, as well as specific membrane 
receptors127. Granule contents are released into the extracellular space or into the 
phagosome by a process termed neutrophil degranulation which results in 
degradation of the invading microbes or of ECM components128. Furthermore, 
neutrophils are an important source of toxic oxygen species under inflammatory 
conditions and cause endothelial dysfunction and tissue injury129. Neutrophil serine 
proteases are implicated in various non-infectious inflammatory mechanisms130. It 
has been shown that inhibition of these proteases could reduce neutrophil infiltration 
and neutrophil-mediated injury in different models of inflammation, such as collagen-
induced arthritis, endotoxin-induced acute lung injury, and ischaemia and reperfusion 
injury131–133. Although the destructive activity of these proteases has been in the main 
focus so far, it becomes more and more clear that these enzymes may have also an 
important regulatory role in the local inflammatory response130. For example, 
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extracellular neutrophil serine proteases are contributed in proteolytic modification of 
cytokines and chemokines and activation of specific cellular receptors130.  
Neutrophils are present in lesional skin in inflammatory EBA patients and BP 
patients as well as in experimentally EBA or BP diseased mice43,68,134,135. A direct 
relationship between disease severity and number of infiltrating neutrophils has been 
reported136. The depletion of neutrophils protects mice from developing disease in 
the antibody transfer model of EBA137, and, in addition, also from experimental BP136. 
A comparable effect was observed when recruitment of neutrophils from the 
circulation to the skin was prevented137,138. These findings indicate that neutrophils 
play an essential role in the effector phase of the pathogenesis. After recruitment of 
neutrophils into the skin, they are activated by the immobilized IC via FcγR leading to 
the generation of ROS and the release of granule constituents including elastase, all 
of which have been proven to be essential factors for autoantibody mediated tissue 
damage117,137,139. This tissue damage process depends strictly on the binding of 
autoantibodies to Fc-receptors140, indicating a pathogenic role of these receptors in 
neutrophil activation. By using a modified ex vivo model of EBA, it has been shown 
that neutrophils are not only necessary but also sufficient to cause the tissue 
damage141.  
Neutrophil elastase (NE) together with further serine proteinases, such as 
proteinase 3 and cathepsin G142 are encoded by highly homologous genes in human 
and mice. The neutrophil granule-associated serine protease genes are tightly 
regulated and expressed only during the promyelocytic stage of neutrophil 
maturation143 and proteins are stored in their mature active form in cytoplasmic 
azurophilic granules of naïve neutrophils144,145. Active NE is released upon activation 
of neutrophils. The term elastase originates from the ability of the enzyme to release 
soluble peptides from insoluble elastin, which was used as one of the first substrates 
to characterize the activities of an enzyme128. NE has a large substrate repertoire 
with the capacity to degrade most components of the ECM, including elastin, 
collagens and fibronectin146. This enzyme regulate the release of toll-like receptore 
(TLR)4-induced CXCL8147,148. NE could also be detected in the lesional skin in 
mouse models of BP. NE-deficient mice do not develop experimental BP despite 
normal IgG and C3 deposition could be found at the basal membrane zone149 and 
NE inhibitors blocked disease development in the animals. Reconstitution of NE-
deficient mice with intradermal injection of wild type neutrophils results in recovering 
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susceptibility to experimental BP149, indicating a significant role of neutrophils in 
disease pathogenesis. This protease has been detected in BP blister fluid and within 
lesional/perilesional skin sites on BP patients150. Moreover, an ex vivo model also 
suggest that elastase is essential for granulocyte-mediated proteolysis resulting in 
dermal-epidermal separation in EBA and BP patients’ skin139. 
Taken together, these data suggest neutrophils as the major effector cells 
executing the tissue damage mediated by pathogenic antibodies. Therefore, 
delineation of the molecular mechanisms how neutrophils cause tissue damage and 
visualization of NE in vivo will help to understand pathogenesis of the AIBDs such as 
EBA and provide a novel therapeutic avenue specifically targeting the terminal phase 
of the disease.  
Given an important role of NE in many neutrophil mediated diseases, monitoring 
the NE activity could be a helpful research tool. The NE proteolytic activity can be 
detected by semiquantitative assays like zymography using elastin as a 
substrate151,152. Enzyme activity detection is also possible by using fluorophore-
labelled elastin, in which solubilisation of elastin results in release of the fluorophore 
and subsequent increase in fluorescence intensity correlating with NE activity. 
Development of chromophoric and fluorescent NE substrates enables faster and 
quantitative measurements. Some substrates such as NMeOSuc-AAPV-pNA (4-
nitroanilide)153 and its fluorescent variant (4-methyl-7-coumarylamide)154 are used in 
research and diagnostic purposes to determine soluble NE activity which is efficiently 
hydrolysed by human NE. However, the short tetrapeptide substrate sequence does 
not extend into the Pʼ site of the enzyme active centre which negatively affects the 
substrate specificity. As a consequence, the substrate is also cleaved by proteinase 
3, but the the hydrolysis speed is much faster by human NE155. Due to a lower 
substrate specificity of the mouse variants of the enzymes, differential determination 
of both protease activities is difficult156. In order to increase the specificity of the NE 
substrates, some attempts were performed to screen potential substrate sequences 
which include Sʼ-Pʼ subsite interaction146,155. Such a substrate sequence has been 
identified in both mouse and human leukemogenic PML-RARα protein, which allows 
sensitive and specific detection of mouse and human NE157.  
However, all of the methods described so far are limited to the detection of 
protease activities in supernatants and provide no information about their role in 
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complex systems like living organism. To close this gap, much effort has been made 
to develop new imaging technique which enables the detection of biological 
processes in intact tissues or even living animals. Fluorescence imaging has become 
a powerful technique to visualize biology in its native physiological settings in a living 
subject158–161. Proteolytic degradation of peptides and detecting peptidase activity in 
living cells can be monitored by using peptides containing a foerster or fluorescence 
resonance energy transfer (FRET) fluorophore pair. FRET, a potent technique for 
studying molecular interactions inside living cells, is extensively used in biomedical 
and biological research, including cell biology, medical diagnostics, optical imaging 
and drug discovery. FRET is a physical phenomenon of energy transfer whereby 
energy created by fluorescence excitation of one molecule as a donor is transferred 
to an adjacent molecule as an acceptor162. This will be possible only when the 
donor/acceptor (D/A) fluorophore pair are close to each other (<100 Å) and in a 
favorable orientation. Due to such a short distance, the principle of energy transfer 
does not occur by emission of a photon that is captured by the acceptor fluorophore, 
but merely electromagnetic energy transfer as a consequence of dipole moments. 
The efficiency of FRET depends highly on distance and decays with distance, as 
formulated in Foerster’s law163. Because of its sensitivity to distance, which is 
comparable to the size of biomolecules or the distances of molecular interactions, 
FRET has become suitable for studying the dynamics and interactions of biological 
molecules, for the detection of conformational changes in a protein (when the 
distance between donor and acceptor changes) or protein degradation164,165 (when 
the donor and acceptor fluorophore are separated as a result of substrate cleavage), 
as well as for monitoring cellular events in vivo166–168. This event can be imaged by 
multiphoton microscopy which becomes a powerful technique for monitoring the 
cellular dynamics in tissues. 
Due to distance-dependent nature of FRET interaction, spatial separation of two 
fluorophores as a consequence of protease activity can be easily detected as this will 
result in increased emission from the donor fluorophore at the expense of emission 
from the acceptor fluorophore162 (Figure 4). This strategy has been used with 
peptides containing a fluorescein group as donor and a tetramethylrhodamine group 
as acceptor. The donor and the receptor are separated by six amino acids, in which 
energy transfer from donor to acceptor occurred with intact peptides but was lost 
when the peptides were separated as the result of degradation169. By using two 
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fluorophores and their stoichiometry in the reporter, a ratiometric read-out of FRET 
(D/A emission ratio) can be achieved by detection of donor fluorescence and 
sensitized emission of the acceptor, which is excited by receiving energy from the 
donor170,171. Since the cleavage of the reporters is irreversible, a dynamic read-out 
can not be identified by the protease reporters. However, due to amplification of the 
signal by functioning as a substrate, the sensitivity for detection of protease activity is 
sufficiently high. This is in contrast to activity-based probes, which act as a suicide 
inhibitor and react covalently with an enzyme, leading to an enzyme to reporter ratio 
of 1:1172. 
According to the detection of NE at the cell surface of activated neutrophils, direct 
detection and quantification of membrane-bound activity might help to investigate the 
role of NE in inflammation. In addition, spatial information of protease activity as well 
as information about a local accumulation of the signal can be achieved by using this 
approach.  
 
 
 
 
 
 
 
 
 
Figure 4 Principle of the FRET protease sensor (Ref.
165
, modified). Donor and acceptor 
fluorophore molecules are designed with spectral overlap on a peptide substrate sequence. Close 
proximity of the fluorophores results in FRET process and acceptor fluorescence will be emitted at the 
expense of donor fluorescence. Cleavage of the peptide backbone results in separation of donor and 
acceptor fluorophores, thereby preventing FRET and increased emission from the donor with loss of 
acceptor fluorescence. 
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1.3.2. The regulatory role of neutrophils  
Although the essential role of neutrophis in AIBDs as executors of tissue damage 
by releasing proteases and other toxic metabolites has clearly been shown, the 
regulatory role of neutrophils is less investigated. Since innate immunity is essential 
in host defence, molecules targeting innate immune mechanisms are effective in the 
most relevant autoinflammatory diseases173–175. In addition to the regulatory function 
of neutrophils facilitated by classical mediators such as cytokine regulation, 
chemokine production, activation of complement and adhesion molecules, and their 
respective receptors176,177, a novel group of molecules has been suggested as 
important proinflammatory factors of innate immunity. These molecules are 
summarized as "endokines", "alarmins", or damage-associated molecular patterns 
(DAMPs), as they are activated or released under cell stress conditions178. Myeloid 
related proteins (MRPs) are involved in general modes of functioning like regulation 
of the protein kinases179, antimicrobial activity180–183, and a regulatory role in 
inflammatory reactions184–187. Among these molecules, phagocytic MRPs, especially 
MRP-8 (S100A8) and MRP-14 (S100A9), are the most abundant proteins expressed 
by myeloid cells, which represent ~45% of neutrophil and ~1% of monocyte cytosolic 
proteins186,188–191. MRP-8/-14 proteins are two calcium-binding factors which belong 
to the S100 family and are characterized by two calcium binding EF-hand motifs 
connected by a central hinge region. The EF-hand contains a calcium binding loop 
flanked by α-helices resulting in a helix-loop-helix motif192. All S100 proteins have 
tendency to form homodimers, however, the preferred form for human MRP-8 and 
MRP-14 is the MRP-8/MRP-14 heterodimer under physiological conditions193,194, 
although in the mouse, there are some reports indicate that MRP-8 and MRP-14 may 
exist also as monomers195–197. Nevertheless, the function of human and mouse MRP-
14 proteins are considered homologous196–198.  
The MRP-8/-14 complex has several pro-inflammatory properties, such as the 
activation of monocytes199, the amplification of cytokine production200, and the 
regulation of migration of myeloid derived suppressor cells201. MRP-8/-14 complexes 
are also able to amplify inflammatory responses by induction of leukocyte trafficking, 
enhancing transendothelial migration and production of ROS through activation of 
NADPH oxidase202. They serve as a ligand for the receptor for advanced glycation 
end products (RAGE)203 as well as the lipopolysaccharide receptor complex 
consisting of TLR4, MD2 and CD14194,199,203,204 and thereby enhance inflammatory 
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responses in infection and autoimmunity199,205,206. MRP-8 is the active part of 
complex, which specifically binds to TLR4 initiating the recruitment of the adaptor 
protein myeloid differentiation primary response gene 88 (MyD88), activation of MAP 
kinases ERK1/2, p38, and protein kinase C (PKC)194,199,204 (Figure 5). MRP-8 and -14 
are assumed to be crucial determinants in the initiation and development of 
inflammatory processes, especially regarding their role in neutrophil recruitment and 
cellular activation.  
 
 
 
 
 
 
 
 
Figure 5 Targets and binding of MRP-8/-14 proteins. MRP-8/-14 promotes proinflammatory 
responses on various cell types (left panel) through a CD14-independent binding to TLR4 (right 
panel). As an amplificator of inflammatory processes, they may be involved in a number of chronic 
inflammatory diseases such as rheumatoid arthritis (RA), psoriasis, or systemic lupus erythematosus 
(SLE). 
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1.4. Hypothesis and aims of the study 
As provided by several lines of evidence, neutrophils have been identified as the 
most essential cells in the effector phase of AIBD. Although the involvement of many 
players such as complement factors, neutrophil proteases and ROS have been 
recognized in this scenario, the mechanisms how neutrophils regulate and execute 
the disease still remains unclear. According to my hypothesis, neutrophils contribute 
to the effector phase by two ways, indirectly by the secretion of MRP-8/-14 proteins 
leading to amplification and maintenance of the inflammatory loop as well as directly 
by the release of tissue-destructing elastase (Figure 6).  
MRP-8/-14 proteins are highly expressed in activated and circulating myeloid cells 
and are secreted upon stimulation207. Increased local and systemic protein 
expression has been correlated to various chronic inflammatory diseases190,205,207. 
However, the functional role of these proteins in chronic inflammation is still a matter 
of debate. While some studies have implicated a role for MRP-8/-14 in experimental 
inflammatory arthritis models205,208 and in human autoimmune-mediated diseases 
including RA190,205, other studies have failed to confirm these results209. Currently, no 
data exists on the expression and potential function of MRP-8/-14 in AIBD. Different 
to the latter proteins, the essential pathogenic function of neutrophil elastase in 
human and experimental AIBD has been well documented. However, until now the 
role of this enzyme in disease has been shown only indirectly, either by 
determination of protease activity in cell extracts and supernatants, by inhibitor 
studies, or by histological localization of the protein in the diseased tissue. 
Nonetheless, to understand the pathophysiological mode of action of neutrophil 
elastase in disease, a direct approach allowing their quantification and localization of 
the enzyme activity at its site of action in vitro and in vivo is required. By combined 
studies in humans as well in different models of AIBD, the following questions will be 
addressed: 
1. Are levels of MRP-8/-14 proteins elevated in human and experimental AIBD? 
2. Do MRP-8/-14 proteins contribute to the pathology of AIBD? 
3. Can MRP-8/-14 proteins affect elastase-mediated tissue damage? 
4. How can neutrophil elastase mediate tissue damage in presence of protecting 
proteases inhibitors? 
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5. At which site of inflammation is neutrophil activation and elastase activity 
observed in vivo? 
By answering these questions, I hope to identify novel therapeutical targets which 
could help to develop new strategies in the treatment of AIBD. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Hypothetical direct and indirect role of MRP-8/-14 in the amplification and 
chronification of inflammatory response in autoimmune skin disease EBA and BP. Neutrophils 
are activated by immune complex and complement factors release tissue-destructing elastase and 
MRP-8/-14. The latter proteins amplify the inflammatory cascade by activation of macrophages (MØ) 
or barrier cells which release further proinflammatory cytokines and chemokines leading to the 
recruitment and activation of additional neutrophils enhancing and maintaining the inflammatory 
response.  
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Antibodies 
 
Specificity Isotype Clone Conjugate Manufacture Application 
Donkey α-rabbit IgG IgG Polyclonal 
DyLight 
649 
Biolegend IHC 
Goat α mouse IgG IgG Polyclonal 
Alexa Fluor 
488 
Invitrogen IHC 
Goat α-mouse IgG IgG Polyclonal 
Alexa Fluor 
680 
Invitrogen IHC 
Goat α-rabbit IgG IgG Polyclonal 
Alexa Fluor 
488 
Invitrogen WB 
Goat α-rabbit IgG IgG Polyclonal IRDye800 Rockland WB 
Isotype mouse IgG1 IgG1, κ MOPC-21 - Biolegend IHC 
Isotype mouse IgG1 IgG1, κ DAK-GO1 APC Dako FACS 
Isotype mouse IgG1 IgG1, κ DAK-GO1 FITC Dako FACS 
Isotype mouse IgG2a IgG2a, κ DAK-GO5 PE Dako FACS 
Isotype mouse IgG2b IgG2b, κ DAK-GO9 FITC Dako FACS 
Isotype rabbit IgG IgG Polyclonal - 
University of 
Lübeck 
in vivo 
Isotype rabbit IgG IgG Polyclonal 
Alexa Fluor 
488 
University of 
Lübeck 
in vivo 
Isotype rat IgG2a IgG2a, κ RTK2758 - Biolegend IHC 
Isotype rat IgG2b, IgG2b, κ RTK4530 - Biolegend IHC 
Mouse α-human CD3 IgG1 UCHT1 APC Dako FACS 
Mouse α-human CD14 IgG2a, κ M5E2 PE 
BD 
Pharmingen 
FACS 
Mouse α-human CD16 IgG1, κ DJ130c FITC Dako FACS 
Mouse α-human MRP8/14 IgG1 27E10 - 
Acris 
Antibodies 
IHC, WB 
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Specificity (continued) Isotype Clone Conjugate Manufacture Application 
Mouse α-human MRP8/14 IgG1 27E10 - 
Acris 
Antibodies 
IHC, WB 
Rabbit α-mouse COL VII IgG Polyclonal - 
University of 
Lübeck 
 
in vivo 
Rabbit α-mouse COL VII IgG Polyclonal 
DyLight 
649 
University of 
Lübeck 
in vivo 
Rabbit α-mouse COL XVII IgG Polyclonal - 
University of 
Lübeck 
in vivo 
Rabbit α-mouse MRP8 IgG Polyclonal - 
University of 
Münster 
IHC, WB 
Rabbit α-mouse MRP8 IgG Polyclonal Cy3 
antibodies-
online 
IHC 
Rabbit α-mouse MRP8 IgG Polyclonal Cy5.5 
University of 
Münster 
IHC 
Rabbit α-mouse MRP14 IgG Polyclonal - 
University of 
Münster 
IHC, WB 
Rabbit α-mouse MRP14 IgG Polyclonal Cy3 
antibodies-
online 
IHC 
Rabbit α-mouse MRP14 IgG Polyclonal Cy5.5 
University of 
Münster 
IHC 
Rabbit α-rat ERK 1 IgG Polyclonal - Santa Cruz WB 
Rat α-mouse Ly-6G IgG2a, κ 1A8 PE-Cy7 
BD 
Pharmingen 
FACS 
Rat α-mouse Ly-6G/Ly-6C IgG2b NIMP-R14 - Santa Cruz IHC 
Rat α-mouse C3 IgG2a RMC11H9 - Cedarlane IHC 
APC: allophycocyanin; CD: cluster of differentiation; COL: Collagen; Cy: cyanine; ELISA: enzyme-linked 
immunosorbent assay; ERK: extracellular signal-regulated kinase; FACS: fluorescence-activated cell sorting; 
FITC: fluorescein isothiocyanate; IHC: immunohistochemistry; Ly: lymphocyte antigen; MRP: myeloid related 
protein; PE: phycoerythrin; WB: western blot  
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2.1.2. Reagents 
 
Chemicals/Reagents Manufacture 
Acetone Merck, Darmstadt, Germany 
Ammonium persulfate (APS) Serva, Heidelberg, Germany 
Aqua dest (Aqua ad iniectabilia)  B. Braun, Melsungen, Germany 
BOC-Ala-Pro-Nva-4-chloro-SBzl, substrate buffer Bachem, Bubendorlf, Switzerland 
Bovine serum albumin (BSA), low endotoxin  PAA Laboratories, Pasching, Austria 
Citric acid Merck, Darmstadt, Germany 
DABCO Roth, Karlsruhe, Germany 
Desoxynukleotide (dNTPs) Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Serva, Heidelberg, Germany 
Ellman´s Reagent (5,5´-dithiobis (2-nitrobenzoic 
acid)) 
Sigma-Aldrich, Steinheim, Germany 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt, Germany 
Fetal calf serum (FCS) PAN-Biotech, Aidenbach, Germany 
Fluoromount-G mounting buffer  SouthernBiotech, Birmingham, AL, USA 
Formaldehyd, 35 % Merck, Darmstadt, Germany 
Glycerol Sigma-Aldrich, Steinheim, Germany 
Glycin Biomol, Hamburg, Germany 
Granulocyte colony-stimulating factor (G-CSF) Peprotech, Hamburg, Germany 
Goat serum PAN-Biotech, Aidenbach, Germany 
Hank's Balanced Salt Solution (HBSS), 10x PAN-Biotech, Aidenbach, Germany 
Hydrogen peroxide Merck, Darmstadt, Germany 
Hydroxyethyl piperazine ethanesulfonic acid (HEPES) Merck, Darmstadt, Germany 
Ketamin, 10%  WDT, Garbsen, Germany 
Lipidated FRET-probe for neutrophil elastase (NEmo-2) Cell Biology and Biophysics Unit, EMBL, 
Heidelberg, Germany 
Low-range Amersham Rainbow Marker GE Healthcare Europe, Freiburg, 
Germany 
Luminol (5-amino-2,3-dihydro-1,4-phthalazindione) Sigma-Aldrich, Steinheim, Germany 
Magnesium chloride hydrate (MgCl2.6H2O) Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
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Chemicals/Reagents (continued) Manufacture 
Nonidet P-40 Sigma-Aldrich, Steinheim, Germany 
Ponceau S Sigma-Aldrich, Steinheim, Germany 
Pancoll human (density 1,077 g/mL)  PAN Biotech, Aidenbach, Germany 
Paraformaldehyde Sigma-Aldrich, Steinheim, Germany 
Paraplast Plus (Paraffin) Roth, Karlsruhe, Germany 
Plasmasteril Fresenius, Oberursel, Germany 
ProLong Gold antifade reagent with DAPI  Invitrogen, Eugene, OR, USA 
Tetramethylbenzidine, TMB Sigma-Aldrich, Steinheim, Germany 
Penicillin PAA Laboratories, Pasching, Austria 
Plasmasteril  Fresenius Kabi, Bad Homburg, 
Germany 
Recombinant mouse collagen VII University of Lübeck , Germany 
RNAlater RNA Stabilization Reagent Qiagen, Hilden, Germany 
Roti-ImmunoBlock Roth, Karlsruhe, Germany 
Roti
®
-Load 1 protein loading buffer, reducing  Roth, Karlsruhe, Germany 
Rotiphorese® Gel 30 Roth, Karlsruhe, Germany 
RPMI 1640, modified Biochrom, Berlin, Germany 
Sodium Chlorid (NaCl) Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) ICN Biomedicals, Meckenheim, 
Germany 
Sodium fluoride (NaF) Sigma-Aldrich, Steinheim, Germany 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Steinheim, Germany 
Sulfuric acid (H2SO4) Merck, Darmstadt, Germany 
Tetramethyl-ethylenediamine (TEMED) SERVA Electrophoresis, Heidelberg, 
Germany 
Triton X-100  Sigma-Aldrich, Steinheim, Germany 
Tris Roth, Karlsruhe, Germany 
Tween 20 Sigma-Aldrich, Steinheim, Germany 
Xylazin (RompunR), 2% Bayer, Leverkusen, Germany 
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2.1.3. Enzymes, inhibitors, stimuli  
 
Substance Manufacture 
A-1-Antitrypsin from human plasma Sigma-Aldrich, D-Steinheim, Germany 
Collagenase type IV 
Worthington Biochemical Cooperation, 
Lakewood, NJ, USA 
Complete Protease Inhibitor Cocktail Tablets Roche Diagnostics, D-Mannheim, Germany 
Elastase, Human Neutrophil Calbiochem, D-Darmstadt, Germany 
Murine collagen Type VII (mCOLVII) University of Lübeck , Germany 
 
 
2.1.4. Consumable materials  
 
Consumable material Manufacture 
15 mL- und 50 mL-Tubes Sarstedt, D-Numbrecht 
Embedding cassette (Histosette) Sanowa, D-Leiman (G. Kisker) 
Embedding medium, Tissue-Tek O.C.T.™ Compound Sakura Finetek, D-Staufen 
Embedding molds, Tissue-Tek Intermediate Cryomold  Sakura Finetek, D-Staufen 
Falcon cell strainer (70 micron) BD Falcon, Franklin Lakes, NJ, USA 
FEATHER® microtome blade A35 and C35 pfm medical, D- Koln 
Gel tubes, BD Microtainer SST™ Tubes BD, Franklin Lakes, NJ, USA 
Glass bottom culture dishes, No. 1.5 coverglass MatTek Corporation, Ashland, MA, USA 
Immobilon-P Membrane, PVDF, 0.45 µm Carl Roth, Karlsruhe, Germany 
LightCycler 480 Multiwell Plate Roche, Penzberg, Germany 
LightCycler 480 Multiwell Sealing Foil Roche, Penzberg, Germany 
Microlance sterile needles; 26G, 27G, 30G BD, Drogheda, Ireland 
µ-Slide VI 0.4 uncoated microscopy chamber Ibidi BioDiagnostics, Munich, Germany 
µ-Slide 8 well ibiTreat microscopy chamber Ibidi BioDiagnostics, Munich, Germany 
PAP PEN Kisker Biotech, Germany 
Polystyrene FACS tube with lid BD Falcon, Franklin Lakes, NJ, USA 
Plastipak sterile syringe (1 ml) BD, Madrid, Spain 
Thermo nunc ImmunoPlate for ELISA  Thermo Fisher Scientific; Denmark 
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2.1.5. Devices 
 
Device Manufacture 
Confocal microscope Leica (SP5) Leica, Wetzlar, Germany 
Electrophoresis power supply Consort, Turnhout, Belgium 
ELISA Reader Tecan Sunrise  Tecan, Crailsheim, Germany 
Fluorescent microscope Olympus IX81  Olympus, Hamburg, Germany 
Incubator, 37°C, with CO2 Thermo Scientific, Langenselbold, Germany 
Incubator, 37°C, without CO2 Thermo Scientific, Langenselbold, Germany 
Incubator, 65°C Memmert, Dschwabach, Germany 
LightCycler
®
 480 Real-Time PCR system Roche, Penzberg, Germany 
Light microscope  Zeiss, Gottingen, Germany 
Light microscope Olympus BX41 (Camera: 
Nikon DSRi1) 
Olympus, Hamburg, Germany 
LSR II Flow Cytometer BD Bioscience, NJ, USA 
Microcentrifuge with high speed Hettich, Tuttlingen, Germany 
Microm STP 120 Spin Tissue Processor Thermo Scientific, Langenselbold, Germany 
Microplate Luminometer LB 96V Berthold Technologies, Bad Wildbad, Germany 
NanoDrop spectrophotometer PeqLab, Erlangen, Germany 
Odyssey infrared imaging system  LICOR, Bad Homburg, Germany 
Paraffin-Microtome SM 2000R  Leica, Nussloch, Germany 
Protein gel electrophoresis system Bio-Rad, Munick, Germany 
SDS ABI 7900 system Applied Biosystems, Darmstadt, Germany 
Shandon Cytospin Cytocentrifuge Thermo Electron, Astmoor, Runcorn, Cheshire, UK 
Shaker Type 3015  GFL, Burgwedel, Germany 
Shaker Type KL2 Edmund Buhler, Hechingen, Germany 
Thermal Cycler MJ Mini  Bio-Rad, Munchen, Germany 
Tissue homogenizer and vessels IKA-Werke, Staufen, germany 
TriM Scope multi-photon microscope LaVision BioTec, Bielefeld, Germany 
Vacuum pump ME2 Vacuubrand, Wertheim, Germany 
Water bath Typ 12B Julabo, Seelbach, Germany 
xCELLigence system  Roche, Penzberg, Germany 
XLPlanN 25×1.05 WMP Objective Olympus, Hamburg, Germany 
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2.1.6. Primer sequences 
 
Primer Sequence Amplicon size (bp) 
B2M, forward 5- TTC TGG TGC TTG TCT CAC -3 
104 
B2M, reverse 5- CAG TAT GTT CGG CTT CCC ATT -3 
Mrp-8, forward 5- CCT TTG TCA GCT CCG TCT TC -3 
80 
Mrp-8, reverse 5- CAA GGC CTT CTC CAG TTC AG -3 
Mrp-14, forward 5- CAC CCT GAG CAA GAA GGA AT-3 
95 
Mrp-14, reverse 5- TGT CAT TTA TGA GGG CTT CAT T-3 
All primers were manufactured and supplied by Metabion international, Martinsried, Germany. 
 
2.1.7. Reagent kits 
 
 
2.1.8. Human blood and serum samples  
This study enrolled 30 consecutive patients (20 patients with BP and 10 patients 
with EBA) as well as 20 sex/age matched healthy control individuals who admitted to 
Department of Dermatology, Universitätsklinikum Schleswig-Holstein in Lübeck. 
Approval for these studies was obtained from the Institutional Review board at the 
University of Lübeck (Lübeck, Germany; Az. 12-202A) according to the Declaration of 
Helsinki. All volunteers gave written informed consent. 
 
 
 
Reagent Kit Manufacture 
GenElute™ Direct mRNA Miniprep Kit Sigma-Aldrich, MO, USA 
First Strand cDNA Synthesis Kit Thermo Fisher Scientific, MA, USA 
Light Cycler480 SYBR Green I Master Mix Roche, Mannheim, Germany 
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2.1.9. Mouse strains 
Mrp-14-deficient mice (Mrp-14-/-) and their C57BL/6 wild type controls were 
provided by Thomas Vogl, Department of Immunology, University of Münster 
(Germany). Mrp-14-/- mice were generated as described previously210 by targeted 
gene disruption which 760 bp of the genomic sequence containing exon 2 and the 
adjacent intron region was replaced with the pMC1-derived neomycin-poly(A) 
expression cassette. This mutation results in deletion of the initial start codon. Mrp-
14-/- mice are phenotypically normal and since MRP-8 and MRP-9 proteins form a 
hetrodimer, expression of both proteins are absent in mice lacking a functional Mrp-
14 gene. 
Lys-eGFP mice were provided by Dr. Mario Pieper from general animal facility of 
University of Lübeck (Germany). Lys-eGFP mice were generated as described 
previously211 by deleting a fragment containing the coding part of exon 1 (including 
the start codon) as well as parts of intron 1 and inserting EGFP-Lox-Tk-neo Lox 
cassette. This was achieved by knocking the enhanced green fluorescent protein 
(eGFP) gene into the murine lysozyme M (lys) locus and using a targeting vector, 
which contains a neomycin resistant (neo) gene flanked by LoxP sites and ‘‘splinked’’ 
ends, to increase the frequency of homologous recombination. As a result, a mouse 
line was generated in which eGFP was expressed specifically in the myelomonocytic 
lineage. 
Neutrophil elastase-deficient (NE-/-) mice were provided by Prof. Dr. Enno 
Schmidt from Department of Dermatology at University of Lübeck. NE-/- mice were 
generated as previously described212,213. Gene inactivation was achieved by deletion 
of restriction enzyme sites in exon one (ATG start codon disruption) and exon two 
(frameshift mutation upstream of catalytic active site). 
For each set of experiments, all animals (male and female) were selected at the 
age of 10-16 weeks and housed under specified pathogen free conditions during 
breeding and experiments. Average body weights of the mice were measured and all 
injections, immunizations and bleedings were performed on anaesthetized mice. All 
animal studies have been reviewed and approved by the Animal Research Ethics 
Board of the Ministry of Environment, Kiel, Germany. 
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2.2. Methods 
2.2.1. Induction of systemic antibody transfer model of EBA 
To induce experimental EBA, mice were immunized according to a slightly 
modified protocol published elswhere117. Rabbit IgG against murine COLVII were 
transferred into mice, which induced a subepidermal blistering disease closely 
reproducing clinical, histological and immunopathological features seen in patients 
with EBA. IgG from sera of sensitized New Zealand white rabbits with recombinant 
forms of the glutathione S-transferase (GST)-tagged NC1 domain of murine COLVII 
were purified by protein affinity chromatography using protein G and then steril 
filtrated. The mice were subcutaneously injected at intervals of 2 days (Figure 7). 
Mice were treated s.c. with 0.5 mg IgG/g body weight/injection on days 0, 2, 4, 6, 8, 
and 10. Mice in the control groups received identical antibody concentrations of 
untreated rabbits (irrelevant IgG). Each experiment consisted of four groups as 
follow: 
1. Mrp-14-/- mice  + irrelevant rabbit IgG (isotype) (4 mice) 
2. Mrp-14-/- mice  + amCOLVII (12 mice) 
3. Wild type mice  + irrelevant rabbit IgG (isotype) (4 mice) 
4. Wild type mice  + amCOLVII (10 mice) 
 
 
 
 
 
 
Figure 7 Protocol of the induction of experimental systemic EBA. EBA was induced in wild 
type (C57BL/6) as well as Mrp-14
-/-
 mice by transfer of rabbit IgG against mouse COLVII. Purified 
rabbit pathogenic IgG or normal rabbit control IgG was injected subcutaneously (systemic antibody 
transfer model of EBA). 
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A clinical examination of the animals under anesthesia (freshly prepared 2 µg/g 
body weight xylazine and 94 µg/g body weight ketamine) was performed on days 4, 
8, 12 and 16. Furthermore, on day 0 and 8, blood samples were collected by 
puncture of the tail vein (gel tubes; collected blood volume 25-50 µl). On day 16, the 
experiment was terminated and the animals were sacrificed by cervical dislocation 
under anesthesia. At this time point, blood (400-500 µl) was collected from the heart 
to determine the serum levels of MRP-8/-14 proteins. Moreover, skin samples from 
different regions of the body were collected for histological examination and for 
further analysis. The blood samples were first stored on ice and then centrifuged at 
13.000xg for 2 min to prepare serum. The serum was then aliquoted and stored at -
20°C.  
Termination criteria which resulted in removal of an animal from the experiment 
were defined as large and open skin infections, long-legged transition of animals, and 
more than 20% weight loss in all experimental groups. 
 
2.2.2. Induction of local antibody transfer model of BP 
The induction of a local experimental BP was carried out with a rabbit anti-
mCOLXVII antibody which was locally administrated into the ears of the mice. Rabbit 
anti-mouse COLXVII IgG from sera of sensitized rabbits with recombinant fragments 
of murine COLXVIIA (aa497-573 of murine COLXVII) tagged with a glutathione-S-
transferase (GST) were purified by protein affinity chromatography using protein G 
and then steril filtrated214. On day 0 of the experiment, mice were anesthetized 
(freshly prepared 2 µg xylazine and 94 µg ketamine per g body weight, respectively) 
and antibodies were intradermally injected into the base of one ear (Figure 8). As a 
control, the second ear was treated with IgG of non-immunized rabbit. Each injection 
volume was 40 µL (2 mg antibody). 
All subsequent steps were performed on anesthetized animals. On days 1 and 2, 
a clinical examination with regard to the percentage of infestation was performed at 
the ear skin of the animals and additionally documented by photographs. The 
assessment of the disease state was performed in comparison to the control ear 
treated with the irrelevant antibody. On day 0, 25-50 µl blood samples were taken by 
puncture of the tail vein. After an observation period of 48 hours (h), the experiment 
 MATERIALS AND METHODS 31 
was terminated and the animals were sacrificed by cervical dislocation. At this time 
point, a further blood sample was taken by puncture of the heart (400-500 µl 
collected blood volume) and the skin samples were collected for further histological 
analysis. The termination criteria refered to those described in section 2.2.1. Each 
experiment consisted of two groups as follow: 
1. Mrp-14-/- mice (16 mice) 
+ Irrelevant rabbit IgG (isotype, left ear) 
+ amCOL17 (right ear) 
2. Wild type mice (10 mice) 
  + Irrelevant rabbit IgG (isotype, left ear) 
  + amCOL17 (right ear) 
 
 
 
 
 
 
Figure 8 Protocol of the induction of experimental local BP. BP was induced in wild type 
(C57BL/6) as well as Mrp-14
-/-
 mice by transfer of rabbit IgG against mouse COLXVII. Purified rabbit 
pathogenic IgG or normal rabbit control IgG was injected intradermally into the ear (local antibody 
transfer model of BP). 
 
 
2.2.3. Quantification of clinical symptoms 
The clinical disease severity was determined using the scoring system described 
elsewhere117,215 . Briefly, the disease severity was expressed as percent of total body 
surface area. The affected skin was defined as the skin with alopecia, erosion, 
redness, or peeling of the epidermis (blistering). Then the percentage of the affected 
skin was determined in relation to the total surface in individual parts of body. To 
calculate the overall infestation of an animal, the individual parts of the body were 
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assigned to their percentage of the total size of the animal which then multiplied by 
the percentage of infestation of the body parts (= clinical severity). This value 
includes the size of each body regions and their relative percentage infestation in the 
calculation. In order to minimize subjective assessment of the errors, the group 
affiliation of the animals was blinded by a second person. Accordingly, the calculation 
of clinical severity is written as a formula as follows: 
Clinical severity = A ∗ 0.025 + B ∗ 0.025 + C ∗ 0.005 + D ∗ 0.005 + E ∗ 0.05 + F ∗ 0.09 
+ G ∗ 0.1 + H ∗ 0.4 + I ∗ 0.05 + J ∗ 0.05 + K ∗ 0.1 + L ∗ 0.1 
 
A to L indicate the percentage of infestation in the left ear (A), right ear (B) left eye 
(C), right eye (D), snout (E) head / neck (F), tail (G), hull (H), left front leg (I), right 
front leg (J), the left hind leg (K) and right hind leg (L). 
 
2.2.4. Histological methods 
For preparation histological samples, the skin tissue was shaved and freed from 
fatty tissue prior to embedding. H&E staining was performed by Department of 
Clinical and Experimental Pathology (Research Center Borstel). 
 
2.2.4.1. Paraffin tissue sections 
Tissues were embedded in paraffin according to established protocols216. 
Collected tissues were fixed immediately in 4% paraformaldehyde for 24 h at 4°C, 
then placed in embedding cassettes (Histosettes) in 4% formalin followed by 
automatic embedding in paraffin overnight using a tissue processor (Autotechnikon). 
Samples were dehydrated by a reducing series of alcohols (70%> 80%> 90%> 96%> 
3 x 100% ethanol for 1 h each), then transferred to xylol as intermedium (twice, 1 h 
each) and finally saturated with liquid paraffin (60°C) (twice for 2 h each). The final 
samples were casted at the casting station in Paraplast Plus and attached to paraffin 
blocks on the embedding cassettes. 
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Procedures for creating paraffin sections of 3 micron thickness were performed by 
using a microtome SM 2000R with A35-disposable blades. Paraffin blocks were 
cooled down on ice before cutting. After slicing, sections were straightened in a 20°C 
water bath and then transferred on microscope slides followed by smoothing in a 
45°C water bath before they were dried on a 37°C hot plate.  
 
2.2.4.2. Cryogenic tissue sections 
To prepare frozen sections, embedding molds were filled with O.C.T embedding 
compound and skin samples were then placed vertically without air bubbles. The 
embedded samples were frozen in liquid nitrogen and stored at -80°C216. The cryo-
blocks were cut on a frozen Cryo-Mikrotom CM 3000 with CM-C35 disposable blades 
in sections of 5 micron thickness and stored until use at -80°C. 
 
2.2.5. Immunohistochemical staining 
2.2.5.1. IgG and complement factor C3 deposition 
Immobilized IgG and complement factor C3 were simultaneously detected in 
tissue samples by immunofluorescence staining of frozen sections using a method 
described by Sitaru et al117 with slight modifications. Briefly, sections were thawed at 
room temperature (RT), dried, and blocked with 1x Roti-ImmunoBlock solution (1:10 
in phosphate buffered saline; PBS) to minimize nonspecific background staining for 
30 min at RT. Thereafter, the sections were placed in a humid chamber and 
incubated with rat anti-mouse C3 antibody (5 µg/ml) for 30 min at RT in the dark. 
After two washing steps with PBS on a shaker (10 min each, RT, dark), specimen 
were incubated with the secondary antibodies AlexaFluor488-conjugated goat anti-
rat IgG (10 µg/ml) and DyLight649-conjugated donkey anti-rabbit IgG (5 µg/ml) for 30 
min at RT in the dark. After washing, residual liquid was removed from the slides and 
ProLong Gold antifade reagent supplemented with 4',6-diamidino-2-phenylindole 
(DAPI) was added to the samples and specimen were mounted with coverslipes. The 
stained sections were stored before and after microscopic evaluation at -20°C. 
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2.2.5.2. Detection of neutrophils and MRP-8/-14 
Neutrophil Marker (NIMP-R14) was used for detection of neutrophils of mouse 
origin by immunofluorescence. For this purpose, frozen mouse skin cryosections 
were thawed at RT, dried, and fixed by ice-cold aceton for 10 min. The staining 
procedure was carried out as described in the section 2.2.5.1, except that rat anti-
mouse NIMP-R14 antibody (0.5 μg/ml) was used as a detecting antibody. 
Alternatively, MRP-8/-14 proteins were detected by Cy5.5-conjugated rabbit anti 
mouse MRP-8 or MRP-14 IgG (1.97 and 1.87 µg/ml, respectively). 
 
2.2.6. Molecular biological methods 
In this study, the gene expression levels of Mrp-8/-14 were confirmed by 
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). 
 
2.2.6.1. Isolation of mRNA from mouse skin samples 
After collecting the skin samples derived from diseased and healthy control mice, 
specimen were directly transferred to RNA Stabilization Reagent (RNAlater) and 
stored at 4°C. The mRNA isolation was performed by using the GenElute™ Direct 
mRNA Miniprep Kit according to the recommendations of the manufactures. For 
lyses and homogenization of tissues, lysis solution containing proteinase K (1 ml) 
was added to an appropriate tube and the skin samples were solubilized immediately 
until no visible pieces remain. Lysates were subsequently incubated at 65°C for 10 
min to inactivate nucleases and other proteins. To prepare mRNA for binding, 64 µl 
of the 5M NaCl solution was added to the respective skin tissue lysate. Oligo(dT) 
beads were mixed thoroughly and 25 µl of the beads solution was added to each 
lysate and thoroughly mixed. After hybridization of mRNA with the oligo(dT) beads for 
10 min at RT, complexes were pelleted by centrifuging for 5 min at maximum speed 
in a microfuge. The supernatants were carefully discarded. Afterwards, the pellets 
were resuspended in 350 µl of washing solution. Suspensions were transfered into a 
GenElute spin filter-collection tube assembly and samples were spun for 1-2 min at 
maximum speed in a microfuge. Flowthroughs were discarded and washing was 
repeated two times with 350 µl of low salt wash solution. For elution, spin filters were 
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transfered into fresh collection tubes and 50 µl of preheated elution solution (65°C) 
were pipetted onto the spin filters. Tubes were incubated for 2-5 min at 65°C and 
spun for 1-2 min. The flow-throughs containing of the purified mRNA were collected 
and residual mRNA was removed from the beads by a repeated elution step. RNA 
samples were stored at -80°C. 
 
2.2.6.2. Measurement of RNA quantity 
DNA, RNA, and protein concentrations were determined by the NanoDrop 
spectrophotometer. Nuclease-free water was used for cleaning before and after 
measurements and the initialization of the device and the device software. For the 
calibration function of the zero point and also verification, the elution buffer from the 
GenElute™ Direct mRNA Miniprep Kit was used. Respective mRNA eluates were 
combined and concentrations and quality of mRNA were spectrophotometrically 
estimated by measuring absorbance at 260 and 280 nm. 
 
2.2.6.3. cDNA synthesis from isolated mRNA 
The cDNA synthesis was performed by using First Strand cDNA Synthesis Kit as 
recommended by the manufactures. All components of the kit and mRNA samples 
were kept on ice. Poly(A)+ mRNA (10 ng), Oligo(dT)18 Primer (1 µl/sample), and 
DEPC-treated water (to 11 µl) were added into a sterile, nuclease-free tube on ice in 
the indicated order. Tubes were mixed gently, centrifuged briefly and incubated at 
65°C for 5 min. After cooling down on ice, 5X Reaction Buffer (4 µl), RiboLock RNase 
Inhibitor (20 u/µl; 1 µl), 10 mM dNTP Mix (2 µl), and M-MuLV Reverse Transcriptase 
(20 u/µl; 2 µl) were added into each tube in the indicated order. Tubes were then 
incubated for 60 min at 37°C and the reaction was terminated by heating at 70°C for 
5 min. Reversed transcribed cDNA samples were stored at -20°C. 
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2.2.6.4. Analysis of MRP-8/-14 gene expression by Real time RT-PCR  
Quantitative RT-PCR was performed by using the Light cycler® 480 SYBR Green 
I Master Kit according to recommendation of the manufactures. These analyses were 
performed as previously described217 with some modifications using mouse-specific 
primer pairs (2.1.6). All reagents were kept on ice. PCR-grade water (2 µl/sample), 
SYBR Mix (2×5 µl/sample), and Primer Mix (10 µM; 1 µl/sample) were added into a 
sterile, nuclease-free tube on ice in the indicated order and mixed carefully. Then, 
PCR-Mix (8 µl) was added into each well of the LightCycler® 480 Multiwell Plate and 
the cDNA template (2 µl) was added to each target gene well. Standard cDNA was 
diluted 1:1, 1:10, 1:100; 1:103, 1:104 and added into the plate. The Multiwell plate 
was sealed, centrifuged at 1500 × g for 5 s, and transfered into the plate holder of the 
LightCycler 480 Real-Time PCR system. LightCycler experimental protocol was 
setup as follows: denaturation program at 95°C for 10 min, amplification program for 
45 cycles at 95°C for 10 s, 64°C for 5 s, and 72°C for 10 s, and melting curve 
program at 95°C for 10 s and at 65°C for 10 s. Data were analyzed using the 
comparative cycle threshold (Ct) and target gene Ct values were normalized to the 
corresponding Ct values of a houskeeping gene (B2M). 
 
2.2.7. Protein separation and analysis 
2.2.7.1. ELISA analysis 
MRP-8 and MRP-14 concentrations were determined in serum samples of 
patients and mice by ELISA. Murine blood samples were collected by Microtainer Gel 
Tubes and allowed to clot for a minimum of 30 min. Samples were centrifuged for 90 
s at 13.000 g. Sera from human (section 2.1.8) and mice were analyzed by Dr. 
Thomas Vogl, Department of Immunology, University of Münster (Germany) by 
ELISA as described199,218.  
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2.2.7.2. SDS-PAGE  
In sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) 
proteins are separated according to their polypeptide length which allows estimating 
their molecular weight. Proteins were separated on a discontinuous gel system 
consisting of stacking and separating gel using a method of Laemmli219 with 
modification. The stacking gel contains a lower pH (pH 6.8) and a lower acrylamide 
concentration (5%) as compared to the running gel (15%, pH 8.8), allowing the 
proteins to be concentrated into a tight band in a lane before entering the running gel. 
After polymerization, gels were mounted in a Mini-protean II apparatus and equal 
amounts of protein extracts (10 µg) as well as low molecular weight protein marker 
were subjected in protein loading buffer (Roti-Load 6x, reducing) to the lanes. Gels 
were run in electrophoresis buffer (25 mM Tris, 200 mM Glycin, and 3.5 mM SDS) for 
30 min (30 V, 35 mA, 15 W) and 1.5 h (400 V, 35 mA, 15 W) using a Consort 
electrophoresis power supply. 
 
 
SDS polyacrylamide gels Stacking Gel (5%) Running Gel (15%) 
Tris-Base (125 mM, pH = 6.8) 1.9 ml 9.4 ml 
Rotiphorese Gel 30 (30%) 2.5 ml 12.5 ml 
Distilled water (Milli Q) 10.1 ml 2.2 ml 
SDS (0.1%) 150 µl 250 µl 
Ammonium persulfate (APS, 10%) 100 µl 150 µl 
TEMED (0.2%) 30 µl 12.5 µl 
SDS: sodium dodecyl sulfate; TEMED: tetramethyl-ethylenediamine 
 
 
2.2.7.3. Western blot and immunodetection 
Following electrophoretic separation, proteins were transferred to a PVDF 
membrane by electroblotting (1.5 h, 100 V, 250 mA, 15 W) in blotting buffer (25 mM 
Tris, 150 mM Glycin, and methanol 100% (20% v/v)) for 30 min. After transfer, 
membranes were incubated in blocking buffer (1:10 Roti-ImmunoBlock in MilliQ; pH 
7.4) and washed 4×5 min in rinsing buffer (PBS-Tween 20; pH 7.4). Membranes 
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were incubated for 1h with the primary antibodies rabbit anti mouse MRP-8 (2 μg/ml), 
rabbit anti mouse MRP-14 (1.9 μg/ml), or rabbit anti-rat ERK 1 (0.4 μg/ml), 
respectively, all dissolved in blocking buffer. After repeated washing, membranes 
were incubated with IRDye800-conjugated goat anti-rabbit IgG (0.2 μg/ml) and finally 
washed 4×5 min in rinsing buffer. Protein bands were visualiyzed by scanning with 
an Odyssey infrared imaging system and and relative density of protein bands was 
analyzed using Odyssey software 1.2. 
 
 
2.2.8. Cell culture, isolation, and activation 
2.2.8.1. Jurkat T cell culture 
Jurkat cells are lymphoid cells derived from an acute T-cell leukemia which do not 
express NE220. These cells were grown in RPMI 1640 medium supplemented with 
10% FCS and maintained at 37°C with 5% CO2. Cells were cultured in a density of 
0.05 × 106 cells/ml with a medium change twice a week. Total cell number as well as 
their viability was determined with trypan blue staining. 
 
2.2.8.2. Isolation and differentiation of PMNs 
Human neutrophils were isolated from citrated blood from healthy donors by 
dextran sedimentation (Plasmasteril) followed by pancoll density centrifugation48. 
Briefly, citrated peripheral blood was diluted with 1 volume PBS-D and Plasmasteril 
(1 volume of blood) was added. To remove erythrocytes, cell pellets were allowed to 
settle for 30 min and leukocyte rich supernatants were transfered onto the Pancoll 
solution and centrifuged at 850 g for 24 min at RT. Cell pellets were dissolved in 5 ml 
cold Aqua dest for 40 s and erythrocyte lysis was stoped by adding 5 ml 2xPBS. 
Cells were washed and centrifuged two times at 200g for 10 min at 4°C and 
suspended in CL-medium (RPMI 1640 buffered with 25 mM HEPES without phenol 
red) before use. Total cell number as well as their viability was determined with 
trypan blue staining. Viability of isolated human neutrophils exceeded 98% in all 
experiments.  
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Murine neutrophils were differentiated in vitro from bone marrow (BM) cells. 
Briefly, mice were sacrificed by cervical dislocation. The femurs and tibias were cut 
out and after removing muscles, the bones were placed into HBSS-Prep (Ca-Mg-free 
HBSS supplemented with 20 mM HEPES and 0.5% FCS) to prevent dry-out. After 
cutting the ends of the bones, the BM was flushed into conical tube with HBSS-Prep 
using syringe with a 25G needle. Isolated BM was homogenized through an 18 G 
needle to disaggregate larger BM pieces and preceded through a 70 micron cell 
strainer. Suspensions were sedimented at 400xg for 5 min and resuspended in 10 ml 
of erythrocyte lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA; pH 7.2). 
After lyes of erythrocytes for 10 min, HBSS-Prep (30 ml) was added and the 
suspensions were pelleted at 400xg for 5 min. Cells were counted and subsequently 
cultured in RPMI 1640 medium supplemented with 5% FCS and 10 nM granulocyte 
colony-stimulating factor (G-CSF) at 37°C with 5% CO2 for 24 h. Afterwards, the cells 
was placed on 62% percoll gradient in HBSS-Prep and centrifuged for 30 min at 
1000xg. Thereafter, cells at the interface and the upper part of the 62% Percoll 
fractions were carefully removed and discarded. Neutrophil-containing pellets were 
transferred to clean tubes, washed with and then resuspended in CL-medium.  
 
2.2.8.3. Purity of neutrophils 
Flow cytometry or fluorescence-activated cell sorting (FACS) is a well determined 
technique in research laboratories as well as clinical medicine and biology. This tool 
measures optical and fluorescence characteristics of single cells in a stream of fluid 
that physical properties of certain cell populations, such as size (represented by 
forward scatter) and internal complexity (represented by side scatter) can be 
analyzed221. Specific antigens or proteins on cell membranes or inside cells can also 
be analyzed by using conjugated antibodies to fluorescent dyes in which the 
fluorescent molecules on labeled cells are excited to a higher energy state by 
passing a light source221. When the electrons return to their ground state, the 
fluorochrome molecules emit light energy at higher wavelengths221. Since purified cell 
populations are frequently used in experimental studies, FACS can be a suitable 
procedure to purify cell populations of known phenotype. Here, FACS was applied to 
analyze the purity of human and murine neutrophils for further experiments. 
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The purity of the PMN preparation was determined by analyzing the forward and 
side scatters as well as by measuring expression of CD16 and Ly-6G, markers of 
human and murine PMNs, respectively. Isolated human or murine PMNs were 
resuspended in fluorescence-activated cell sorting (FACS) buffer (PBS-D without 
Ca2+ and Mg2+ + 0.1% BSA). For analysis, human cells (2×105 - 106 cells/ml) were 
incubated for 15 min at 4°C with CD16-FITC, CD14-PE, and CD3-APC, while murine 
PMNs were stained with Ly-6G-PE-Cy7, CD11b-APC, and CD3-FITC. For all these 
antibodies, corresponsding isotypes were also applied. The cells were centrifuged at 
450 g for 5 min at 8°C and washed with FACS buffer. Fluorescence intensities as well 
as forward and side scatter intensities were quantified by BD LSR II Flow Cytometer 
and analyzed by FCS Express Flow Cytometry software. 
 
2.2.8.4. Activation of neutrophils by immobilized immune complex 
Activation of neutrophils by immobilized immune complex (IC) was performed in 
vitro as described previously with modification214. Briefly, immobilized IC was 
prepared using recombinant murine COLVII and rabbit amCOLVII IgG. Wells of 
ibiTreat microscopy chambers or 96-well plates were coated with 1 μg recombinant 
COLVII in 100 µl PBS at 4°C overnight. Following blocking with PBS containing 1% 
BSA and 0.05% Tween-20, surfaces were covered with 100 μg rabbit amCOLVII in 
100 μl PBS containing 1% BSA and 0.05% Tween-20 for 1 h at 37°C and plates were 
finally washed with CL-medium. Control wells received normal rabbit control IgG 
instead of rabbit amCOLVII IgG. Neutrophils were applied on IC as well as irrelevant 
isotype antibody and prepared for measurement of activation parameters. 
 
2.2.8.5. Determination of neutrophil activation measurement 
Neutrophil activation is accompanied with several factors such as generation of 
ROS and release of elastase as well as neutrophil adhesion. ROS production and 
elastase release are considered as the central of neutrophil defence mechanisms 
and progression of several inflammatory diseases129,222. Beside the importance of 
neutrophil activation in the host defense, their activation by the immobilized IC after 
recruitment into the skin also leads to the generation of ROS and the release of 
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granule constituents including elastase, all of which have been proven to be essential 
factors for autoantibody-mediated tissue damage117,137,139. In addition to release of 
ROS and elastase, an IC-induced neutrophil adhesion was also observed during 
activation214.  
Generation of ROS by neutrophils was measured by chemiluminescence assay. 
In this assay, a probe such as luminol (5-amino-2,3-dihydro-1,4-phthalazindione) 
reacts with ROS including O2-, OH and hydrogen peroxide in the target fluid which 
result in production of light photons223. Herein, ROS production was determined by 
measurement of chemiluminescence as described elsewhere214,224. Briefly, 
neutrophils (106 cells/ml) in CL-medium supplemented with 60 μg/ml luminol were 
preincubated for 30 min at 37°C and subsequently distributed in 200 μl aliquots in an 
intransparent 96 well microtiterplate, coated with IC or with corresponding control 
proteins as described in section 2.2.8.4. Chemiluminescence was recorded for 60 
min and data were expressed as relative light units (RLU) by using Microplate 
Luminometer and the data was processed with MicroLumatPlus software.  
Neutrophil degranulation was also analyzed as another neutrophil activation 
parameter by measurement of the amount of elastase released as described 
elsewhere225. Briefly, neutrophils activated by immobilized IC were centrifuged for 20 
min at RT. Supernatants were added to a 96-well plate containing CL-medium and 
subsequently a series dilution was performed. Thereafter, substrate solution 
containing substrate buffer, DMSO, BOC substrate, and Ellman’s Reagent was 
applied and reaction was measured by Tecan Microplate ELISA Reader powered by 
Magellan data analysis software.  
Furthermore, neutrophil adhesion was monitored by phase-contrast microscopy. 
In parallel, neutrophil adhesion was quantified by real-time impedance measurement 
by using the xCELLigence system. The xCELLigence system is based on a new 
method which provides a possibility to investigate the real-time analysis of the 
adhesion, migration, and invasion proprieties of cells in physiologically relevant 
conditions226,227. The real-time kinetic data enable to characterize more accurately 
the short-lived cellular events. Cells are cultured in specific plates (E-Plates) on a grid 
of gold microelectrodes in their base which are connected to a computer system 
recording the impedance changes during an electrical circuit226,227. These changes 
are converted into cell index value that may be influenced by several parameters, 
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such as cell number, cell size, cell-substrate, or cell-cell attachment227–229. Therefore 
in present study, the relative change in measured electrical impedance was used to 
represent cell adhesion, and it was expressed as the arbitrary unit of cell index. 
 
2.2.9. Determination of neutrophil elastase activity by the FRET 
reporter NEmo-2 
2.2.9.1. FRET reporter performance in vitro  
Activity of NE in vitro was determined by the cleavage of FRET reporter and 
analyzed by confocal microscopy. Laser scanning confocal microscopy is an 
essential and invaluable instrument in the medical and biological research which 
enable for imaging three-dimensional reconstructions, single optical sections, 
multiple wavelength images, and living cell and tissue sequences230. The basic 
principle of a confocal microscope is that the laser light from excitation source as well 
as emitted fluorescence from sample passes through two pinholes, one placed in 
front of the light source and one in front of the photodetector230. Both pinholes in front 
of light source and detector as well as the focused point on the sample are all 
confocal with one another230. By contrast to conventional imaging microscopy, this 
confocal approach prevents the detection of non-confocal fluorescence emissions in 
focal planes which are away from the region of interest and therefore eliminates the 
detection of out-of-focus lights230. Of note, a multi-dimensional view of living cells is 
possible by using advanced confocal imaging microscopy231. In present study, this 
system was used to monitor dynamic and cellular processes of the Jurkat T cells as 
well as neutrophils in an in vitro assay.  
To detect of NE activity on neutrophils, small-molecule fluorescent ratiometric NE 
monitoring reporter based on energy transfer was used. The reporter, NE monitoring-
2 (NEmo-2), consist of a short human and murine NE specific peptide substrate with 
a specific cleavage site between the valine residues146 flanked by ethylenglycol 
(PEG)-linkers which function as spacers and to increase solubility, a suitable 
fluorophore is coupled at each end to build a FRET-pair165 (Figure 9). NEmo-2 
reporter has a lipid anchor164 which enable it to be used as a membrane-targeting NE 
reporter. The FRET-pair for this lipidated reporter has been designed as red-shifted 
phlorophores to allow excitation with the 405 nm laser line and to avoid cell damage 
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by high-energy light165. Coumarin 343 and carboxymethylrhodamine (TAMRA) are 
the fluorophores as donor and acceptor, respectively164,165. Coumarin dye has been 
selected because of less tendency to form nonfluorescing complexes164. To prevent 
diffusion of the intact reporter through the plasma membrane of the cell or its C-
terminal part after cleavage, negative charges are included in the substrate sequence 
by replacing the C-terminal glutamine by two glutamic acid residues165. Presence of 
two fluorophores, instead of a fluorophore and a nonfluorescent quencher, allows for 
ratiometric readout of reporter cleavage165. Upon cleavage of the reporter, the donor 
fluorophore stays with the lipidated cleavage fragment at the cell surface while the 
cleavage fragment carying the acceptor fluorophore is lost165. To enhance this 
property and to prevent overall internalisation of the intact reporter as well as the 
released part upon cleavage, negative charges have been introduced by including 
two glutamate residues close to the acceptor fluorophore165 (Table 1). 
 
 
 
 
 
 
 
 
Figure 9 Membrane-targeting lipidated neutrophil elastase (NEmo-2) monitoring fluorescent 
reporter (According to Ref.
165
). The NE-specific peptidic target sequences are shown by single letter 
amino acid code. Two negative charges were introduced for NEmo-2 to prevent internalization from 
the cell membrane. Arrows indicate the cleavage sites.  
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In the intact reporter, donor and acceptor fluorophores are in proximity which 
allows an energy transfer upon excitation of the donor to the acceptor. Cleavage of 
the substrate sequence by the enzyme of interest, here NE, induces separation of 
the fluorophores, which is detected by an increase of donor fluorescence and loss of 
FRET (Figure 9). In this study, ratiometric FRET reporters which have previously 
been developed165 were used to monitor NE activity in neutrophils. 
 
Table 1 Synthesized lipidated NE FRET reporter. 
 
TAMRA: (5-and 6-)carboxytetramethylrhodamine; F1, F2: fluorophores as FRET-pair 
 
 
2.2.9.2. Acceptor photobleaching 
To analyze the FRET efficiency, acceptor photobleaching was used as previously 
described232–235. The basic principle is to measure donor intensity before and after 
acceptor bleaching, thus providing an internal control by eliminating the occurrence 
of FRET. In the case of true FRET, an increase in donor fluorescence will result; from 
the portion of the donor fluorescence that was recovered after acceptor inactivation. 
The ratio of the donor fluorescence intensity before and after acceptor 
photobleaching reports the FRET efficiency232–235. FRET efficiency is calculated as 
the ratio of two intensities generated in the same detection channel but from the 
same sample before and after acceptor bleach. The donor fluorescence will be 
unquenched after photobleaching of the acceptor. The difference of fluorescence 
intensity of the donor before and after photobleaching gives a direct indication to the 
FRET efficiency and can be quantified as follows: 
FRETeff = (Dpost - Dpre) / Dpost 
where Dpost is the fluorescence intensity of the donor after photobleaching and Dpre is 
the fluorescence intensity of the donor before photobleaching. The FRET efficiency 
Name F1/F2 Donor λ exc/emi (nm) Accepor λ exc/emi (nm) 
NEmo-2 Coumarin 343/TAMRA 450/490 545/575 
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(FRETeff) is considered positive when Dpost > Dpre. In this regard, the imaging 
conditions for donor and acceptor fluorescence was defined by seting up the imaging 
conditions (Donor = coumarin 343, excitation 405 nm, emission 470-510 nm; 
Acceptor = TAMRA, excitation 561 nm; emission 570-610 nm). Donor detection was 
performed only by switching off the acceptor detection channel and setting the laser 
light of the acceptor down to 0%. Acceptor detection was done by setting the donor 
excitation light down to 0%, turnning off the donor detection channel, turnning on the 
acceptor detection channel instead and then setting the excitation laser line of the 
acceptor for adequate excitation light. A region of interest (ROI) was drawn around 
the area of the cell to bleach. The measurement was started by imaging the donor 
and acceptor before bleaching, followed by the bleaching of the acceptor and finally 
imaging the donor and acceptor after bleaching. The imaging conditions before and 
after bleaching were identical. FRET efficiencies were calculated by provided data236. 
 
2.2.9.3. NE reporter imaging on Jurkat T cells 
For imaging experiments, cells were resuspended in a pH independent imaging 
medium (IM) (20 mM HEPES, pH 7.4, 115 mM NaCl, 1.2 mM MgCl2, 1.2 mM CaCl2, 
1.2 mM K2HPO4, 2 g/l D-glucose) at RT and cell counts were performed. Jurkat T 
cells (30,000-40,000 cells) were diluted in 100 μl IM at RT and incubated with 2 μM 
NEmo-2 for 3 min. After addition of 100 μl IM, cell suspensions were spread on glass 
slides. In some experiments, the cells were incubated with 100 μM alpha1-antitrypsin 
(A1AT) from human plasma for 15 min at RT prior to addition of the reporter. 
Reporter cleavage was induced by addition of 1 μl NE (0.5 ng/μl). Slides were 
mounted with Fluoromount-G and stored at 4°C until analysis. 
For direct imaging experiment, cells were plated after incubation with inhibitor and 
reporter on microscopy Ibidi chambers and were imaged by confocal microscopy in 
time series of 30 min with 1 image/min. To induce reporter cleavage, 1 μl human NE 
(hNE; 0.5 ng/μl) was added to the NEmo-2 harboring cells to induce reporter 
cleavage and incubated for 3 min.  
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2.2.9.4. Incubation of human or mouse neutrophils with NEmo-2 
Human or mouse neutrophils were resuspended in PBS and cell counts were 
performed. Neutrophils (30,000-40,000 cells) were incubated with 2 μM NEmo-2 in 
100 μl IM at RT and for 3 min. IM (100 μl) was added and subsequently cell 
suspensions were spread on glass slides. In some experiment, the cells were 
incubated with 10 μM A1AT derived from human plasma for 15 min at RT prior to 
addition of the reporter. For imaging of neutrophils, cells were allowed to settle on 
Ibidi microscopy chamber without washing and were imaged by confocal microscopy 
for a time course of 30 min. 
For analyzing of inhibitory effects of CD18 antibodies, 30,000-40,000 mouse BM 
neutrophils were diluted in 100 μl IM at RT. For inhibition of elastase, 100 μM A1AT 
from human plasma was incubated for 15 min at RT prior to addition of the reporter. 
Cells were incubated with 10 µg/ml purified NA/LE rat anti-mouse CD18 or 10 µg/ml 
purified NA/LE rat IgG1 Isotype Control for 5 min at RT and then incubated with 2 μM 
NEmo-2 for 3 min. IM (100 μl) was added and the cell solution was spread on 
ibiTreat microscopy chamber and were imaged by confocal microscopy for a time 
course of 30 min. 
 
2.2.9.5. Confocal fluorescence microscopy settings and image analysis 
Images were acquired on Leica confocal microscopes (SP5) equipped with HCX 
PL APO Ibd.BL 63x 1.4 oil objective with the following settings: the donor was excited 
with a 405 nm diode laser and emission was sampled between 470-510 nm. 
Sensitized emission of the acceptor was sampled between 570-610 nm. The pinhole 
was set to 150 μm. Images were processed with ImageJ 1.38r software 
(http://rsb.info.nih.gov/ij/) using background subtraction, smoothing with a median 
filter, thresholding and calculation of D/A ratio images. Cells were selected as ROI to 
quantify mean pixel values per cell.  
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2.2.10. Monitoring of neutrophil elastase enzyme activity by using 
the FRET sensor NEmo-2 in vivo 
2.2.10.1. Multi-photon fluorescence microscopy  
Assessment of neutrophil elastase activity in vivo was performed by analyzing 
cleavage of NEmo-2 using multi-photon microscopy (MPM). MPM has developed into 
a powerful and invaluable imaging techniqe in biomedical and biological 
investigations237,238. This optical microscopy tool enables the study of biological 
function in vivo noninvasively such as cellular and subcellular processes in living 
tissue237,238. Basically, MPM is supported by two-photon fluorescence excitation 
whose adequate combined energy is able to promote a molecular transition from 
ground state to an excited state237,238. This kind of excitation process provides 
several unique advantages, such as higher spatial and temporal resolution, reduced 
specimen photodamage, low photon toxicity, and elevated penetration depth237,238. In 
contrast to confocal imaging with a linear ultraviolet or visible light laser excites 
fluorophores inside the sample, in MPM microscopy, an infrared or near-infrared 
laser offers pulsed illumination in which the photon density falls off quadratically with 
distance from the focal plane237–239. Therefore, due to the quadratic dependence of 
two-photon absorption on intensity, sufficient density of photons for simultaneous 
absorption of two photons by fluorophores is limited to the focal point237–239. As a 
consequence, out-of-focus fluorescence is never generated as excitation and 
subsequent light detection is localized to a single point237–239. This also helps to 
reduce photobleaching and photon toxicity limited to the focal point. Furthermore, 
due to less scattering and absorbing of near-infrared light by biological samples, 
fluorescence can be excited deeper into biological tissues237,240. 
To provide the ability of image analysis in vivo, the FRET technique was 
transferred from the confocal to the MPM. For this purpose, Jurkat T cells or 
neutrophils were loaded with NEmo-2 as described in sections 2.2.9.4 and 2.2.9.5, 
respectively. The individual channels > 560 nm and 800 nm for the acceptor and 495-
560 nm and 800 nm for the donor were smoothed by smooth time and threshold 
cutoff. Donor fluorescence and sensitized acceptor emission was imaged and D/A 
ratio images were calculated. For further analysis, Jurkat and neutrophil cells were 
analyzed and the ratio was plotted by time. 
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2.2.10.2. Neutrophil labeling and transfer in vivo into an EBA mouse model 
Intradermal administration of cells into the mouse ear was performed as 
described elsewhere241,242 and used with slight modifications. Briefly, BM neutrophils 
of Balb/c mice were isolated and differentiated as described in section 2.2.8.2 and 
subsequently treated with a cell tracker or FRET probe. To monitor neutrophils in 
vivo, a cell tracker (CellTracker Red CMTPX), a fluorescent dye appropriate for 
monitoring cell movement or location, was used to track the dynamic of the cells. The 
lyophilized component was dissolved in steril DMSO to a final concentration of 10 
mM. Stock solution was diluted to a final working concentration of 5 µM in serum-free 
medium pre-warmed to 37°C. Neutrophils were harvested by centrifugation and the 
supernatant was aspirated. The cells were resuspended gently in pre-warmed 
CellTracker dye working solution and incubated in cell culture medium for 30 min. 
Neutrophils were centrifuged and the medium was replaced with fresh, pre-warmed 
medium and incubated for another 30 min at 37°C. Cells were washed with and 
resuspend in PBS. Neutrophils were labeled with NEmo-2 in the presence of A1AT 
as described in the section 2.2.8.7.  
To analyze the neutrophil kinetics in vivo, a local antibody transfer mouse model 
of EBA was used. Balb/c mice were intraperitoneally anesthetized using a solution of 
Fentanyl (16 µg/ml), Midazolam (0.4 mg/ml), and Medetomidine (50 µg/ml). 
Subsequently, hair removal cream was applied on the ears to get rid of the hairs. 
BM-neutrophils (10×106 cells) were taken up in 100 µl sterile imaging buffer and 
aliquot of 10 µl cell suspension was intradermally injected using an insulin syringe 
(30-gauge needle) into the ventral side of the mouse ear. Since dermis layer in the 
ear is susceptible to damage due to thinness, injection procedure was performed by 
using a dissecting microscope to minimize the area of trauma and consequently the 
risk of artifacts. Thus, 2 h after injection, local antibody transfer model of EBA was 
induced by application of affinity purified rabbit α-mouse COLVII IgG labeled with 
Dylight 594 (7.5 µg) as well as an irrelevant antibody of the same isotype (rabbit IgG) 
were also intradermally administrated as described above into the different mouse 
ears.  
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2.2.10.3. Intravital multi-photon imaging of neutrophil activation 
For intravital MPM imaging, Balb/c mice were used for respective experiments to 
prevent occurrence of a phenomenon so-called ‘speckling’ (a pattern of dots)243,244. 
Under this condition, in pigmented mice (like C57BL/6 mice) laser light can be 
absorbed by melanin-containing dermal cells resulting in compromising the image 
quality as well as inducing heat damage that the later can trigger an inflammatory 
response characterized by the neutrophil invasion241. To achieve the best outcome, 
ear skin was used for MPM imaging which is commonly preferred243–248. Due to 
accessibility and the minimal requirements of preparation before imaging, mouse ear 
skin is a matter of choice as the imaging site enables fast preparation and 
reproducible conditions for generating consistent results241. Hair removal was 
performed to reduce the interference from hairs which is essential to prevent 
autofluorescence compromising contrast and to prevent the absorption of laser light 
by hairs obscuring effective illumination of cells and tissue structures241. Intravital 
imaging of ear pinnae of anaesthetized mice was carried out as described 
elswhere242,248,249. Briefly, mice were placed in a lateral recumbent position on a 
custom made imaging platform in which the ventral side of the ear pinna rested on a 
coverslip. A strip of Durapore tape was placed lightly over the ear pinna and affixed 
to the imaging platform to immobilize the tissue. Care was taken to minimize 
pressure on the ear. Images were captured towards the anterior half of the ear pinna 
where hair follicles are sparse.  
For focal skin tissue damage and to induce sterile injury in a spatially and 
temporally controlled manner, a laser ablation technique was applied which has been 
described previously241,250 with slight modifications. A highly localized injury was 
induced by a focused two-photon laser pulse at a limited area within the ear dermis 
for a short period of time. The wavelength of the two-photon laser was set at 740 nm 
with a pulse length of approximately 200 femtosecond (fs) and laser power of 23.6 
mW. A small injury region of 20 x 20 µm for 3 to 5 seconds (sec) was created as 
indicated by a bright autofluorescent area around the focal point of the beam. 
Imaging was performed by using a TriM Scope two-photon microscope equipped 
with an XLPlanN 25×1.05 WMP Objective. FRET reporter was exited with 920 nm. 
Emitted light was detected by 4 wavelength separated PMTs (<435 nm, 453-495 nm, 
495-560-560 nm and >560 nm). Image processing was done using Imaris Software 
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(Bitplane, Zurich, Switzerland) using background subtraction, smoothing with a 
median filter, thresholding and calculation of D/A ratio images. Cells were selected as 
ROIs to quantify mean pixel values per cell. Of note, to confirm that an operational 
FRET process is present, the acceptor was directly excited which results in direct 
fluorescent signal of the acceptor.  
 
2.2.11. Statistical analysis 
All data were first tested using the D'Agostino and Pearson normality omnibus 
tests for presenting a normal distribution. In cases with normal distribution of data, 
the statistical analysis was performed using the two-side, independent t-test or one- 
way ANOVA and a post-test Bonferroni's Multiple Comparison Test. The data were 
presented, unless indicated otherwise, as mean ± SEM. In cases with non-normal 
distribution of data, the analysis was performed using the Mann-Whitney or Kruskal -
Wallis tests and the Dunn's Multiple Comparison test (95 % confidence interval) as 
post-tests which was stated otherwise in the legend of the figures. Data were 
analyzed with GraphPad Prism version 5.0. The p<0.05 was accepted to indicate 
statistical significance. 
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3. RESULTS 
In the present study, the role of the neutrophil proteins MRP-8/-14 and neutrophil 
elastase in the regulation and execution of the effector phase of two autoimmune 
diseases, EBA and BP, was investigated. While the first part is focused on the 
analysis of MRP-8/-14 expression in human diseases as well as in murine disease 
models, the second part addressed the question of a potential functional role of these 
proteins in the pathogenesis of EBA and BP. Finally, mechanisms of proteolytic 
tissue damage as a consequence of neutrophil activation were investigated by 
visualization neutrophil protease activity (elastase) in experimental models of EBA 
and BP in vitro as well as in vivo. 
 
3.1. Protein concentration analysis of MRP-8/-14 levels in 
human serum of the BP patients 
MRP-8 and its heterodimeric partner MRP-14 proteins are cytosolic calcium-
binding proteins belonging to the S100 family. Although principally located in the 
cytosol of phagocytes like neutrophils they may function as danger signals outside of 
the cell. Increased levels of MRP-8/-14 expression are observed in many chronic 
diseases like cancer, RA, inflammatory and AIDs disorders. The expression of MRP-
8/-14 in AIBD has not been investigated so far. Therefore, MRP-8/-14 serum levels 
were measured in 20 patients with BP, 10 patients with EBA as well as 20 sex/age 
matched healthy controls. Serum levels of MRP-8/-14 were highly increased in the 
patients with BP (p = 0.0003) and EBA (p = 0.02) as compared to healthy individuals 
(Figure 10). While in healthy individuals median concentration of MRP-8/-14 were 
found around 2000 ng/ml, significant higher level could be detected in sera of BP 
patients (median ~7500 ng/ml). EBA patients also expressed elevated level of MRP-
8/-14 (median ~2500 ng/ml) although less prominent as compared to the BP group. 
These results clearly indicate that AIBD patients are characterized by an increased 
serum level of MRP-8/-14 proteins. 
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Figure 10 MRP-8 and MRP-14 concentrations in the sera of BP and EBA patients as well as 
healthy control individuals. Serum levels of BP patients (n=20), EBA patients (n=10), and healthy 
donors (n=20) were analyzed by ELISA. The data were expressed as medians with interquartile range. 
Indicated statistically significant differences between the respective patient groups and healthy 
controls were calculated using the Mann-Whitney test. 
 
 
3.2. MRP-8/-14 expression in experimental EBA and BP  
Based on the findings in human, expression of MRP-8/-14 was analyzed in 
experimental AIBD. A previous, more generalized study using whole genome 
expression analysis of inflamed tissue in experimental EBA led to the identification of 
33 distinct and differentially expressed gene modules regulated in disease251. Among 
these, both Mrp-8 and Mrp-14 belong to the group of the top ten of the highly 
upregulated genes, with an expression increased more than 60-fold as compared to 
the healthy controls. To confirm these initial findings, we investigated the gene and 
protein expression of MRP-8/-14 in both experimental EBA and BP. 
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3.2.1. Experimental antibody transfer models of EBA and BP in wild 
type mice  
To investigate the role of MRP-8/-14 in experimental EBA and BP, C57BL/6J 
mouse strain was used for antibody transfer models of EBA and BP. A systemic 
antibody transfer model of EBA was induced by administration of pathogenic rabbit 
amCOLVII IgG. After repetitive administration of pathogenic rabbit amCOLVII IgG or 
IgG from non-immunized rabbit (isotype), all mice were examined on days 4, 8, 12 
and 16 for EBA typical skin lesions, and finally the percentage of diseased skin in 
relation to body surface were calculated as the severity of the disease (Figure 11A). 
At the end of the experiment (day 16), skin lesions on the mice skin were examined. 
Four days after antibody administration, local inflammation was developed on the 
different parts of the mice skin that had received the pathogenic antibody (Figure 
11A). This inflammatory response was manifested in the form of redness, scabs and 
peeling of the epidermis (Figure 11B). Injection of pathogenic antibody induced about 
20% of affected skin on the surface of the mice body.  
Due to the low pathogenicity of our anti-mCOLXVII antibody, animals did not 
develop disease sympotom in the systemic antibody transfer model of BP even after 
administration of high antibody doses. To circumvent this, a local antibody transfer 
model of BP was used as already described before252. In this model, the pathogenic 
antibody was injected intradermally in the ear base once resulting in a local 
inflammatory response and blistering in the area of the injection site within 24 h 
observed. To establish the local antibody transfer model of BP, the pathogenecity of 
the pathogenic amCOL17 IgG was first determined in vivo. Ears of C57BL/6J wild 
type mice were intradermally injected with different doses of the antibody, including 
0.125, 0.25, 0.5, 1, and 2 mg, respectively. After administration of antibodies, all mice 
were examined for BP typical skin lesions, and finally the percentage of diseased 
skin in relation to body surface was calcuated as the severity of the disease. After 24 
and 48 h, skin lesions on the ear were examined. Just 24 h after antibody 
administration, local inflammation was developed on the ears that had received the 
pathogenic antibody (Figure 11A). The two highest dosages of antibody (1 and 2 
mg/ear) lead to the induction of clinical symptoms of the disease in the wild type 
mouse ears (Figure 11B). This inflammatory response was manifested in the form of 
redness, scabs and peeling of the epidermis (Figure 11B). Injection of 1 mg and 2 mg 
antibody induced about 5% and 30% of affected skin on the surface of the ear, 
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respectively. Therefore, a dose of 2 mg/ear was selected for the following 
experiment.  
To determine the histopathology of the diseases in the skin induced by 
pathogenic antibodies, lesional skin tissues were used further analysis. Therefore, 
H&E Staining was used to monitore the changes in the tissue sections. All animals 
treated with pathogenic IgGs showed inflammation of the skin by infiltration of 
inflammatory cells like neutrophils in the dermis, thickening of the epidermis, and 
blister formation (Figure 11C). Moreover, blister formation by splitting the epidermis 
from the dermis could be observed.  
Furthermore, since neutrophils are the major producers of MRP-8/-14 proteins, 
neutrophil recruitment was examined as a potential mechanism by which their MRP-
8/-14 proteins may amplify inflammation and tissue damage in the skin. Therefore, 
we then determined the neutrophils in the affected skin in experimental EBA and BP. 
The neutrophils in the skin was determined using immunofluorescent staining with 
monoclonal antibody NIMP-R14253, a neutrophil-specific marker. Figure 11D shows 
representative images from each treatment group. There were an increased number 
of NIMP positive cells in all wild type animals treated with amCOL VII or XVII IgG 
when compared to the control groups treated with irrelevant isotype antibody. This 
histologic analysis revealed that the neutrophils are present in the diseased part of 
skin in pathogenic wild type mice. The number of neutrophils was substantially 
increased relative to healthy part of the skin in control mice. 
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Figure 11 Experimental systemic EBA and local BP in wild type mice. Mice were treated with 
pathogenic rabbit amCOLVII or COLXVII IgG for experimental EBA and BP as well as rabbit isotype 
antibody for control group. For systemic model of EBA, antibody was injected on day 0, 2, 4, 6, 8 and 
10 and mice were scored on days 4, 8, 12 and 16 for clinical symptoms (skin lesions). For local model 
of BP, antibody was injected intradermally once only and mice ears were scored 48 h after antibody 
injection for ear skin lesions. (A) Disease development in systemic EBA as well as local BP model 
animals by injection of amCOLVII IgG and amCOLXVII IgG, respectively. In BP model, a dose of 2 
mg/ear was selected for the following experiment. (B) Mice phenotypes were photographically 
documented and representative images were mapped. (C) Infiltration of inflammatory cells and 
dermal-epidermal separation was determined by histology (H&E staining) of mice skin in EBA and BP 
models at day 16 (systemic experimental EBA) or day 2 (local experimental BP) in sections of skin 
treated with pathogenic antibodies. Scale bar: 500 µm. (D) NIMP immunofluorescent staining of skin 
tissue was performed for diseased as well as control groups. Cryosections (5 μm) of skin tissue were 
incubated with neutrophil marker (NIMP-R14) and subsequently with secondary antibody (Alexa Fluor
®
 
488 Goat anti-mouse IgG). NIMP positive neutrophils (green areas) were detected in all pathogenic 
amCOL VII (upper) and XVII (lower) treatment groups, but not in irrelevant isotype treatment animals. 
Scale bar: controls, 50 µm; pathogenic EBA, 10 µm; pathogenic BP, 5 µm. 
(B) 
(A) 
(C) 
(D) 
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3.2.2. Quantitative Mrp-8/-14 gene expression in EBA and BP 
Gene expression of Mrp-8 and Mrp-14 in the affected skin of experimenal EBA 
and BP as well as control skin from healthy mice was quantified by quantitative RT-
PCR. The expression of these two genes was normalized to the mean expression of 
the housekeeping gene b2M. In experimenal EBA, Mrp-8 and Mrp-14 genes were 
upregulated by 64-fold and 101-fold, respectively, as compared to controls (Figure 
12A). A comparable effect was seen in BP where Mrp-8 and Mrp-14 expression in 
diseased mice exceeds those of healthy controls by 23-fold and 18-fold, respectively 
(Figure 11B).  
In the next step, it was investigated whether the upregulation of the gene 
expression of Mrp-8/-14 reflect the situation at the protein level in mice suffering from 
experimental EBA and BP. 
 
 
 
 
 
 
 
 
Figure 12 Upregulation of Mrp-8 and Mrp-14 genes in experimental EBA and BP. Gene 
expression of Mrp-8 and Mrp-14 detected by using RT-PCR in EBA (A) BP (B). The gene expressions 
were presented as relative value where the gene expression in healthy individuals was set as one. 
Mrp-8 and Mrp-14 genes were upregulated in the diseased skin by 64-fold and 101-fold in EBA as well 
as 23-fold and 18-fold in BP as compared to the healthy control. Results of one experiment containing 
3 mice/group are expressed as mean±SD. 
 
 
 
(A) 
 
(B) 
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3.2.3. Expression of MRP-8/-14 proteins in experimental EBA and BP 
in vivo 
To determine whether the upregulation of the MRP-8 and MRP-14 also exist on 
protein level in the inflamed skin, the protein expression was determined by 
immunofluorescence staining. Samples of lesional skin of anti-mCOLVII-treated 
diseased mice as well as skin of healthy mice treated by irrelevant antibodies of the 
same isotype derived from the experiment shown in section 3.2.1 were taken on day 
16 and cryosections were prepared. Immunofluorescence staining of specimen 
revealed that MRP-8/-14 proteins were found in the diseased skin but absent in the 
healthy control skin (Figure 13A). The results showed that protein expression of 
MRP-8 and MRP-14 was predominantly and abundantly found within the 
inflammatory cellular mass and stained polymorphonuclear cells in the affected skin 
compared with healthy control skin.  
Furthermore, to quantify the protein levels of MRP-8/-14 proteins in the skin 
lesions, SDS-PAGE electrophoresis and western blot analysis was performed to 
analyze the semi-quantitative changes of these protein levels in the affected skin 
comparing with healthy control skin. Equal protein loading was controlled by using 
ERK 1 as a reference protein. Reliable assessment of the changes in target protein 
expression levels requires the measurement of both the target protein and the 
loading control protein in their linear dynamic ranges. In this regard, MRP-8/-14 
expression levels were normalized to the expression of extracellular-signal-related 
kinase 1 (ERK 1, p44). The results indicate that these proteins are not expressed in 
the healthy skin but expressed by diseased skin samples in experimental EBA and 
BP diseases (Figure 13B). 
 
 
 
 
 
 
      RESULTS 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Expression of MRP-8 and MRP-14 proteins in skin tissue in experimental EBA 
and BP. (A) Cryosections (5 μm) of skin tissues from wild type mice treated with rabbit amCOLVII and 
amCOLXVII as well as normal rabbit IgG were were incubated with MRP-8 and MRP-14 rabbit anti 
mouse conjugated to Cy5.5 and analyzed by confocal microscopy. MRP-8/-14 positive proteins (red 
areas) were detected in all pathogenic amCOL VII (left) and XVII (right) treatment groups, but not in 
irrelevant isotype treatment animals. Both expression of MRP-8 and MRP-14 were highly expressed in 
the affected skin comparing with healthy control skin. Expression of MRP-14 was weaker than MRP-8 
especially in BP model. (B) MRP-8 and MRP-14 protein levels in EBA and BP diseased skin as well as 
control animals were examined using Western blot. Equal quantities of protein (5 µg) were loaded in 
each lane. amCOL: anti mouse collagen. Scale bar: 100 µm. 
 
 
(A) 
 
(B) 
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3.3 Experimental EBA and BP in Mrp-14-deficient mice  
According to the results shown above, MRP-8/-14 was found to be elevated on 
transcription and protein level in AIBD patients as well as in experimental models of 
the diseases. Consequently, in the next step the functional role of these proteins in 
AIBD was investigated by using Mrp-14 deficient mice in experimental AIBD. 
 
3.3.1. Experimental EBA in MRP-14 deficient mice 
MRP-8 and MRP-14 form a heterodimeric complex in the cytosol of monocyte and 
neutrophil cell types circulating in peripheral blood. Since MRP-8 and MRP-14 
expression levels were upregulated significantly in the diseased skin, the next series 
of experiments were designed to determine the presence of MRP-8 and MRP-14 in 
serum of diseased mice. The serum levels of heterodimeric complex of MRP-8 and 
MRP-14 were detected by ELISA. While in diseased wild type mice protein 
complexes were clearly present, they were undetectable in Mrp-14 knockout mice 
(Figure 14). These data provide direct evidence that in Mrp-14 knockout mice, no 
functional MRP-8/-14 heterodimers are expressed. 
 
 
 
 
 
 
 
 
Figure 14 Serum levels of MRP-8 and MRP-14 proteins in experimental EBA. Experimental 
EBA was induced in wild type (WT) and Mrp-14 knockout (KO) mice and MRP-8 and MRP-14 
concentrations in the sera were quantified at the end of the experiment (day 16) by ELISA. Data of 
one representative experiment is shown. 
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Since MRP-8 and MRP-14 are not functional in Mrp-14-/- mice, the role of MRP-8/-
14 proteins was investigated in experimental EBA, where C57BL/6J-Mrp-14-/- mouse 
strain was compared with its corresponding wild type control (C57BL/6J) in a 
systemic antibody transfer model of EBA described in section 3.2.1. As shown in 
Figure 15A, MRP-14-deficient as well as wild type controls started to develop the 
clinical symptoms of EBA on day 8 after the first injection of the pathogenic antibody 
injection and the disease severity increased over time, with the strongest effect seen 
at day 16 (Figure 15A, B). Mice which received irrelevant antibodies did not develop 
disease. According to my initial hypothesis, I expected that Mrp-14-deficient mice 
should show a less severe skin disease as compared to the wild. However, in 
contrast to my hypothesis, no significant difference in disease severity between 
knockout and wild type mice was observed (Fig. 15A). This was confirmed after 
integration of the data derived from mice which had received pathogenic IgG (Figure 
15C). In accordance with these findings, a more detailed analysis of the affected skin 
regions performed at day 16 revealed no significant difference between knockout 
mice and wild type control animals (Figure 15D). Although the distribution of skin 
lesions over the body differs slightly in their intensity between knock out and their 
wild type controls in individual body regions, due to the high variations within the 
groups, no significant difference could be identified. Animals with deficiency in Mrp-
14 are not protected from EBA and disease activity is comparable to that of wild type 
control animals when the entire observation period and the whole body surface are 
considered. 
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Figure 15 Experimental EBA in Mrp-14-deficient and wild type mice. Mice were treated with 
pathogenic rabbit amCOLVII IgG or irrelevant rabbit IgG control on day 0, 2, 4, 6, 8 and 10 and were 
scored on days 4, 8, 12 and 16 for clinical symptoms (skin lesions). (A) The disease development was 
represented as the percentage of the affected skin on the body surface over the entire observation 
period. (B) On the last day of the experiment (day 16), the phenotype of the mice was 
photographically documented and representative images of each group were mapped. (C) Data of 
disease activities derived from mice which had received pathogenic antibodied were integrated and 
presented as area under the curve (AUC). (D) Comparision of the infestation of individual body 
regions at day 16 between knockout and wild type animals treated with pathogenic antibodies. The 
data represent two independent experiments with 18 mice (12 and 6 mice for pathogenic and isotype 
IgG-injected group) in each experiment. amCOL: anti-murine collagen, KO: knockout, WT: wild type. 
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3.3.2. Experimental local antibody transfer model of BP in mice with 
MRP-14 protein deficiency 
To investigate the role of MRP-8/-14 proteins in experimental local BP, 
pathogenic amCOL17 IgG as well as irrelevant rabbit IgG (isotype) were 
intradermally injected into the base of right and left ear of C57BL/6J-Mrp-14-/-, 
respectively as described in section 3.2.1. Same procedure was performed for the 
corresponding wild type animals. According to our initial hypothesis, a less severe 
skin disease as compared to the wild types was expected in Mrp-14-deficient mice in 
the local antibody transfer model of BP. Disease symptoms became visible 24h after 
administration of pathogenic IgG and increased further during the next 24h (Fig 16A, 
B). No lesions have been observed on the ears of mice which had received irrelevant 
isotype antibody. However, similar to EBA mouse model, no significant differences 
between knockout and wild type mice could be observed at any time point (Fig. 16B). 
These findings were confirmed after integration of the data over the time (Figure 
16C). Taken together, these data clearly show that animals with deficiency in MRP-
14 protein are neither protected to BP nor to EBA.  
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Figure 16 Experimental local antibody transfer model of BP in Mrp-14-deficient mice and 
corresponding wild types. Mrp-14-deficient mice as well as wildtype animals received 2 mg 
amCOLVII IgG into the right ears and 2 mg isotype antibody into the left ear which a representative 
inflammatory symptoms and lesions were found on the skin with scabs, redness, and peeling of the 
epidermis. Ears were examined 24 (day 1) and 48 h (day 2) for skin lesions. The disease development 
was represented as the percentage of the affected skin on the body surface over the entire 
observation period. (A) The percentage of the disease infestation on the ear surface was represented. 
(B) On the last day of the experiment (day 2), the phenotype of the mice was photographically 
documented and representative images of each group were mapped. (C) Data of disease activities 
derived from mice which had received pathogenic antibodied were integrated and presented as area 
under the curve (AUC). The data represent two independent experiments with 26 mice (13 and 5 mice 
for pathogenic and isotype IgG-injected group, respectively) in each experiment. amCOL: anti-murine 
collagen, KO: knockout, WT: wild type. 
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3.3.3. Histological analysis of mice with MRP-14 protein deficiency in 
experimental EBA and BP  
Although the investigation of the Mrp-14-deficient mouse strain at the level of 
clinical symptoms did not revealed differences between knokout and wild types in 
experimental EBA or BP, differences may occure within the inflamed tissue. 
Therefore, IgG binding, complement deposition and tissue inflammation was 
analyzed by histology. 
From the experiments described in 3.1.1 and 3.1.3, skin samples of the mice were 
taken on day 16 for frozen sections. By using immunofluorescence staining, 
deposition of the injected amCOLVII IgG as well as deposition of complement C3 in 
the experiment was detected. Appropriate controls of the fluorescent staining, i.e. 
negative control (uncolored), isotype control (replacement of the primary antibody by 
IgG of the same isotype), and secondary antibody control (no primary antibody 
staining) were used and showed no unspecific fluorescence signal (data not shown). 
Binding of the amCOLVII IgG and complement C3 could be detected in skin samples 
of both knockout and wild type controls treated with amCOLVII IgG (Fig. 17A). Both 
proteins were located in close proximity to each other in the DEJ. As expected, no 
deposit of rabbit IgG or complement C3 could be observed in the samples from mice 
treated with the isotype control (Fig. 17A). In consistent with the observation in 
experimental EBA, IgG and C3 deposition were observed in both knockout and 
wildtypes controls treated with amCOL17 IgG but not in the mice treated with control 
antibodies (Fig. 17B).  
In addition, changes in the tissue sections were examined by using H&E Staining. 
All animals treated with pathogenic amCOLVII IgG showed inflammation of the skin 
by infiltration of inflammatory cells in the dermis, thickening of the epidermis, and 
blister formation (Figure 19). Moreover, blister formation seen as splitting of the 
epidermis from the dermis could be observed. Animals treated with irrelevant rabbit 
IgG had no cell infiltration as well as having a thin epidermis without blistering. In 
both model of EBA and BP, no difference between Mrp-14-/- and wild type mice could 
be observed with regard to their clinical or histological phenotype. 
 
 
      RESULTS 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Deposition of rabbit IgG and complement C3 in Mrp-14-deficient mice and 
corresponding wild types. Cryosections of skin samples from knockout mice and the corresponding 
wild type controls were derived from the experiment described in section 3.1.1. Deposition of rabbit 
IgG (top panel) and the complement factor C3 (middle panel) was assessed by immunofluorescece 
staining and colocalization of both proteins was shown the overlay (lower panel) in EBA and BP. Skin 
samples of mice treated with pathogenic antibody are shown on the left side and animals treated with 
irrelevant rabbit IgG of the same isotype in the right side. Data of one representative experiment out of 
three is shown. Scale bar: 50 µm. 
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Figure 18 Histology of the skin of Mrp-14
-/- 
and control mice in EBA and BP mouse models.  
Paraffin sections of skin samples from Mrp-14
-/- 
mice and the corresponding wild type controls from the 
experiment described in sections 3.1.1 and 3.1.3. Skin inflammation in experimental EBA and BP in 
Mrp-14
-/-
 and wild type mice. Infiltration of inflammatory cells and dermal-epidermal separation was 
determined at day 16 (EBA) or day 2 (BP) in sections of skin with H&E staining. Mrp-14
-/- 
and wild type 
controls do not differ in the histopathology of both disease model. Data of one representative 
experiment out of three is shown. Scale bar: 100 µm. 
  
 
In summary, the results of this study clearly show that expression of MRP-8/-14 is 
elevated in both human and experimental AIBD. However, although a significant 
increase in MRP-8/-14 expression in lesional skin of mice with experimental EBA and 
BP could be observed, the lacking difference in clinical symptoms as well as in 
histopathology between wild type controls and  MRP-14-/-  mice indicate that MRP-8/-
14 proteins do not contributed in the development of these diseases. Therefore, it 
has to be concluded that MRP-8/-14 are upregulated but not functionally involved in 
the pathogenesis of experimental AIBD. 
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3.4. Imaging of neutrophil elastase enzyme activity in the 
effector phase of AIBD 
As evident from the results of the previous part of this study, MRP-8/-14 proteins 
appear to be not functionally involved in the pathogenesis of experimental AIBD 
during the effector phase of the disease. As a consequence, a direct or indirect 
regulation of neutrophil effector mechanisms like the release of elastase by these 
proteins in EBA and BP models can not be expected and will not further be 
investigated here. Regardless to the role of MRPs, the determination of where and 
how neutrophils are activated as well as where and when neutrophil proteases 
mediate tissue damage in autoimmune inflammation represents a hallmark in the 
understanding of the pathogenesis of AIBD. Although the significant pathogenic role 
of neutrophil elastase in experimental AIBD has been clearly investigated, so far the 
role of this enzyme in disease has been shown only indirectly, either by 
determination of protease activity in cell extracts and supernatants, by inhibitor 
studies, or by histological localization of the protein in the diseased tissue. For better 
understanding of the pathophysiological mechanism of neutrophil elastase in 
disease, a direct approach allowing their quantification and localization of the enzyme 
activity at its site of action in vitro and in vivo is required. Therefore in this part, a 
method was established by using NE FRET reporter NEmo-2 to visualize NE activity 
on Jurkat T cells, human and murine neutrophils in vitro as well as in experimental 
EBA in vivo. 
 
3.4.1. Human blood and murine BM-derived neutrophils 
To analyze the activity of neutrophil elastase, highly purified neutrophils isolated 
from humans and mice were required. While human neutrophils could be isolated in 
sufficient amounts from peripheral blood, adequate numbers of murine cells could be 
isolated only from the bone marrow. Since a relevant portion of these BM-cells 
represent immature neutrophils, BM-cells were isolated and neutrophil precursors 
were terminally differentiated by culture in presence of G-CSF for 24h. The purity of 
neutrophils was assessed by analysis in flow cytometry. Samples were labeled with 
monoclonal antibodies CD16 and Ly-6G to identify the human and murine 
neutrophilic lineage, respectively. For human neutrophils, there was a clear 
      RESULTS 68 
population with purity of 91.23% determined using CD16 antibody (Figure 19A). 
Isolated murine bone marrow derived neutrophils were tested with Ly-6G antibody 
and a purity of 93.46% was achieved (Figure 19B). 
 
 
 
 
 
Figure 19 Purity of human and murine neutrophils. Neutrophils were purified from human 
blood (A) or differentiated from murine bone marrow cells (B). Purified neutrophils were analyzed by 
flow cytometry and their distributions according to their forward scatter (FS) and side scatter (SS) are 
given (left panels). Neutrophils were identified by their surface expression of CD16 (> 91% purity) or 
Ly-6G (> 93% purity), respectively (right panels). Results of one representative experiment out of two 
are shown. 
 
 
3.4.2. IC-induced neutrophil activation 
In AIBD, neutrophils become activated after recruitment into the skin by the 
immobilized IC leading to the generation of ROS and the release of granule 
constituents including elastase, all of which have been proven to be essential factors 
for autoantibody-mediated tissue damage117,137,139. It has been shown that 
neutrophils are not only required but also sufficient to cause the tissue damage141. 
However, to protect the tissue from unwanted damage, in blood serum as well as 
peripheral tissues high amounts of protease inhibitors as well as oxygen radical 
scavengers are expressed. For this reasons, it is still unclear how neutrophils can 
mediate and execute tissue damage in AIBD and other inflammatory diseases. 
Neutrophil activation proceeds in a sequence of extravasation, directed migration 
towards the site of inflammation, adhesion, and, finally, execution of potential 
damaging functions such as the release of ROS and proteases. To investigate how 
 
(A) (B) 
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neutrophil proteases mechanistically mediate tissue damage under physiological 
conditions, the interdependency between the different steps was investigated by a 
delineation of the process. In a first approach an in vitro model was established, were 
neutrophils were activated by immobilized immune complexes (IC) and the 
physiological relevance of cell adherence for the subsequent release of ROS and 
elastase was analyzed.   
Activation of neutrophils was performed by using immobilized IC in vitro. 
Immobilized IC was prepared using recombinant murine COLVII and rabbit 
amCOLVII IgG. Neutrophils immediately adhered to surfaces coated with immobilized 
IC as seen by a dramatic change of their morphology while after contact to uncoated 
surfaces cells remained round shaped (Figure 20A). To get a first hint on the 
molecules involved in IC-induced adhesion, cells were preincubated with blocking 
antibodies against CD18, the common β-chain of β2-integrins. These type of 
integrins have been shown to mediate many inflammatory adhesion processes in 
neutrophils254–257. As expected, inhibition of CD18 by blocking antibodies dramatically 
reduced the IC-induced morphological changes of neutrophils (Figure 20A) while no 
such effect was observed in samples which received antibodies of an unrelated 
isotype control.  
These results provide first evidence of a CD18-mediated neutrophil adhesion to 
immobilized IC. However, to monitor and quantify the cell adhesion in a real time 
process, neutrophil adhesion on immobilized IC was analyzed by using impedance 
measurement226. In this detection system, increased cell adhesion directly correlates 
with an increase of the electrical impedance (expressed as cell index) of the cell 
layer. Confirming the previous microscopical analysis, neutrophil adhesion increased 
immediately after addition of the cells to the IC-coated wells and reached a peak after 
25 min. Thereafter, a continuous decrease was observed and background levels 
were reached after 150 min (Figure 20B). The cell index of the control neutrophils 
exposed to uncoated surfaces increased only slightly over the 3 h (Figure 20B) and 
these results were confirmed after quantification of cell adhesion by integration of the 
cell indices which are represented as the area under the curve (Figure 20C). As seen 
in the microscope before, treatment of cells with CD18 resulted in a significant partial 
inhibition by approximately 50% (Figure 20B, C). A comparable effect was observed 
when murine neutrophils were used instead of human cells and 2-integrin were 
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blocked with an anti-murine CD18 antibody, indicating no principal difference 
between both species with regard to this function (Figure 20D, E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 IC-induced neutrophil adhesion. Neutrophils were exposed for 1 to 3 h to 
immobilized IC or uncoated surfaces (control) alone or in presence of anti-CD18 IgG (IC + anti-CD18 
IgG) or isotype control (IC + isotype IgG), respectively. (A) Morphology of human neutrophils was 
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analyzed by phase-contrast microscopy 1 h after the stimulation. (B) Adhesion kinetics was 
determined by real-time impedance measurement for 3 h and (C) data were integrated and 
represented as the area under the curve (AUC). (D) For IC-induced adhesion in murine neutrophils, 
cells were exposed for up to 5 h to the uncoated surfaces (control) or surfaces coated with IC (IC) in 
the presence of anti-mCD18 IgG (IC + anti-CD18 IgG) or an corresponding isotype control (IC + 
isotype IgG) and cell adhesion was determined by real-time impedance measurement. (E) Adhesion 
was further quantified by integration of cell indices and represented as AUC. Data of one 
representative out of 3 experiments is shown. Statistically significant differences between groups 
treated with IC/anti-CD18 IgG and IC/isotype-treated controls are indicated. 
 
 
In the next step, the functional impact of IC-induced neutrophil adhesion on 
further cell functions like degranulation and ROS generation was analyzed. After 
exposure to IC, neutrophils immediately started to generate ROS which peaked after 
10 min and reached background levels after 40-60 min. Noteworthy, this process was 
not affected by the blockage of CD18 (Figure 21A, B). Furthermore, determination of 
the elastase enzyme activity in the same supernatants revealed that blocking CD18 
did not result in a reduced but slightly enhanced IC-induced liberation of the protease 
(Figure 21C). 
Taken together, these results show that immobilized IC induces a tight neutrophil 
adhesion which is at least partially dependent on β2-integrins. Furthermore, these 
data indicate that tissue-damaging neutrophil functions like ROS production and 
elastase release are clearly independent from CD18-mediated neutrophil adhesion. 
From these findings, one would conclude that neutrophil-mediated tissue damage 
should not be affected by modulation of cell adhesion. By contrast, in a most recent 
study, Xinhua Yu in our group could show in an ex vivo model of EBA that blocking 
adhesion with CD18-antibodies results in a complete abrogation of neutrophil-
induced tissue destruction. Vice versa, increasing adhesion of neutrophils by co-
stimulation of cells with the chemokine CXCL4 resulted in augmented tissue damage 
(unpublished results). It becomes clear that the role of neutrophil adhesion in the 
conflicting findings between elastase release as IC-induced cell function and 
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observed proteolytic tissue damage cannot be resolved by the classical methods of 
determination of protease activities in cell free supernatants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Effect of anti-CD18 antibodies on IC-induced activation. Neutrophils were exposed 
for 1 h to immobilized IC or uncoated surfaces (control) alone or in presence of anti-CD18 IgG 
(IC+anti-CD18 IgG) or isotype control (IC+isotype IgG), respectively. ROS production was determined 
by measurement of chemiluminescence in the presence of luminol in parallel samples for 60 min (A) 
and data were represented as integrals of light intensity determined for 1 h (B). Degranulation was 
determined by the amount of elastase released into the supernatant and given as percentage of their 
respective total amount (C). Data are presented as mean ± SEM derived of 3 experiments.  
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3.4.3. Visualiziation of lipidated FRET-protease reporter NEmo-2 on 
Jurkat T cells 
The analysis of free elastase activity in supernatants provides no information of 
the local activity of the enzyme in small microenvironments which may be of high 
physiological relevance. For this reasons, a method for measuring elastase activity in 
close proximity to cell membranes using the lipidated FRET-based elastase substrate 
NEmo-2 was established. To analyze the characteristics and the performance of the 
reporter on cells, NEmo-2 was applied to Jurkat T cells. Since these cells do not 
express endogenous elastase, they are unable to cleave or modulate the reporter by 
themselves. Cells were incubated with the reporter for 5 min and subsequently 
analyzed by confocal microscopy. Coumarin 343 (donor; D) was excited with a 405 
nm diode laser and emission was sampled between 470-510 nm. Sensitized 
emission of TAMRA (acceptor; A) was sampled between 570-610 nm. Donor 
fluorescence and sensitized acceptor emission was imaged and D/A ratio images 
were calculated. Donor emission and sensitized emission of the acceptor were 
sampled by confocal fluorescence microscopy and D/A-ratio images were calculated 
using ImageJ software. 
The NEmo-2 was found to accumulate exclusively on the cell membrane and no 
intracellular signal was observed (Figure 22A, video 1A-C). For the intact reporter the 
D/A-ratio was low. In the next step, cleavage of the cell-bound reporter was induced 
by addition of exogenous neutrophil elastase. While the D/A ratio remained 
unchanged in control samples without NE, addition of NE resulted in a time-
dependent increase of the D/A-ratio (Figure 22B, video 1D-F), indicating an effective 
proteolytical cleavage of the reporter. Normalization of the D/A-ratio to the starting 
value resulted in 3-fold increase (Figure 22C). The condition was reproduced using at 
least three cells and normalization of the mean of D/A-ratio to the starting value 
resulted in more than 2-fold increase (Figure 22D). 
Of note, the TAMRA signal disappeared after cleavage, indicating that the 
TAMRA bearing fragment was lost from the cell-surface. TAMRA did not get 
internalized, since no intracellular signal was observed. Interestingly, the Coumarin 
343 bearing lipidated part was not internalized, but stayed at the cell membrane. 
Nevertheless, all changes were applied as the D/A ratio. 
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Figure 22 Elastase-mediated cleavage of NEmo-2 FRET reporter on Jurkat T cells. Jurkat T 
cells were incubated with the reporter for 5 min and bound reporter was determined by confocal 
microscopy. NEmo-2 localized exclusively on the cell membrane. Donor fluorescence and sensitized 
acceptor emission was imaged and D/A ratio images were calculated. NE was added after 4 min of 
incubation. (A, B) Representative confocal images of donor (D) and acceptor (A) fluorescence 
intensities and the corresponding D/A ratios are shown. Look up table (LUT): blue = low D/A ratio, 
intact NEmo-2; red = high D/A ratio, indicative for cleaved NEmo-2. Scale bar: 5 µm. (C) D/A ratios 
were normalized to the starting value and plotted over time. After addition of exogenous NE (min 4), a 
strong increase in the D/A emission ratio (3-fold) was observed. (D) D/A-ratio normalized to the 
starting value for at least three cells resulted in more than 2-fold increase. Asterisks indicate 
statistically significant differences (p < 0.05). 
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3.4.4. Determination of the FRET efficiency by acceptor 
photobleaching 
The FRET effect is based on a transmission of a part of the emission energy of 
the donor to the acceptor fluorophore resulting in reduction of the donor signal. The 
best straight forward approach to prove that an observed FRET signal reflects a true 
interaction between two molecules is to use direct acceptor photobleaching to 
remove (photo-inactivate) the acceptor, thus frustrating the occurrence of FRET and 
monitor the reappearance of the donor fluorescence258–260. To confirm an operational 
FRET process for the NEmo-2 reporter, the acceptor fluorophore was bleached on 
Jurkat T cells which do not express NE. Acceptor photobleaching was performed by 
elimination the acceptor fluorophore with a high energy laser pulse at the excitation 
maximum of the acceptor. As a consequence, intensity of donor fluorophore will 
increase and can be measured quantitatively. This procedure was carried out before 
and after addition of hNE. In the absence of hNE, acceptor photobleaching results in 
enhancement of fluorescent signal of the donor in Jurkat cells and as a 
consequence, the emission ratio of post-bleach donor/pre-bleach donor was highly 
increased (Figure 23A). Therefore, bleaching of the acceptor in the intact reporter 
resulted in an increasing donor and decreasing acceptor fluorescence intensity and 
consequently, the D/A ratio increased (Figure 23A). However, such an increase was 
not observed when the reporter was enzymatically degraded by the addition of hNE 
prior to the bleaching process (Figure 23B). While the method is quantitative, the 
efficiency was calculated for the Jurkat cells and fluorescence intensity of donor, 
acceptor, and respective efficiency was shown (Figure 23C). In absence of hNE, the 
efficiency of acceptor photobleaching was ~37% which in presence of hNE, it was 
reduced to ~9% (Figure 23C). This result shows directly the presence of an 
operational FRET energy transfer between the molecules of the fluorophores on the 
cell membrane of Jurkat T cells.   
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Figure 23 Analysis of operational FRET phenomenon by acceptor bleaching on Jurkat T 
cells. Coumarin 343 (donor; D) was excited with a 405 nm diode laser and emission was sampled 
between 470-510 nm. Sensitized emission of TAMRA (acceptor; A) was sampled between 570-610 
nm. Donor fluorescence and sensitized acceptor emission was imaged and D/A ratio images were 
shown (A) in absence of hNE or (B) in presence of hNE. Photobleaching was carried out on a half of a 
single cell, indicated by an arrow. LUT: blue = low D/A ratio, intact NEmo-2; red = high D/A ratio, 
indicative of cleaved NEmo-2. Scale bar: 20 µm. (C) Acceptor photobleaching was quantified for 
Jurkat T cells. Donor and acceptor fluorescence intensities as well as FRET efficiency were calculated 
in the absence or presence of hNE. 
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3.4.5. Binding and stability of NEmo-2 on neutrophils 
After having shown the stable membrane-binding of NEmo-2 to Jurkat cells, in the 
next step the interaction of the reporter with neutrophils was analyzed. In a first 
approach murine and human neutrophils were incubated with NEmo-2 and cells were 
analyzed by fluorescence microscopy. Surprisingly, the reporter was cleaved on the 
neutrophil membrane even in absence of any exogenous elastase (Figure 24A, B left 
panel). Therefore, no difference was observed after addition of exogenous hNE 
(Figure 24A, B middle panel). Since during cell culture always a low amount of dead 
or dying cells occur, this effect could be caused by elastase derived from leaking 
cells leading to unwanted reporter cleavage. To overcome this problem, neutrophils 
were incubated with the protease inhibitor A1AT. This macromolecular inhibitor is 
membrane-impermeable and, thus, selectively blocks the extracellular pool of NE. In 
presence of A1AT, no spontaneous FRET loss was observed indicating that 
cleavage of NEmo-2 was efficiently prevented (Figure 24A, B right panel). Under 
these conditions, donor as well as acceptor fluorescence remained stable as evident 
from spectral analysis (Figure 24C).  
Taken together, this set of experiments showed that NEmo-2 binds to Jurkat T 
cells as well as murine neutrophils and reporter cleavage by elastase can be 
detected by a loss of FRET. Furthermore, neutrophil-derived elastase is able to 
cleave NEmo-2 enabeling the detection of this enzyme activity on single cell level. 
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Figure 24 Determination of NE activity on murine BM neutrophils. Neutrophils from wild type 
mice were incubated with NEmo-2 in the presence or absence of inhibitor (A1AT). HNE was added to 
neutrophils to achieve maximal reporter cleavage. (A) Donor fluorescence and sensitized acceptor 
emission were imaged and D/A ratio images were calculated. NEmo-2 was rapidly cleaved on 
neutrophils in the absence of A1AT but no cleavage was found in the presence of A1AT. LUT: blue = 
low D/A ratio, intact NEmo-2; red = high D/A ratio, indicative of cleaved NEmo-2. Scale bar, 10 μm. (B) 
D/A ratios showed a ~4-fold increase in the absence of inhibitor over the presence of A1AT. Data of 
one representative experiment with ˃5 cells per group is shown. (C) Change in fluorescence emission 
spectrum of NEmo-2. Neutrophils were analyzed in presence or absence of inhibitor and the emission 
spectra between 450 and 650 nm were recorded. Enzymatic cleavage of the probe leads to strong 
increase in donor fluorescence and a decrease in acceptor fluorescence in absence of inhibitor.  
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3.4.6. Elastase activity in adherent neutrophils 
The establishment of a method which enables the detection of elastase enzyme 
activity in close proximity to the cell membrane provides a new tool for tackling the 
question how cell adhesion can modulate tissue damage without affecting elastase 
release or ROS production (section 3.4.2). To prevent damage from the host, the 
potentially harmful proteinases such as neutrophil elastase are under tight control of 
various proteinase inhibitors such as A1AT which are ubiquitous presented in 
vasculature and surrounding tissues. Although neutrophil elastase has been shown 
to be the key proteinase excuting tissue damage in the experimental EBA, it is 
unclear how this enzyme executes its proteolytical function in the presence of 
inhibitor molecules. To clarify this, elastase activity was determined on neutrophils on 
single cell level by using NEmo-2. To mimic the situation in vivo where proteinase 
inhibitor are present in the local inflamed tissue, the protease activity was evaluated 
in neutrophils in an in vitro experimental setting where neutrophils were activated by 
immobilized IC in presence of A1AT. Neutrophils firmly attached to the surface with 
immobilized IC but not to the control surface coated with irrelevant IgG. Surprisingly, 
although A1AT was present, cleavage of Nemo-2 was observed on the surface of 
neutrophils stimulated with IC, which became visible after 5 min and significant after 
10 min of incubation as compared to the controls (Figure 25A, video 2A-F). As 
expected, no change of the D/A ratio and, therefore, no elastase activity was 
detectable under the latter conditions (Figure 25B). Based on these observations, it 
can be hypothesized that the IC-induced neutrophil adhesion creates a closed space 
between cell and surface where macromolecular inhibitors have no or limited access 
to and in which the released elastase can accumulate in an active state. 
Since the CD18 blockage could specifically inhibit the IC-induced neutrophil 
adhesion, it provides a tool to investigate the role of adhesion in elastase activity 
using this FRET-based in vitro experiment. In accordance to the data presented in 
Figure 26, cleavage of Nemo-2 was observed on neutrophils attached to IC-coated 
surfaces but not to surfaces with unrelated antibodies (Figure 26A). However, 
elastase enzyme activity was significantly reduced on neutrophils which attached to 
IC in the presence of adhesion-blocking antibodies directed against CD18. These 
findings were confirmed by quantitative analysis of the D/A ratios of several cells 
under the same conditions after normalization to the starting value and plotting over 
time. Normalization of the D/A-ratio to the starting value for IC-situmulated 
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neutrophils in the presence of CD18 antibody resulted in an increase of 1.2-fold 
which is lower than D/A ratio for those in absence of CD18 antibody (Figure 26B).  
In summary, these results show for the first time that IC-activated adherent 
neutrophils secrete enzymatically active elastase in close proximity of their cell 
membrane which is resistant to blockade by macromolecular proteinase inhibitors. 
Since blocking of adhesion led to a complete abrogation of this effect, it is likely that 
cell adhesion protects proteases from an access of inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Elastase enzyme activities on IC-activated neutrophils in presence of protease 
inhibitors. Neutrophils were preincubated with NEmo-2 in presence of A1AT and allowed to adhere to 
immobilized IC or irrelevant antibodies of the same isotype. Cells were analyzed by confocal 
microscopy and fluorescence intensities of the donor and acceptor as well as the ratio of the 
intensities of D/A are shown. (A) Cells were able to spread on immobilized IC (but not unrelated 
antibodies) and as a consequence, cleavage of reporter was observed even in the presence of 
inhibitors which became visible after 5 min and significant after 10 min of incubation as compared to 
 
(B) 
 
(A) 
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the controls. LUT: blue = low D/A ratio, intact NEmo-2; red = high D/A ratio, indicative of cleaved 
NEmo-2. Scale bars: 5 µm for IC-stimulated and 20 µm for unstimulated neutrophils. (B) D/A ratios 
were normalized to the starting value and plotted over time. Data of three independent experiments 
were quantified and compared among these groups. Data are presented as mean ± SEM. Statically 
significant differences were indicated by asterics (*p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 Effect of CD18-antibodies on elastase activities of IC-activated neutrophils. (A) 
Neutrophils were loaded with the elastase FRET probe NEmo-2 in presence of A1AT and 
subsequently exposed to uncoated surfaces (upper left panel), to immobilized IC in presence of 
unrelated IgG (upper right panel), or IC in presence of anti-CD18 antibodies (lower left panel) and cells 
were analyzed by confocal microscopy. Fluorescence intensities of the donor and acceptor as well as 
the ratio of the intensities of D/A are shown.Representative data drived from three independent 
experiments are shown. LUT: blue = low D/A ratio, intact NEmo-2; red = high D/A ratio, indicative of 
cleaved NEmo-2. Scale bar: 20 µm. (B) Donor and sensitized acceptor emission was collected for 
different time points and normalized D/A ratio images were calculated. Data of three independent 
experiments were quantified and compared among these groups. Data are presented as mean ± SEM. 
Statically significant differences were indicated by asterics (*p<0.05).  
 
 
 
(B) 
 
(A) 
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3.5. Monitoring neutrophil elastase activity in vivo 
NE has been implicated in the pathogenesis of several key pathologies of 
AIBDs149,261,262. Results from the section above provide a reasonable model how 
neutrophils could exert a proteolytical damage even in the presence of high 
concentrations of proteinase inhibitors. However, the situation in vivo differs 
substantially from the rather linear and defined conditions of the in vitro experiment. 
In the living organism, neutrophils are exposed not only to a single stimulus like 
immobilized IC but to a variety of different activators and inhibitors which may vary 
during different phases of the inflammatory process. Furthermore, inflammation 
appears as a highly dynamic process where neutrophil migration, adhesion, 
detachment, and degranulation may occur in several repeated sequences. Therefore, 
the determination of elastase activity under conditions in vivo appears to be 
mandatory to prove the relevance of this model. Elastase protein has been detected 
in intact tissues so far only by immunohistology which provides no information of the 
activity status of the enzyme. Alternatively, the determination of protease activity in 
tissue extracts leads to the loss of the spatial information. Consequently, in the next 
series of experiments the application of FRET reporters for the analysis of elastase 
activity by MPM in vivo was performed. 
 
3.5.1. FRET reporter performance on Jurkat and neutrophil cells in 
vitro by MPM 
In a first approach, settings on the multi-photon microscope were established, 
which allow the detection of intact and processed reporter as shown previously for 
confocal microscopy (section 3.4.3 and 3.4.5). Therefore, both Jurkat cells and 
neutrophils were incubated with the reporter and donor (D) fluorescent emission and 
the sensitized emission of the acceptor (A) was imaged by MPM. For neutrophils, the 
inhibitor A1AT was used to prevent unwanted cleavage of the reporter. NEmo-2 was 
exited with 920 nm. Emitted light was detected by 4 wavelength separated PMTs 
(<435 nm, 453-495 nm, 495-560-560 nm and >560 nm). NEmo-2 was rapidly cleaved 
in the presence of exogenous elastase on Jurkat cells (Figure 27A) and by activation 
of neutrophils by immobilized IC (Figure 27B). Therefore, results obtained previously 
by confocal microscopy could be directly reproduced by using the MPM. 
      RESULTS 83 
 
 
 
 
 
 
 
 
Figure 27 Performance of NEmo-2 reporter on Jurkat cells and neutrophils by using 2-
photon microscopy. To study NEmo-2 performance in the context of a living cell-based model by 2-
photon microscopy, Jurkat T cells and neutrophils were incubated with the reporter. Donor 
fluorescence and sensitized acceptor emission was imaged and D/A ratio images were calculated. 
D/A ratios were normalized to the starting value and plotted over time. After addition of exogenous NE 
(min 4) in the case of Jurkat cells (A) and activation of neutrophils by IC (B), a strong increase in the 
D/A emission ratio was observed.  
  
 
3.5.2. Monitoring of neutrophil responses to tissue damage 
To analyze elastase activity in vivo, a local model of EBA was established in mice 
by application of a single dose of amCOLVII IgG into the ventral side of the ear. In 
this model, neutrophils were raised and labeled in vitro and subsequently adoptively 
transferred in to the inflamed ear.  
However, as a prerequisite to this technique, infiltration of neutrophils and their 
migration towards the pathogenic antibody have to be documented in inflamed 
tissue. To examine the migration and influx of neutrophils following binding of 
pathogenic antibodies to their antigens in vivo, experimental EBA was induced locally 
by application of anti-mCOLVII IgG labeled with DyLight 649 intradermally into the 
ear of lys-eGFP mice. In these mice, eGFP gene is inserted into lysozyme M (lys) 
 
(A) 
 
(B) 
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locus which is expressed specifically in myelomonoytic cells263,264. Consequently, 
eGFP is present specifically in the myelomonocytic lineage with the strongest 
expression in mature neutrophils, while cells from other lineages remain non-
labeled211. Recruitment of GFP-labeled neutrophils to the site of damage was 
investigated 24h after antibody injection in inflamed ear. Green neutrophils could be 
observed in high numbers in regions where the red-labeled pathogenic antibodies 
were present (Figure 28A, video 3A). A virtual side view based on the combining of 
several stacked images confirmed these data and indicated the presence of 
neutrophils in close proximity to the antibodies (Figure 28B, video 3B). These results 
show that the intrinsic neutrophils migrate to the area of tissue damage which 
antibody is present. 
 
 
 
 
 
 
 
 
 
Figure 28 Migration of intrinsic neutrophils to the site of pathogenic antibodies. Local 
antibody transfer model of EBA was induced by a single dose injection of anti-mCOLVII labeled with 
DyLight 649 intradermally into the ventral ear skin of lys-eGFP mice. Neutrophil migration towards 
pathogenic antibody was monitored by two-photon microscopy. Results indicate the recruitment of 
neutrophils in close proximity of the antibody. Top image (A) as well as a side view generated by stack 
analysis demonstrates the close proximity of neutrophils to the pathogenic IgG (B). EGFP appears as 
green color while deposition of anti-mCOLVII is shown in red. Results of one experiment are shown.  
 
 
(A) 
 
(B) 
      RESULTS 85 
In the next step, the functional integrity of adoptively transferred neutrophils was 
monitored by their capacity to move within the tissue. To identify exogeneous 
neutrophils and to examine their cellular dynamics, neutrophils were first labeled by 
cell tracker component and injected into the ventral side of the mouse ear. To induce 
migration of these cells, an inducible model of sterile skin injury was used in which a 
brief intense two-photon laser pulse causes focal, dermis-restricted tissue damage. 
Focal tissue damage was set 2 h after injection of neutrophils and cell migration was 
imaged by MPM. Focal injury induced a first neutrophil migration into the area of 
tissue damage after 5 min and cells accumulated as an increasing cluster at the 
damage site that lasted more than 30 min (Figure 29A, video 4A). Track analysis was 
performed to provide a clear state of neutrophils as well as their direction toward the 
tissue damage (Figure 29B, video 4B, C). Red dots represent neutrophils and lines 
show the direction of these cells from the early step to the final area by shifting their 
colors from blue to red, respectively. These data indicate that the injected neutrophils 
respond adequately to a damage signal and that quality and numbers of cells are 
suitable for the further experiments. 
 
 
 
 
 
 
 
 
 
 
(Figure legend on the following page) 
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Figure 29 Response of adoptively transferred neutrophils to focal tissue damage. BM-
derived neutrophils from Balb/c mice were labeled with cell tracker and injected intradermally into the 
ventral ear skin 2 h before laser-induced focal tissue damage was set. Neutrophil recruitment towards 
focal damage (white arrow; green spot) was recorded by multi-photon microscopy over a 30 min time-
lapse (A). Neutrophils (red dots) were identified and cell migration was followed by track analyses (B). 
Tracks are indicated by colored lines. Migration areas of neutrophils are shown by direction lines 
which their color shifts from blue to red reflecting from the early step to the final area, respectively. 
Results of one representative experiment out of three experiments are shown. Scale bar: 50 µm. 
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3.5.3. Neutrophil activation in experimental EBA in vivo 
To analyze NE activity in vivo, experimental EBA was induced locally in the ear by 
application of anti-mCOLVII IgG intradermally simultaneously with administration of 
inhibited and FRET probe-labeled BM-derived neutrophils into the ear of wildtype 
Balb/c mice. Irrelevant isotype antibody was injected together with neutrophils as a 
control. Intravital multi-photon imaging of NE activity on the surface of injected 
neutrophils by NEmo-2 probe indicate elastase enzyme activity on neutrophils in 
pathogenic antibody treated mice ear (Figure 30A) as compared to the controls 
(Figure 30B). Neutrophils accumulated in regions of anti-mCOLVII IgG deposition 
(Figure 30A). Monitoring of neutrophils confirmed the FRET loss on NEmo-2 sensor 
as cleaved by NE released from activated neutrophils by IC even in the presence of 
A1AT. While only low elastase activity could be detected in ears treated with the 
irrelevant isotype antibody, the percentage of activated cells significantly increased in 
neutrophils in ears treated with the pathogenic antibody (Figure 30C). The 
percentage of activated cells was defiened as the D/A ratio value comparing with the 
cell number observed in donor chanel. Since the donor signal of the cells is different, 
some value exceeds the maximum percent. These results provide clear evidence 
that, despite the presence of tissue protease inhibitors, NE activity is detectable in 
diseased tissue.  
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Figure 30 NE activities on activated neutrophils by IC in an in vivo mouse model of EBA. 
NEmo-2-labeled neutrophils as well as anti-mCOLVII antibody were injected in presence of A1AT into 
the ear of wildtype Balb/c mice (A). Irrelevant isotype antibody served as control (B). NE activity on the 
(A) 
(B) 
 
(C) 
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surface of administrated neutrophils in mice ears was quantified by multi-photon microscopy. Images 
of donor and acceptor fluorescence were processed to calculate ratio values (A, B). Scale bars: 30 
and 50 μm for (A) and (B), respectively. Results of one representative experiment out of 13 are 
shown. NE activity was quantified as the percentage of activated cells which was defined as the D/A 
ratio value comparing with the cell number observed in donor chanel (C). Data are given as mean 
value out of 8 (amCOLVII IgG) and 5 (control isotype IgG) independent experiments. Observations 
indicated significantly increased the number of activated neutrophils comparing with unstimulated 
cells.  
 
 
According to the current models of neutrophil activation, neutrophils should 
migrate from the periphery to the site of inflammation where they undergo a tight 
adhesion and exert further effector functions. Following our model, this tight adhesion 
is a prerequisite for protecting neutrophil proteases from an access to proteinase 
inhibitors. To examine whether the observed elastase activity in anti-mCOLVII-
treated tissue is indeed associated with an increased adhesion of the cells, the 
capacity of neutrophils to migrate to a second inflammatory signal after first contact 
to pathogenic antibody was determined. To this end, focal tissue damage was 
applied in the area which anti-mCOLVII antibodies were bound to their antigens 
(Figure 31, video 5; blue area). The tissue damage signal still induced the attraction 
of injected neutrophils from distant sites, which became visible after 10 min. 
However, different to the result obtained in tissue treated with the pulse alone (Figure 
29A, video 4A), in presence of pathogenic antibody, neutrophils became adherent 
during their migration and did not accumulate around the damage site (Figure 31, 
video 5). In summary, these findings suggest that increased elastase activity indeed 
correlates with enhanced adhesion of the cells.  
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Figure 31 Damage-induced neutrophil migrations in presence of IC. NEmo-2-labeled 
neutrophils (fluorescence depicted as D/A ratio together with donor signal, bright small dots) as well as 
anti-mCOLVII antibody conjugated to DyLight 649 (blue color) were simultaneously injected in 
presence of A1AT into the ear of wildtype Balb/c mice. After 2h, focal tissue injury was applied (arrow) 
and the dynamics of administrated neutrophils was subsequently monitored over 90 min. Results of 
one representative experiment out of three are shown. Scale bar: 50 μm. 
 
 
In the next step, spatial dynamics of elastase activity on the cells in vivo was 
analyzed. According to the findings derived from the static model in vitro, FRET 
reporter cleavage appeared to be rather homogenously distributed on the surface, 
most likely on the side of attachment to the surface with no significant changes over 
time (Figure 25A, video 2A-C). However, analysis of single cells in vivo revealed a 
completely different pattern. When neutrophils were bound to the pathogenic 
antibody, NE activity was only seen in very small defined areas on the cell surface 
(Figure 32, Video 6). Furthermore, regions of enzyme activity displayed high temporal 
dynamics and persisted mainly less than 30 sec (Figure 32, Video 6). As a result, 
increased D/A ratio were emitted only in some of the time sequences which the 
adhesion site might be visible. 
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Figure 32 NE activities at the adhesion site of activated neutrophils in vivo. Local EBA was 
induced by single injection of anti-mCOLVII to the ventral side of ear. Thereafter, neutrophils were 
labeled with NEmo-2 reporter in presence of A1AT. NE activities were determined on single neutrophil 
at different time-points over a 15 min time-lapse by multi-photon microscopy. D/A ratio (violet color) 
together with donor signal (green color) are shown. Result of one representative experiment is shown. 
Scale bar: 10 μm. 
 
      RESULTS 92 
Based on findings shown in the previous part, neutrophils respond to the signals 
derived from tissue damage and migrate to this point. Irrespective to adoptively 
transferred cells, endogenous neutrophils are also recruited to the site of damage. As 
a consequence, activation of endogenous neutrophils and the subsequent release of 
NE may also affect the sensitive reporter on the transferred neutrophils. To analyze 
the potential cleavage of NEmo-2 on the transferred neutrophils by elastase derived 
from endogenous sources, a NE-deficient (NE-/-) mouse strain was used. For this 
purpose, experimental EBA was induced locally by administration of anti-mCOLVII 
IgG intradermally simultaneously with administration of inhibited and FRET probe-
labeled neutrophils into the ear of NE-deficient mice. NE activity was observed on the 
surface of injected NEmo-2-labeled neutrophils as imaged by intravital multi-photon 
which indicate elastase enzyme activity on neutrophils in inflamed area of pathogenic 
antibody treated mice ear (Figure 33). Imaging of neutrophils confirmed the FRET 
loss on NEmo-2 sensor as cleaved by NE derived from exogenous activated 
neutrophils by IC in the presence of A1AT. These results provide obvious state that 
NE activity is detectable in diseased tissue by NE released by exogenous neutrophils 
which NE-derived from intrinsic neutrophils are excluded. 
 
 
 
 
 
 
 
Figure 33 NE activities on exogenous activated neutrophils in an in vivo NE
-/- 
mouse model 
of EBA. NEmo-2-labeled neutrophils as well as anti-mCOLVII antibody were injected into the ear of 
NE-deficient (NE
-/-
) mouse in presence of A1AT. NE activity on the surface of administrated 
neutrophils in mice ears was quantified in presence of IC. Images of donor and acceptor fluorescence 
were processed to calculate ratio values. Since the excitation wavelengths of anti-mCOLVII and 
acceptor are in the same range, antibody and direct acceptor emissions are shown as a single image 
(lower left panel).Scale bars: 30 μm. Results of one representative experiment are shown.  
 
      RESULTS 93 
Taken together, a novel method allowing the detection of NE activity in close 
proximity to cell membranes of living cells has been established in this study. By 
using a lipidated FRET-based proteases sensor, NE enzyme activity could be 
detected in experimental models of EBA in vitro and in vivo even in the presence of 
protease inhibitors. Although elastase release from activated neutrophils was shown 
to be independent from cell adhesion, resistance of protease activity to 
macromolecular inhibitors was strictly reliant on neutrophil adherence. These findings 
provide evidence for a model, in which adherent neutrophils release proteases in a 
sealed gap between cell and the attached surface where an access of the inhibitors 
to the proteases is prevented. 
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4. DISCUSSION 
Neutrophils are involved in the pathomechanism of AIBDs as an important 
component of effector and regulatory pathways124. They contributed as executors of 
tissue damage in the concept of effector function by releasing several aggressive 
components such as ROS and serine proteases like elastase126,149. In addition to this 
effector phase, neutrophils are considered as regulators of inflammation which 
communicate with other immune cells by cell-cell contacts or secretion of 
mediators124. Although the fundamental pathogenic function of neutrophils has been 
under broad investigation in the tissue damage of human and experimental AIBDs, 
the neutrophil regulatory mechanisms as well as their mode of action in execution of 
the disease remain unclear. In the current study, the potential of neutrophils to 
regulate disease by MRP-8/-14 proteins as well as to execute tissue damage by NE 
was investigated. Currently, in vitro and in vivo quantification of NE activity on a 
single cell at the site of action as well as expression and potential function of MRP-8/-
14 in AIBDs is not described so far. Therefore, the understanding of MRP-8/-14 
proteins as well as NE contribution in the pathogenesis of EBA or BP diseases could 
help to identify novel therapeutical targets for developing new strategies in the 
treatment of AIBDs.  
 
4.1. Involvement of neutrophils as executors of tissue damage 
In experimental models of AIBDs, neutrophils are present at high numbers at the 
autoimmune lesional sites136,265 which are recruited in a successive multistep fashion 
of adhesion, chemotaxis, and migration from the blood to inflammatory sites266. They 
are well equipped with an arsenal of microbicidal effector molecules, including ROS 
and proteinases. That weaponry may not only be harmful for pathogens but it could 
also damage components of the host tissues. Moreover, aberrant activation of 
neutrophils is believed to be an important factor of several disease processes, 
associated with immune-mediated damage to host tissues267. Of the various 
enzymes secreted by neutrophils at the sites of inflammation, NE represents an 
inflammatory serine protease mediating important protective functions under 
physiological and pathophysiological conditions including remodeling of the ECM and 
host defense against infections128,268. While it plays a beneficial role in innate host 
defense, unbalanced NE can lead to organ damage and dysfunction269,270. Beside 
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the reports of NE implication in numerous inflammatory and chronic diseases like 
AIBD, COPD, or cystic fibrosis149,271–274, there is also some evidence of the presence 
of lesional elastase activity in dermatitis275 and a destructive role of NE in bullous 
diseases such as EBA and BP139,276. NE-deficient mice do definitely not develop 
experimental BP despite a normal IgG and C3 deposition found at the basal 
membrane zone149. Reconstitution of NE-deficient mice with intradermal injection of 
wild type neutrophils results in a recovered susceptibility to experimental BP149, 
indicating a significant role of neutrophils in disease pathogenesis. Therefore, 
neutrophil counts and NE activity can be considered as clinical parameters to 
determine the inflammatory status in many diseases such as AIBDs. Moreover, it has 
been shown that inhibition of neutrophil proteases could reduce neutrophil infiltration 
and neutrophil-mediated injury in different models of inflammation, such as collagen-
induced arthritis, endotoxin-induced acute lung injury, and ischaemia and reperfusion 
injury131–133. Consequently, a specific imaging agent would prove invaluable for 
understanding the biological functions of NE and the development of NE inhibitors. 
Under inflammatory condition, neutrophils transmigrate from the blood vessels 
into the tissue and become activated at sites where large amounts of inhibitory 
molecules are present277,278. Nevertheless, proteolytic properties of neutrophil 
proteases remain active despite the presence of inhibitors277,278. It has long been 
unclear how neutrophil activation and elastase activity can occure in vivo and how 
neutrophil elastase subsequently mediate tissue damage in presence of protecting 
proteases inhibitors. This highlights the relevance of novel tools for the detection of 
NE activity and the understanding of the contribution of NE in the pathogenesis of 
neutrophil-dominant inflammatory diseases. Until now, analysis of neutrophil 
activation in terms of protease release is limited to the determination of the enzymes 
or the corresponding enzyme activity in solution, e.g. in body fluids or culture 
supernatants. A site-specific analysis of neutrophil degranulation on single-cell level 
in diseased tissue, organs, or living animals was not possible so far. In this study, a 
method was established by using a FRET reporter to visualize neutrophil protease 
activity (NE) in experimental models of autoimmunity to COLVII (EBA) in vitro and in 
vivo. Therefore, the providing better visualization of neutrophil activation and 
subsequently enzyme release in disease could help to develop new strategies to 
prevent the host from harmful attacks by these cells. 
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NE activity was visualized on mouse BM differentiated as well as human 
peripheral neutrophils by using lipidated FRET reporter NEmo-2. The lipidated 
reporter NEmo-2 has been synthetized for monitoring of NE activity on neutrophil cell 
membranes which were previously successfully applied for in vitro analysis165. 
However, before analyzing the NE activity on the neutrophils, Jurkat T cells were 
used as controls which do not express endogenous elastase. As shown, NE activity 
could be detected on the cell surface in the presence of exogenous NE. In the 
absence of the exogenous elastase, the reporter was stable on the cell membrane 
for several hours. This provides first evidence of a proper interation between donor 
and acceptor fluorophores which are in close apposition on the cell membrane 
whereby the excitation energy of the donor fluorophore is transferred to the nearby 
acceptor. To confirm this interaction between the two fluorophores and to prove the 
presence of appropriate FRET efficiency, acceptor photobleaching was performed by 
comparing donor fluorescence intensity on the cell surface of Jurkat T cells before 
and after quenching the acceptor. Photo-inactivation of the acceptor fluorophore 
results in an increase of the donor signal, confirming the occurrence of FRET 
process between the molecules of the fluorophores. 
NE activity was also found to be localized on neutrophils. However, the reporter 
was not stable here and rapidly degraded also on the surface of unstimulated cells. 
This unwanted cleavage resulted most likely from NE derived from leaking 
neutrophils which is seen also as background activity in the supernatants of 
unstimulated cell (Figure 21C). To avoid this cleavage and to stabilize the reporter on 
the cell membrane, the inhibitor A1AT was used. Antiprotease A1AT, a 55-kDa 
serum glycoprotein, is primarily  synthesized in the liver and inactivates NE which is a 
monomeric, approximately 30-kDa glycoprotein270. Its major function is to protect 
tissue elastin from NE-mediated destruction by irreversible covalent binding to the 
enzyme279–281. Since NE is capable of degrading most of the constituents of 
connective tissue matrices, its inhibitor A1AT is thought to play a critical role in 
connective tissue turnover in homeostasis and tissue injury/inflammation279,282. In 
presence of A1AT, no elastase activity was detected on neutrophils and the reporter 
remains stable on the surface comparable to Jurkat cells. 
Apart from the advantage of using inhibitor which helps for stabilizing the reporter 
on neutrophils, the complete blocking of NE by inhibitory molecules disable 
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determination of NE as a consequence of neutrophil activation. However, although 
elastase activity is inhibited on neutrophils in presence of A1AT in vitro, it does not 
neccessarily reflect the physiological conditions. In vivo, neutrophil protease activity 
is preserved in the extracellular environment even when inhibitors are present. The 
accurate and detailed process is not completely clear and remains a topic of some 
debate. Nevertheless, it has been shown that a massive quantity of the proteases 
released from neutrophil granules bind to the plasma membrane where their catalytic 
activity is preserved283–285. Therefore, it is suggested that this tight binding to the cell 
membrane makes the extracellular neutrophil proteases inaccessible to circulating, 
large molecule endogenous inhibitors, and therefore remain resistant130,283–285. Other 
studies have proven that protease inhibitors can be suppressed and inactivated by 
the large proportions of proteases and oxidants released by neutrophils that 
accumulate to the site of inflammation285. Soluble mediators such as proteases, 
cationic peptides, and ROS released by transmigrating leukocytes may influence 
epithelial permeability and function286,287. This influence together with the importance 
of soluble substances in neutrophil-epithelial interactions is emphasized where toxic 
mediators are not released by neutrophils into circulation, but they are released only 
once they are adherent to the endothelium, interstitium, or epithelium286,287. It is 
hypothesized that released proteases are compartmentalized between the adherent 
neutrophil and the ECM. This microenvironment excludes the large, circulating 
protease inhibitors and results in achievement of high concentrations of 
proteases130,285,288,289. This hypothesis so called ‘‘protected space’’ or ‘‘closed space’’ 
hypothesis which has been proposed three decades ago and used to explain the role 
of neutrophil adhesion in antibody dependent cellular cytotoxicity and anti-tumor 
immunity254–257. However, to my knowledge, this hypothesis has not been proven 
experimentally.  
By using a membrane-bound protease sensor in this study, this hypothesis is 
supported by the direct evidence that IC-induced neutrophil adhesion is required for 
elastase to escape from the access of proteinase inhibitors. Our results suggest that 
a fine cooperation exists between IC-induced adhesion and NE in the tissue damage. 
To test this hypothesis, the neutrophil protease activity was determined in an in vitro 
experimental setting where neutrophils were activated by immobilized IC in presence 
of A1AT. Therefore, neutrophils were preincubated with Nemo-2 reporter and A1AT 
as NE inhibitor was applied to the neutrophils. NE has no membrane domain, but its 
    DISCUSSION 98 
overall positive electrostatic potential is thought to induce interaction with the 
negative electrostatic potential of the membrane290. Under physiological conditions, 
this pool of NE might allow a controlled proteolysis directed by migration of the 
neutrophil to the target tissue. As shown here, neutrophils tightly attached to the 
surface with immobilized IC release their elastase enzymes which remain active in 
presence of A1AT. Cleavage of Nemo-2 reporter became visible on the surface of 
neutrophils stimulated with IC shortly after incubation. Noteworthy, IC-induced 
neutrophil adhesion establishes a secluded region between cell and surface whereby 
macromolecular inhibitors are excluded and released elastase can accumulate in an 
active state. Partial blocking of adhesion by anti-human CD18 antibody, which did not 
affect the IC-induced release of elastase, resulted in the complete loss of elastase 
activity in the presence of A1AT. This may indicate that already a limited disturbance 
of the closed space could be sufficient to allow the entry of inhibitory molecules.  
 
4.2. NE activity in vivo 
Due to the importance of NE in the pathogenesis of various diseases, the 
development of techniques to spatiotemporally visualize and quantify disease-
associated NE in vivo is an active field of research in many laboratories. Advances in 
optical imaging techniques could provide new tools for understanding the roles of NE 
in disease onset and progression, as well as in the development and assessment of 
specific NE inhibiting therapies. Clinical applications of NE imaging may also help in 
diagnosis, staging of disease, and monitoring of treatment efficacy. In recent years, 
intense research efforts have been done in recognition of immune responses in the 
skin which lead to better understanding of the immune cell functions in the skin. This 
could help to develop new strategies or improved treatments for inflammatory skin 
diseases and preventing the host more effectively from harmful attacks by immune 
cells. Local microenvironment within a specific tissue such as skin can influence the 
immune cell function. Therefore, as compartment-specific imaging can be readily 
performed291–296, using intravital imaging approaches could be an opportunity to 
address biological questions. Relatively low depth of light penetration and/or spatial 
resolution296 in conventional microscopy techniques such as confocal or fluorescence 
microscopy could influence the quality of in vivo imaging of immune responses in the 
skin. Multi-photon intravital imaging represents a powerful technique with the 
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capacity to address complex immunological questions quantitatively. MPM enables 
the direct in vivo visualization, with high spatial and temporal resolution, of 
fluorescently tagged immune cells, ECM and vasculature in tissues. Therefore, this 
technique has this capacity to perform dynamic and multidimensional imaging and 
track the cell populations at the single-cell level in vivo291,293. Thus, common methods 
of determining immune cell function in the skin are mainly based on histology and 
flow cytometry can be obviously replaced by this powerful alternative approach.  
In the present study, an experimental procedure241 of intravital multi-photon 
imaging was used in mouse ear skin, to address a couple of questions regarding NE 
activity in vivo. Animal models offer an oppourtunity to analyze and understand 
disease mechanisms on a molecular level297. An experimental mouse model of EBA 
was used to address the role of NE on disease pathogenesis in vivo. The response 
of neutrophils during skin inflammation and analysis of neutrophil behavior in the 
context of the skin microanatomy are important points which by using novel FRET 
probes as well as a powerful imaging technique could be addressed. The ultimate 
goal of this part of study was to visualize NE activity in vivo and to proof its potential 
dependency on cell adherence. Although some attempts have been done to detect 
and quantify NE activity in vivo by using a NE-specific near-infrared fluorescence 
imaging agent298,299, but still reliable monitoring of protease activity in a complex 
matrix at the level of intact cells is missing. Moreover, it should be considered that the 
protease activity, rather than its protein quantity, is indicative of disease status. 
Consequently, the immunological methods are limited and rarely applied in screening 
protease inhibitors. Classical biochemical methods for measuring activity of 
proteases300 including liquid chromatography and gel electrophoresis are time 
consuming, and thus, can not be easily adapted for high throughput analysis of 
samples. The commercially available NE detection substrate is optimized towards the 
enzyme of human origin and moreover they can only be used for an in vitro analysis. 
As a consequence, although a substrate sequence with increased specificity towards 
murine NE has been recently identified and optimized146, both sensitivity and 
specificity towards the murine counterpart are insufficient to monitor enzyme activity 
in vivo. Therefore in present study, the use of a newly developed specific NE reporter 
agent, NEmo-2, was described to detect and quantify NE activity in vivo, in real time 
in a mouse model of EBA. To this end, a local EBA mouse model was first validated 
which induced by injecting antibody against COLVII into the ear and results in 
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inflammation and tissue damage in the skin characterized by massive neutrophil 
infiltration and degranulation. As expected and observed in the histopathology of the 
ear skin, antibody administration resulted in a significant increase in the number of 
inflammatory cells, particularly neutrophils. Since neutrophil activation and 
corresponding NE release could be a very fast procedure and because of applying a 
single injection into the ear skin, NEmo-2 reporter-labeled neutrophils were 
administrated intradermally together with pathogenic antibody or irrelevant isotype 
antibody into the ventral side of mouse ear. The fluorescence signal emitting from the 
reporter inside the skin of mouse ear was detected by a multi-photon imaging 
microscopy. Significantly higher D/A ratios indicating increased levels of NE activity 
were visualized in the ear skin of EBA mice as compared to controls which had very 
low detectable D/A ratio emmision fluorescence. The activation of administrated 
neutrophils immediately started after binding to the pathogenic antibody. By using a 
fluorescent-labeled pathogenic antibody, activated neutrophils which bound to the 
antibody were detectable. Focal skin tissue damage was applied and restricted to the 
dermal layers near to the injection part to attract neutrophils. In control experiment, 
neutrophils migrate rapidly to the site of laser shooting. Interestingly when pathogenic 
antibody is present, neutrophils recruit to the area of tissue damage and they are 
trapped by the antibody. These findings are in agreement with the results indicating 
secretion of active elastase from IC-activated adherent neutrophils in close proximity 
of their cell membrane to the pathogenic antibody which is resistant to blockade by 
proteinase inhibitors in protected space. NE released by non-adherent neutrophils 
lacked activity and, most likely, was blocked by inhibitory molecules penetrating to 
the exposed space. As shown in Figure 32, NE activitiy was observed only in 
temporal regions of the cell surface by cleavage of NEmo-2 reporter at the adhesion 
site of activated neutrophils in vivo. This could be due to a gradient of NE located on 
the membrane which might be controlled by an opposing gradient of antiproteases 
and thus restricting highest NE activity in close proximity to the membrane. However 
as mentioned before, NE activity is observed inside the protected space which most 
likely is free of inhibitors. Therefore, observing a partial cleavage by NE on the 
surface of neutrophils is expected. This shows the advantage of the lipidated reporter 
on which the signal is accumulated on single cells. Specificity of the signal was 
shown by using control NE-deficient mice or irrelevant isotype antibody in wild type.  
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Based on these findings, a model can be proposed how IC-activated neutrophils 
contribute to tissue damage in experimental EBA (Figure 34). After recruitment to the 
skin, neutrophils are activated by the immobilized anti-COLVII/COLVII IC via FcγR. 
During activation, neutrophils tightly adhere to the DEJ and form a protected space 
preventing a molecular exchange with the environment. The subsequent 
degranulation process leads on the one hand to a production of ROS which are 
capable to destroy residual amounts macromolecular inhibitors and on the other 
hand to a strong accumulation of proteinases which together results in an overrun the 
inhibitory control mechanisms. As a consequence, uncontrolled elastase activity 
inaccessible to exogenous inhibitors will attack and destroy the structure proteins of 
the DEJ. 
 
 
 
 
 
 
 
 
Figure 34 Model of autoantiboy-induced tissue damage. Neutrophils are activated by the anti-
COLVII-COLVII immune complex via FcγR. Consequently, the activated neutrophils generate ROS 
and release elastase and other proteinases. When neutrophil adhesion is prevented (left panel), 
proteinases will be bound to inhibitors and ROS will be deactivated by scavengers resulting in tissue 
protection. If neutrophils can properly adhere to the target structure during activation (right panel), a 
2-integrin-stabilized closed space will prevent the access of inhibitors and scavangers to proteinases 
and ROS enabling uncontrolled activity of these mediators leading to tissue damage. 
Inhibition of proteinases as a therapeutic concept has been under broad 
investigation since more than 30 years. Despite this scientific effort only the elastase 
inhibitor Sivelestat has been approved for clinical use in Japan301. Patients suffering 
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from EBA and other AIBDs are currently treated with systemic immunosuppressive 
drugs or IVIG and no agents targeting the effector phase of these disorders have 
been developed until now68,302. The ideal treatment of the terminal phase of the 
disease should reduce efficiently neutrophil-mediated tissue damage without 
provoking side-effects like a broad restriction of the host defense against microbial 
invaders. Imaging of NE release in the protected space which is protected from the 
inhibitory effects of inhibitors might open a therapeutic avenue for EBA and other 
related diseases. Breaking the closed space of adherent neutrophils could facilitate 
the access of intrinsic as well as therapeutic inhibitors at the site of tissue damage. 
 
4.3. Neutrophil MRP-8/-14 proteins in the regulation of EBA and 
BP 
The results of the present study revealed a mechanistic explanation how 
proteases released by IC-activated neutrophils could promote tissue damage and 
destruction in vivo. This pathway obviously refers to the mechanisms by which 
neutrophils execute their effector functions in pathophysiology of AIBDs and directly 
cause tissue destruction. However, understanding of the direct pathogenic effects 
mediated by neutrophils covers only a part of the pathogenic potential of these cells. 
Today, it becomes more and more clear that neutrophils have also the capacity to 
regulate the immune response and as a consequence, indirectly influence the 
pathogenesis of the diseases. Therefore, it is hypothesized that neutrophils most 
likely contribute to the effector phase indirectly by the secretion soluble mediators like 
MRP-8/-14 proteins leading to amplification and maintenance of the inflammatory 
loop. Nevertheless, while some evidence have indicated the contribution of MRP-8/-
14 in the regulatory phase of autoimmune-mediated diseases in human and 
experimental models190,205,208, other studies provide a number of question marks on 
these results209, so that the importance of these proteins in autoimmune diseases 
remains as a matter of debate. At the beginning of my studies, the potential role of 
MRP-8/-14 in AIBDs was not investigated. 
Beside their critical functions in normal physiological pathways within cells, 
increased expression of MRP-8 and MRP-14 proteins is associated with many 
chronic diseases in humans such as autoimmune disorders, cancer, atherosclerosis, 
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cardiomyopathies and neurodegenerative diseases194,205,303–306. In most cases, these 
proteins are associated to proinflammatory mechanisms and a significant 
overexpression of them at the sites of inflammation as well as a strong correlation of 
their serum concentrations to inflammation have been indicated190,207,307–309. In this 
study, increased serum concentrations of MRP-8/-14 were observed in EBA and BP 
patients as well as in experimental disease. These results are in agreement of 
previous studies concerning to other AIDs. For example, MRP-8/-14 has been 
detected in serum and synovial fluid of patients suffering from juvenile idiopathic 
arthritis (JIA)175 and a relationship has also been identified between their serum 
concentrations and individual disease activity in long-term studies in children185,218,310. 
Elevated serum concentrations of MRP-8/-14 have also been found in systemic AIDs 
such as systemic lupus erythematosus (SLE) and are related significantly with the 
SLE disease activity index311.  
Increased expression of MRP-8/-14 proteins in diseased tissue is frequently 
associated with an infiltration of neutrophils into regions of acute and chronic 
inflammatory lesions186. Initially, these proteins have been identified in RA, in which 
activated phagocytes expressing MRP proteins are among the first cells infiltrating 
inflammatory lesions in the synovium190,307. Furthermore, phagocytes expressing 
MRP-8/-14 have been observed as proinflammatory cells at sites of intestinal 
inflammation in chronic inflammatory bowel disease312,313. Based on several 
investigations, this heterodimeric protein complex was designated as a potential 
biomarker of disease activity in inflammatory arthritis and other AID states where 
myeloid cells play a crucial role202,207. In AIBDs such as inflammatory EBA and BP as 
well as in their corresponding mouse models, subepidermal blistering is associated 
with varying extents of cellular infiltrates68,90,116,314 in which neutrophils represent the 
most abundant inflammatory cell type. This massive infiltration of inflammatory cells 
into regions of skin lesions could be confirmed in my models of EBA and BP where 
the diseases were induced by transfer of amCOL VII or XVII antibodies, respectively. 
Furthermore, significant numbers of neutrophils identified by their expression of NIMP 
were detected in these infiltrates. Noteworthy, the numbers of neutrophils correlated 
with the numbers of MRP-8/-14-positively stained cells in the lesional skin. These 
data confirm on the cellular level the previously observed increase in expression of 
MRP-8/-14 genes and proteins in diseased tissue. Furthermore, since these proteins 
are mainly expressed by neutrophils, the data suggest that this upregulation is most 
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likely caused by an infiltration of neutrophils. These finding clearly indicate that MRP-
8/-14 proteins as a biomarker of chronic inflammation are not limited to rheumatoid 
arthritis (RA) or inflammatory bowel disease but may be also relevant to detect an 
ongoing inflammation in AIBD. 
While the correlation between disease manifestation and MRP-8/-14 expression 
appears to be rather clear, their functional role in chronic disorders is a matter of a 
controversial debate. To delineate MRP-functions in vivo, we and others have used 
Mrp-14-deficient mice in different disease models. MRP-8 (10 kDa) and MRP-14 (14 
kDa) proteins are constitutively expressed in circulating neutrophils and 
monocytes186,315. Although it has been shown that these two proteins can exist as 
homo- and heterocomplexes, they preferentially form heterodimers or 
heterotetramers in a Ca2+ and Zn2+ dependent way192,316–320. Although MRP-8/-14 
homo- and hetero-oligomers may have distinct roles in cell physiology, it is well 
accepted that the predominant form in which MRP-8/-14 associates in physiological 
and pathological conditions is the heterodimer, even if it has been observed that 
MRP-8 and MRP-9 could also form homodimers318,321. Mrp-8 deficient mice show a 
lethal phenotype322, while Mrp-14 knockout mice are perfectly viable and no major 
differences in inflammatory response have been observed compared to wild type 
animals197. Importantly, I could confirm previous findings that due to the instability of 
MRP-8 in Mrp-14 knockout mice, in these strains both MRPs are not detectable. In 
contrast to my initial hypothesis that a lack of MRP-8/-14 may be protective in AIBD, 
Mrp-14-/- and wild type controls in systemic EBA developed a comparable clinical 
phenotype of the disease. The percentage of regional affected skin did not 
significantly differ between knockout mice and wild type controls. Moreover, 
histological examination of the skin revealed no differences in antibody or 
complement deposition as well as in cell infiltration in both mouse strains. 
Comparable to these results obtained in the EBA model, no significant difference 
could be observed between knockout and wild type mice in local mouse model of BP. 
Mrp-14 deficient animals were capable of developing disease and outcome 
measures of cellular inflammation in the Mrp-14 knock out did not differ significantly 
with the controls. Therefore, MRP-8/-14 proteins do not contribute to the disease 
expression in the antibody transfer models of EBA and BP used here. While these 
findings are in line with results published by Rampersad et al.209 who analyzed the 
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role of MRP-14 in two models of RA, they are in sharp contrast to observations of 
van Lent et al.205 who could show that Mrp-14-deficient animals are significantly 
protected from inflammatory arthritis in a further model of this disease. How can such 
diametrically opposed results be explained? One possibility is that the role of MRP-
8/-14 is different in the respective animal models. In the model of van Lent, an 
antigen-induced arthritis is induced by immunization against methylated bovine 
serum albumin (mBSA). Disease was established by a booster injection of mBSA 
locally in the joint resulting in a chronic destructive localized arthritis. By contrast, 
Rampersad used two models, an acute model by systemic antibody transfer of K/BxN 
serum and the chronic collagen-induced arthritis (CIA) model, which is a de novo-
induced immune response dependent on the H-2q haplotype. Therefore, the mBSA 
model may represent more a general inflammatory response induced in the joints by 
soluble immune complexes with cartilage damage as side effect, while the K/BxN 
and CIA models are systemic models where specifically the cartilage is attacked as 
an immobilized immune complex. Within this view, the models of EBA and BP used 
here may be closer related to the K/BxN model than to the mBSA system. 
Moreover, although the role of MRP-8/-14 in numerous intracellular functions in 
phagocytes has been documented175,191,202,323,324, several conflicting reports exists 
regarding their specific activities, making assessment of some functions difficult. 
Although my results argue against a prominent role of MRP-8/-14 in the 
pathogenesis of AIBDs, a regulatory function of these proteins in the autoimmune 
diseases can not be excluded. First of all, the experimental models used here mainly 
represent the effector phase of the disease. Therefore, a potential role of MRP-8/-14 
during the initial phase of AIBDs is still possible. Indeed, Loser et al. reported on a 
crucial role of MRP-8/-14 on the development of autoreactive CD8+ T cells in a model 
of cutaneous lupus erythematosus206. Furthermore, Petersen and coworkers 
described an effect of these proteins on the maturation of dendritic cells in 
experimental contact dermatitis325. Both reports provide evidence that MRP-8/-14 
may be rather involved in the regulation of the initial phases of chronic inflammation 
than in the effector phase of these diseases. Furthermore, since the MRP-8/-14 
genes are regulated by pro- and anti-inflammatory mediators, together with their 
emerging anti-inflammatory properties, the functions of these proteins might be 
affected by several factors including the cell type and mediator involved in their 
induction in a particular inflammatory milieu, the receptors involved in their 
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recognition and their post-translational modification. For example, although there are 
correlation between MRP-8/-14 and chondrocyte-mediated cartilage destruction in 
RA205, anti-inflammatory properties of the injected proteins are reported in rodent 
models of arthritis326, autoimmune myocadritis327 and  endotoxin-mediated 
inflammation328. Therefore, it might be a point that they are mislabeled as 
‘proinflammatory’ and in some circumstances; their high expression levels may 
actually mediate host protection. For example, MRP-8 and MRP-14 expression 
patterns in incision wounds in skin lead to the suggestion that elevated levels may 
have a therapeutic effect against inflammation in wound healing329, and their positive 
expression in skin may be crucial for the protection against bacterial infections330 and 
UVA-mediated oxidative damage331. In addition, MRP-14 has antinociceptive 
properties that are effective in various acute inflammatory pain models, and the use 
of a C-terminal peptide may represent a potential therapeutic332. Taken together with 
the pro-inflammatory properties described for these proteins, their ability to modulate 
inflammation should also be considered. Functions may be governed by the 
receptors that are activated by the calgranulins. Additionally, post-translational 
modifications may occur in oxidative environments and other factors such as 
proteolytic cleavage by proteases released as a consequence of phagocyte 
activation333, and zinc binding may also have important functional ramifications. 
Finally, a further possible explanation for the lacking disease phenotype of Mrp-14 
knockouts in our experimental systemic EBA and local BP model could be 
compensatory or overlapping mechanisms in Mrp-14-/- mouse. Specifically, MRP-6 
(or S100A12) has been also shown to exhibit its pro-inflammatory activities via 
interaction with RAGE178. This protein has been described as a biomarker of 
neutrophil activation in inflammatory diseases, including RA207,334. Alternatively, 
either other proinflammatory mediators could be involved in compensatory 
mechanisms for MRP-8/-14 protein deficiency or these heterodimer proteins may 
play a less significant role in mouse models of inflammation than in human disease.  
Taken together, my results strongly suggest that MRP-8/-14 proteins are not 
involved in the regulation of the effector phase of EBA and BP. Nevertheless, they 
may represent interesting new biomarkers for autoantibody-mediated immune 
dermatoses. Further studies are required to define a potential role of these proteins 
during the initial phase of AIBD. 
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4.4. Outlook and future perspectives 
NE activity was visualized with FRET reporter as a direct effector in blister 
formation in bullous disease. However, monitoring the activity of different proteases 
which are also involved in the pathogenesis of the disease may help to examine 
complex biological processes in the concept of diseases335. For instance, presence 
of MMP-9 which is an important neutrophil enzyme has been confirmed in the blister 
fluid of lesional skin336. NE can be activated by MMP-9 through cleaving A1AT 
inhibitor262 which confirms a link between MMP-9 and NE in skin pathogenesis. 
Therefore, visualization and monitoring of proteases which contribute to the disease 
pathogenesis could help to provide an outlook for strategies concerning treatment of 
skin diseases. Furthermore, since proteases are active when neutrophils detach to 
the surface, monitoring of simultaneous targeting of adhesion and proteases as a 
therapeutical concept could also be helpful. 
As it was mentioned before, MRP-8/-14 proteins might be involved in the 
regulation of the induction phase of chronic inflammation than in the effector phase of 
these diseases. Therefore, providing an active model of bullous diseases EBA and 
BP by immunization of mice against autologous COLVII or COLXVII, respectively 
could be helpful. However, the self-tolerance has to be overcome for developing 
animal models of autoimmune diseases. Since susceptibility to the inflammatory-type 
EBA is strongly associated with the H2s haplotype19, animals with a C57BL/6 
background develop no clinical symptoms in active models of AIBD120. To circumvent 
this problem, Mrp-14-deficient mice could be backcrossed to a mouse strain like SJL, 
in which the suitable haplotype is expressed.    
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5. SUMMARY 
The prevalence of chronic inflammatory diseases, especially autoimmune 
disorders (AID), has increased dramatically during the last decades in the world. 
Most diseases require a life-long non-curative treatment which is largely limited to the 
application of immunosuppressive drugs. The permanent and severe reduction in the 
quality of life of the patients as well as the enormous economical burden associated 
with these diseases emphasizes the high medical need for the development of novel 
therapeutic options. Since many years, the contribution of the different components 
of immune system to the pathogenesis of AID has been under intensive investigation.  
In the context of autoimmune bullous diseases (AIBDs), neutrophils have been 
identified as essential players in the effector phase of AIBDs. Neutrophil-derived 
mediators are involved in tissue damage and skin blister formation which is the 
hallmark of AIBDs including epidermolysis bullosa acquisita (EBA) and bullous 
pemphigoid (BP). However, although the principal participation of neutrophil 
proteases and ROS has clearly been shown in this course, the precise regulatory 
and executive mechanisms of neutrophils in the disease still remain unclear. In this 
study, it is hypothesized that neutrophils contribute to the effector phase by two 
ways, indirectly by the secretion of myeloid-related proteins (MRP)-8 and -14 leading 
to amplification and maintenance of the inflammatory loop as well as directly by the 
release of tissue-destructing elastase. Therefore, delineation of the mechanisms how 
neutrophils cause tissue damage will establish further information about the 
pathomechanisms of EBA and BP and provide a novel therapeutic avenue 
specifically targets the terminal phase of the disease. 
MRP-8/-14 proteins belong to the group of alarmins or danger-associated 
molecular pattern (DAMPs) and their association with numerous human disorders, 
including acute and chronic inflammatory conditions and autoimmune diseases has 
been shown. In this study it is shown that elevated levels of MRP-8/-14 occur also in 
EBA and BP patients as well as in experimental disease. To clarify whether these 
functions are also relevant in the pathological process of the skin bullous diseases, 
Mrp-14-deficient mice, which are also functional deficient in MRP-8, were tested in 
antibody transfer models of EBA and BP. However, the knockout mice were not 
protected against disease development and their phenotype did not differ from that of 
the wild type controls. In contrast to the original hypothesis, these results indicate 
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that MRP-8/-14 proteins are not involved in the effector phase of EBA and BP. As a 
consequence, MRP-8/-14 do not appear as suitable therapeutic targets for the 
treatment of the effector phase of EBA or BP. 
Neutrophil proteases such as elastase are essentially involved in many 
pathophysiologcal processes and uncontrolled proteolysis is a major reason for 
tissue damage and destruction in chronic inflammatory diseases like asthma, COPD, 
or AIDs. However, due to their low efficacy or severe side effects, antiproteinase 
therapies failed so far as treatment concept for these diseases. Therefore, the 
understanding of the mode of action of proteases under physiological conditions 
could help to develop new strategies to prevent the host from harmful attacks by 
these proteins. So far the role of these enzymes in disease has been shown only 
indirectly, either by appropriate knockout mice or inhibitor studies, determination of 
protease activity in cell extracts and supernatants, or by histological localization of 
the protein in the diseased tissue. For better understanding of the pathophysiological 
mechanism of neutrophil elastase in disease, a direct approach allowing their 
quantification and localization of the enzyme activity at its site of action in vitro and in 
vivo is required. Therefore, a method was established by using NE FRET reporter 
NEmo-2 to visualize NE activity on neutrophils in vitro as well as in experimental EBA 
in vivo. Using these novel tools, an interdependency between immune complex (IC)-
induced neutrophil adhesion and elastase enzyme activity was discovered.  
According to my results, exposure of neutrophils to immobilized IC induces their 
rapid activation in terms of cell adhesion, ROS production and the release of 
elastase. Surprisingly, although blocking of neutrophil adhesion with antibodies to 
CD18 did not affect the release of elastase or ROS, it has been shown in our group 
that IC-mediated tissue damage is significantly reduced under these conditions. 
Analysis of membrane-associated elastase activity in vitro by using the novel FRET-
based protease sensor NEmo-2 revealed the presence of protease activity on 
adherent cells which is resistant to macromolecular protease inhibitors. Most likely, 
the escape of elastase from inhibitor access is enabled by the formation of a closed 
space between cell and surface. This fine cooperation among IC-induced neutrophil 
adhesion and elastase activity in tissue damage was further confirmed in a model ob 
EBA in vivo, where elastase enzyme activity could be imaged on the surface of 
adherent neutrophils in presence of protease inhibitors.  
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Taken together, this study demonstrates that during the effector phase of 
experimental AIBD, MRP-8/-14 proteins do not contribute to these diseases and, 
therefore, may not represent suitable therapeutical targets in this stage. However, 
highly sensitive detection of neutrophil elastase protease activity reveals an essential 
dependency of protease activity in vitro and in vivo on IC-induced neutrophil 
adhesion.  Therefore, prevention of adhesion process in neutrophils by breaking the 
protected space could facilitate the access of intrinsic as well as therapeutic inhibitors 
at the site of tissue damage. These results help to better understand the 
pathophysiological functions of neutrophils in the effector phase of the disease 
particularly the direct effects of NE on tissue degradation and enable us to open a 
previous unseen window for novel therapeutical approaches of AIBD and other 
neutrophil-mediated disorders. 
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6. ZUSAMMENFASSUNG 
Die Prävalenz chronischer Erkrankungen, insbesondere die der Autoimmunität, ist 
während der letzten Dekaden weltweit dramatisch angestiegen. Der überwiegende 
Teil dieser Krankheiten erfordert eine lebenslange Behandlung der Symptome durch 
immunsuppressive Medikation. Auf Grund dem damit verbundenen dauerhaften 
Verlust an Lebensqualität wie auch der enormen sozio-ökonomischen Belastung ist 
die Entwicklung neuer therapeutischer Optionen dringend erforderlich. Seit vielen 
Jahren wird daher die Beteiligung verschiedener Komponenten des Immunsystems 
an der Pathogenese von Autoimmunerkrankungen intensiv erforscht. In der 
Effektorphase von bullösen Autoimmunerkrankungen (autoimmune bullous diseases; 
AIBDs) konnten neutrophilen Granulozyten (Neutrophile) eine zentrale pro-
pathogene Funktion zugewiesen werden. Mediatoren dieser Zellen sind an der 
Gewebeschädigung wie auch der Ausbildung von Blasen beteiligt, beides 
Charakteristika von AIBDs wie der Epidermolysis bullosa acquisita (EBA) oder dem 
bullösen Pemphigoid (BP). Obwohl die prinzipielle Beteiligung von Neutrophilen an 
der Pathogenese von AIBDs über die Freisetzung von Proteasen und reaktiven 
Sauerstoffderivaten bekannt ist, so sind die exakten regulatorischen und exekutiven 
Mechanismen dieser Zellen in dem Krankheitsprozess nicht geklärt. Nach der 
Hypothese der vorliegenden Studie beteiligen sich Neutrophile an der Effektorphase 
dieser Erkrankungen über zwei verschiedene Wege. Über den indirekten Weg einer 
Freisetzung der Myeloid-related Proteine (MRP)-8 und -14 könnte eine Amplifikation 
und Aufrechterhaltung der Entzündung vermittelt werden während über einen 
direkten Weg sezernierte Elastase eine Gewebsschädigung bewirken könnte. Die 
Aufklärung der Mechanismen über die Neutrophile zum Krankheitsbild der EBA und 
des BP beitragen könnte damit zu einem neuen therapeutischen Konzept zur 
Behandlung insbesondere bei bereits manifestierten Erkrankungen führen. 
MRP-8 und -14 gehören zu der Gruppe der Alarmine oder DAMPs (danger-
associated molecular pattern) und ihre Assoziation mit verschiedensten chronisch-
entzündlichen Erkrankungen, insbesondere Autoimmunerkrankungen, konnte bereits 
erfolgreich nachgewiesen werden. In dieser Studie wurde gezeigt, dass sich erhöhte 
Spiegel von MRP-8/-14 auch in EBA- und BP-Patienten und Mäusen mit 
experimenteller AIBD nachweisen lassen. Um zu klären, ob diese Proteine auch eine 
funktioneller Relevanz in bullösen Erkrankungen besitzen, wurden die 
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Krankheitsbilder experimentell durch Übertragung pathogener Antikörper in Mrp-14-
defizienten Mäusen, in welchen ebenfalls kein MRP-8 nachweisbar ist, induziert. Es 
zeigte sich jedoch, dass die Phänotypen der  Mrp-14-defizienten Tiere keine 
signifikanten Unterschiede zu den Wildtypen aufwiesen. Entgegen der initialen 
Hypothese muss daher geschlossen werden, dass MRP-8/-14 nicht an der 
Regulation der Effektorphase der AIBS beteiligt sind und damit auch nicht als ein 
brauchbares therapeutisches Ziel zur Behandlung von AIBD erscheinen.  
Neutrophile Proteasen wie Elastase sind an einer Vielzahl von pathophsiologischen 
Prozessen beteiligt und unkontrollierte Proteolyse ist ein Hauptgrund  für die 
Gewebsschädigung in chronisch-entzündlichen Erkrankungen wie beispielsweise im 
Asthma, der COPD oder in Autoimmunerkrankungen. Auf Grund ihrer geringen 
Effizienz oder ihren schweren Nebeneffekten haben sich jedoch Antiprotease-
Therapien als Behandlungskonzept nicht durchsetzen können. Ein besseres 
Verstehen der Wirkungsweise von Proteasen unter physiologischen Bedingungen 
könnte jedoch zur Entwicklung neuer Strategien zum Schutz des Wirtes vor einem 
Angriff durch diese Proteine führen. Auf die potentielle Rolle von Proteasen im 
Krankheitsgeschehen konnte bisher nur indirekt geschlossen werden, sei es durch 
geeignete Knockout Mäuse oder Inhibitorstudien, histologische Untersuchungen oder 
der Bestimmung von Enzymaktivitäten in Gewebsextrakten oder Kulturüberständen. 
Um die pathophysiologischen Prozesse jedoch erfassen zu können, ist ein direkter 
Ansatz notwendig, welcher gleichzeitig die Bestimmung von Enzymaktivität und 
deren lokale Zuordnung in vitro und in vivo erlaubt. Als Konsequenz wurde in dieser 
Arbeit unter Verwendung des FRET-basierten Elastase-Reporters NEmo-2 eine 
Methode entwickelt, welche einen Fluoreszenz-optischen Nachweis zellassoziierter 
Elastaseaktivität ermöglicht. Mithilfe dieser Methode konnte ein direkter 
Zusammenhang zwischen durch Immunkomplexe (IC) induzierter Adhärenz und 
Elastase-Enzymaktivität nachgewiesen werden. 
Nach meinen Ergebnissen induziert die Stimulation mit immobilisierten IC in 
Neutrophilen eine schnelle Aktivierung in Form einer Zelladhärenz sowie der 
Freisetzung von Sauerstoffradikalen und Elastase. Obwohl die Blockade der 
Adhärenz mittel CD18-Antikörpern keinerlei Effekt auf die Freisetzung von Elastase 
oder Sauerstoffradikalen hatte, so konnte in unserer Gruppe gezeigt werden, dass 
die durch IC vermittelte Gewebsschädigung unter diesen Bedingungen drastisch 
reduziert ist. Mit Hilfe des FRET-Sensors NEmo-2 konnte auf adhärenten 
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Neutrophilen in vitro eine mit der Zellmembran assoziierten Elastaseaktivität 
nachgewiesen werden, welche sich als resistent gegenüber makromolekularen 
Proteaseinhibitoren erwies. Diese Resistenz basiert wahrscheinlich auf der Bildung 
eines abgeschlossenen Raumes ("closed space") auf der Anheftungsseite der Zellen, 
welcher den Zugang der Inhibitoren zu den Proteasen verhindert. Ein solches 
Zusammenspiel von Zelladhärenz und Proteaseaktivität konnte in einem Tiermodell 
der EBA in vivo bestätigt werden, bei dem sich Elastaseaktivität in Gegenwart hoher 
Konzentrationen von Proteaseinhibitoren in adhärenten Neutrophilen nachweisen 
ließ.   
Nach den Befunden dieser Studie tragen die Proteine MRP-8 und -14 nicht zur 
Pathogenese in der Effektorphase von experimentellen AIBDs bei und repräsentieren 
damit auch keine potentiellen therapeutischen Ziele zur Behandlung dieser 
Erkrankungen in diesem Stadium. Jedoch konnte mittels einer hochempfindlichen 
zellbasierten Methode zur Bestimmung der Elastaseaktivität eine direkte 
Abhängigkeit zwischen Proteaseaktivität und Zelladhärenz nachgewiesen werden. 
Damit könnte die Interferenz mit dem Adhäsionsprozess, welche einen Zugang von 
intrinsischen oder therapeutischen Inhibitoren zu den pathogenen Proteasen 
ermöglicht, eine vielversprechende neue Strategie zur Behandlung von AIBD und 
anderen Erkrankungen darstellen. 
  REFERENCES 114 
7. REFERENCES 
 
1.  Kanitakis, J. Anatomy, histology and immunohistochemistry of normal human skin. 
Eur. J. Dermatol. EJD 12, 390–399; quiz 400–401 (2002). 
2.  Kolarsick, P. A. J., Kolarsick, M. A. & Goodwin, C. Anatomy and Physiology of the 
Skin: J. Dermatol. Nurses Assoc. 3, 203–213 (2011). 
3.  James, W. D., Berger, T. & Elston, D. Andrew’s Diseases of the Skin: Clinical 
Dermatology. (Elsevier Health Sciences, 2011). 
4.  Lever, W. F., Elder, D. E. & Elenitsas, R. Lever’s Histopathology of the Skin. 
(Lippincott Williams & Wilkins, 2005). 
5.  Prost-Squarcioni, C., Fraitag, S., Heller, M. & Boehm, N. [Functional histology of 
dermis]. Ann. Dermatol. Vénéréologie 135, 1S5–20 (2008). 
6.  Gayraud, B., Höpfner, B., Jassim, A., Aumailley, M. & Bruckner-Tuderman, L. 
Characterization of a 50-kDa component of epithelial basement membranes using GDA-
J/F3 monoclonal antibody. J. Biol. Chem. 272, 9531–9538 (1997). 
7.  Briggaman, R. A. & Wheeler, C. E. The epidermal-dermal junction. J. Invest. 
Dermatol. 65, 71–84 (1975). 
8.  Weber, L., Krieg, T. & Timpl, R. [Basement membranes--structure, function, 
pathology]. Hautarzt Z. Für Dermatol. Venerol. Verwandte Geb. 35, 279–286 (1984). 
9.  Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson, R. E. Type VII collagen is a 
major structural component of anchoring fibrils. J. Cell Biol. 103, 1577–1586 (1986). 
10. Paulsson, M. Basement membrane proteins: structure, assembly, and cellular 
interactions. Crit. Rev. Biochem. Mol. Biol. 27, 93–127 (1992). 
11. Villone, D. et al. Supramolecular interactions in the dermo-epidermal junction zone: 
anchoring fibril-collagen VII tightly binds to banded collagen fibrils. J. Biol. Chem. 283, 
24506–24513 (2008). 
12. Encyclopedia Britannica, Inc.: 
http://www.britannica.com/EBchecked/topic/547591/human-skin. 
13. Charles A Janeway, J., Travers, P., Walport, M. & Shlomchik, M. J. Principles of 
innate and adaptive immunity. (2001). 
14. Zhernakova, A., van Diemen, C. C. & Wijmenga, C. Detecting shared pathogenesis 
from the shared genetics of immune-related diseases. Nat. Rev. Genet. 10, 43–55 (2009). 
15. Selgrade, M. K., Cooper, G. S., Germolec, D. R. & Heindel, J. J. Linking 
environmental agents and autoimmune disease: an agenda for future research. Environ. 
Health Perspect. 107 Suppl 5, 811–813 (1999). 
16. Kalies, K., Blessenohl, M., Nietsch, J. & Westermann, J. T cell zones of lymphoid 
organs constitutively express Th1 cytokine mRNA: specific changes during the early 
phase of an immune response. J. Immunol. Baltim. Md 1950 176, 741–749 (2006). 
  REFERENCES 115 
17. Tashiro, H., Arai, H., Hashimoto, T., Takezaki, S. & Kawana, S. Pemphigoid 
nodularis: two case studies and analysis of autoantibodies before and after the 
development of generalized blistering. J. Nippon Med. Sch. Nippon Ika Daigaku Zasshi 72, 
60–65 (2005). 
18. Gammon, W. R. et al. Increased frequency of HLA-DR2 in patients with 
autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of 
autoimmunity to type VII collagen is HLA class II allele associated. J. Invest. Dermatol. 91, 
228–232 (1988). 
19. Ludwig, R. J. et al. Generation of antibodies of distinct subclasses and specificity is 
linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J. Invest. 
Dermatol. 131, 167–176 (2011). 
20. Zumelzu, C. et al. Black patients of African descent and HLA-DRB1*15:03 frequency 
overrepresented in epidermolysis bullosa acquisita. J. Invest. Dermatol. 131, 2386–2393 
(2011). 
21. Ludwig, R. J. et al. Identification of quantitative trait loci in experimental epidermolysis 
bullosa acquisita. J. Invest. Dermatol. 132, 1409–1415 (2012). 
22. Yancey, K. B. & Fairley, J. A. Introduction to the milestones in autoimmune bullous 
diseases. J. Invest. Dermatol. 128, E15 (2008). 
23. Yancey, K. B. & Egan, C. A. Pemphigoid: clinical, histologic, immunopathologic, and 
therapeutic considerations. JAMA 284, 350–356 (2000). 
24. Hertl, M., Eming, R. & Veldman, C. T cell control in autoimmune bullous skin 
disorders. J. Clin. Invest. 116, 1159–1166 (2006). 
25. Kouno, M. et al. Ahnak/Desmoyokin is dispensable for proliferation, differentiation, 
and maintenance of integrity in mouse epidermis. J. Invest. Dermatol. 123, 700–707 
(2004). 
26. Simpson, C. L., Patel, D. M. & Green, K. J. Deconstructing the skin: cytoarchitectural 
determinants of epidermal morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 565–580 (2011). 
27. Tsuruta, D., Hashimoto, T., Hamill, K. J. & Jones, J. C. R. Hemidesmosomes and 
focal contact proteins: functions and cross-talk in keratinocytes, bullous diseases and 
wound healing. J. Dermatol. Sci. 62, 1–7 (2011). 
28. Hashimoto, T., Ishii, N., Ohata, C. & Furumura, M. Pathogenesis of epidermolysis 
bullosa acquisita, an autoimmune subepidermal bullous disease. J. Pathol. 228, 1–7 
(2012). 
29. Mihai, S. & Sitaru, C. Immunopathology and molecular diagnosis of autoimmune 
bullous diseases. J. Cell. Mol. Med. 11, 462–481 (2007). 
30. Kneisel, A. & Hertl, M. Autoimmune bullous skin diseases. Part 1: Clinical 
manifestations. J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG 9, 844–856; quiz 
857 (2011). 
31. Otten, J. V., Hashimoto, T., Hertl, M., Payne, A. S. & Sitaru, C. Molecular diagnosis in 
autoimmune skin blistering conditions. Curr. Mol. Med. 14, 69–95 (2014). 
  REFERENCES 116 
32. Amagai, M. & Stanley, J. R. Desmoglein as a target in skin disease and beyond. J. 
Invest. Dermatol. 132, 776–784 (2012). 
33. Hashimoto, T. Immunopathology of IgA pemphigus. Clin. Dermatol. 19, 683–689 
(2001). 
34. Hashimoto, T. Immunopathology of paraneoplastic pemphigus. Clin. Dermatol. 19, 
675–682 (2001). 
35. Hashimoto, T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin. 
Pharmacother. 9, 1519–1530 (2008). 
36. Joly, P. et al. A comparison of oral and topical corticosteroids in patients with bullous 
pemphigoid. N. Engl. J. Med. 346, 321–327 (2002). 
37. Langan, S. M. et al. Bullous pemphigoid and pemphigus vulgaris--incidence and 
mortality in the UK: population based cohort study. BMJ 337, a180 (2008). 
38. LEVER, W. F. Pemphigus. Medicine (Baltimore) 32, 1–123 (1953). 
39. Labib, R. S., Anhalt, G. J., Patel, H. P., Mutasim, D. F. & Diaz, L. A. Molecular 
heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J. 
Immunol. Baltim. Md 1950 136, 1231–1235 (1986). 
40. Stanley, J. R., Tanaka, T., Mueller, S., Klaus-Kovtun, V. & Roop, D. Isolation of 
complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J. 
Clin. Invest. 82, 1864–1870 (1988). 
41. Sawamura, D., Li, K., Chu, M. L. & Uitto, J. Human bullous pemphigoid antigen 
(BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically 
important peptide segments and protein domains. J. Biol. Chem. 266, 17784–17790 
(1991). 
42. Stanley, J. R. Cell adhesion molecules as targets of autoantibodies in pemphigus and 
pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv. Immunol. 53, 
291–325 (1993). 
43. Liu, Z. et al. A passive transfer model of the organ-specific autoimmune disease, 
bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, 
BP180. J. Clin. Invest. 92, 2480–2488 (1993). 
44. Nishie, W. et al. Humanization of autoantigen. Nat. Med. 13, 378–383 (2007). 
45. Schaumburg-Lever G, Orfanos CE & Lever WF. ELectron microscopic study of 
bullous pemphigoid. Arch. Dermatol. 106, 662–667 (1972). 
46. Dvorak, A. M. et al. Bullous pemphigoid, an ultrastructural study of the inflammatory 
response: eosinophil, basophil and mast cell granule changes in multiple biopsies from 
one patient. J. Invest. Dermatol. 78, 91–101 (1982). 
47. Della Torre, R. et al. Clinical presentation and diagnostic delay in bullous pemphigoid: 
a prospective nationwide cohort. Br. J. Dermatol. 167, 1111–1117 (2012). 
48. Kasperkiewicz, M. & Zillikens, D. The pathophysiology of bullous pemphigoid. Clin. 
Rev. Allergy Immunol. 33, 67–77 (2007). 
  REFERENCES 117 
49. Tanaka, T., Parry, D. A., Klaus-Kovtun, V., Steinert, P. M. & Stanley, J. R. 
Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms 
that they define a new family of cell adhesion junction plaque proteins. J. Biol. Chem. 266, 
12555–12559 (1991). 
50. Green, K. J., Virata, M. L., Elgart, G. W., Stanley, J. R. & Parry, D. A. Comparative 
structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: members of a 
new gene family involved in organization of intermediate filaments. Int. J. Biol. Macromol. 
14, 145–153 (1992). 
51. Hopkinson, S. B., Riddelle, K. S. & Jones, J. C. Cytoplasmic domain of the 180-kD 
bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic 
characterization. J. Invest. Dermatol. 99, 264–270 (1992). 
52. Hirako, Y., Usukura, J., Nishizawa, Y. & Owaribe, K. Demonstration of the molecular 
shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer 
formation. J. Biol. Chem. 271, 13739–13745 (1996). 
53. Balding, S. D., Diaz, L. A. & Giudice, G. J. A recombinant form of the human BP180 
ectodomain forms a collagen-like homotrimeric complex. Biochemistry (Mosc.) 36, 8821–
8830 (1997). 
54. Bédane, C. et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react 
with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 
spans the lamina lucida. J. Invest. Dermatol. 108, 901–907 (1997). 
55. Masunaga, T. et al. The extracellular domain of BPAG2 localizes to anchoring 
filaments and its carboxyl terminus extends to the lamina densa of normal human 
epidermal basement membrane. J. Invest. Dermatol. 109, 200–206 (1997). 
56. Giudice, G. J. et al. Bullous pemphigoid and herpes gestationis autoantibodies 
recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. Baltim. 
Md 1950 151, 5742–5750 (1993). 
57. Perriard, J. et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind 
antigenic sites on both the extracellular and the intracellular domains of the BP antigen 
180. J. Invest. Dermatol. 112, 141–147 (1999). 
58. Hofmann, S. et al. Severity and phenotype of bullous pemphigoid relate to 
autoantibody profile against the NH2- and COOH-terminal regions of the BP180 
ectodomain. J. Invest. Dermatol. 119, 1065–1073 (2002). 
59. Di Zenzo, G. et al. Multicenter prospective study of the humoral autoimmune 
response in bullous pemphigoid. Clin. Immunol. Orlando Fla 128, 415–426 (2008). 
60. Di Zenzo, G. et al. Characterization of the anti-BP180 autoantibody reactivity profile 
and epitope mapping in bullous pemphigoid patients. J. Invest. Dermatol. 122, 103–110 
(2004). 
61. Schmidt, E. & Zillikens, D. Diagnosis and clinical severity markers of bullous 
pemphigoid. F1000 Med. Rep. 1, (2009). 
62. Kromminga, A. et al. Patients with bullous pemphigoid and linear IgA disease show a 
dual IgA and IgG autoimmune response to BP180. J. Autoimmun. 15, 293–300 (2000). 
  REFERENCES 118 
63. Döpp, R. et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A 
domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect 
disease activity. J. Am. Acad. Dermatol. 42, 577–583 (2000). 
64. Iwata, Y. et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous 
pemphigoid. Arch. Dermatol. 144, 41–48 (2008). 
65. Christophoridis, S. et al. IgG, IgA and IgE autoantibodies against the ectodomain of 
BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous 
dermatosis. Br. J. Dermatol. 143, 349–355 (2000). 
66. Joly, P. et al. Incidence and mortality of bullous pemphigoid in France. J. Invest. 
Dermatol. 132, 1998–2004 (2012). 
67. Cortés, B. et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. 
Br. J. Dermatol. 165, 368–374 (2011). 
68. Schmidt, E. & Zillikens, D. Pemphigoid diseases. Lancet 381, 320–332 (2013). 
69. Di Zenzo, G., Marazza, G. & Borradori, L. Bullous pemphigoid: physiopathology, 
clinical features and management. Adv. Dermatol. 23, 257–288 (2007). 
70. Schmidt, E., della Torre, R. & Borradori, L. Clinical features and practical diagnosis of 
bullous pemphigoid. Immunol. Allergy Clin. North Am. 32, 217–232, v (2012). 
71. Kobayashi, M. et al. BP180 ELISA using bacterial recombinant NC16a protein as a 
diagnostic and monitoring tool for bullous pemphigoid. J. Dermatol. Sci. 30, 224–232 
(2002). 
72. Yoshida, M. et al. Enzyme-linked immunosorbent assay using bacterial recombinant 
proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J. Dermatol. Sci. 41, 
21–30 (2006). 
73. Sitaru, C. et al. Enzyme-linked immunosorbent assay using multimers of the 16th 
non-collagenous domain of the BP180 antigen for sensitive and specific detection of 
pemphigoid autoantibodies. Exp. Dermatol. 16, 770–777 (2007). 
74. Blöcker, I. M. et al. Epitope mapping of BP230 leading to a novel enzyme-linked 
immunosorbent assay for autoantibodies in bullous pemphigoid. Br. J. Dermatol. 166, 
964–970 (2012). 
75. Elliott, G. T. Two cases of epidermolysis bullosa. J. Cutan. Genitourin. Dis. 13, 10-18 
(1895). 
76. Bernard, P. et al. Incidence and distribution of subepidermal autoimmune bullous skin 
diseases in three French regions. Bullous Diseases French Study Group. Arch. Dermatol. 
131, 48–52 (1995). 
77. Wong, S. N. & Chua, S. H. Spectrum of subepidermal immunobullous disorders seen 
at the National Skin Centre, Singapore: a 2-year review. Br. J. Dermatol. 147, 476–480 
(2002). 
78. Bertram, F., Bröcker, E.-B., Zillikens, D. & Schmidt, E. Prospective analysis of the 
incidence of autoimmune bullous disorders in Lower Franconia, Germany. J. Dtsch. 
Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG 7, 434–440 (2009). 
  REFERENCES 119 
79. Ludwig, R. J. Clinical presentation, pathogenesis, diagnosis, and treatment of 
epidermolysis bullosa acquisita. ISRN Dermatol. 2013, 812029 (2013). 
80. Sitaru, C. & Zillikens, D. Mechanisms of blister induction by autoantibodies. Exp. 
Dermatol. 14, 861–875 (2005). 
81. Hallel-Halevy, D., Nadelman, C., Chen, M. & Woodley, D. T. Epidermolysis bullosa 
acquisita: update and review. Clin. Dermatol. 19, 712–718 (2001). 
82. Gammon, W. R., Briggaman, R. A., Woodley, D. T., Heald, P. W. & Wheeler, C. E., 
Jr. Epidermolysis bullosa acquisita--a pemphigoid-like disease. J. Am. Acad. Dermatol. 11, 
820–832 (1984). 
83. Stewart, M. I., Woodley, D. T. & Briggaman, R. A. Epidermolysis bullosa acquisita 
and associated symptomatic esophageal webs. Arch. Dermatol. 127, 373–377 (1991). 
84. Lunstrum, G. P., Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson, R. E. Large 
complex globular domains of type VII procollagen contribute to the structure of anchoring 
fibrils. J. Biol. Chem. 261, 9042–9048 (1986). 
85. Lunstrum, G. P. et al. Anchoring fibrils contain the carboxyl-terminal globular domain 
of type VII procollagen, but lack the amino-terminal globular domain. J. Biol. Chem. 262, 
13706–13712 (1987). 
86. Christiano, A. M. et al. A missense mutation in type VII collagen in two affected 
siblings with recessive dystrophic epidermolysis bullosa. Nat. Genet. 4, 62–66 (1993). 
87. Heinonen, S. et al. Targeted inactivation of the type VII collagen gene (Col7a1) in 
mice results in severe blistering phenotype: a model for recessive dystrophic 
epidermolysis bullosa. J. Cell Sci. 112 ( Pt 21), 3641–3648 (1999). 
88. Fritsch, A. et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa 
reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118, 
1669–1679 (2008). 
89. Hundorfean, G., Neurath, M. F. & Sitaru, C. Autoimmunity against type VII collagen in 
inflammatory bowel disease. J. Cell. Mol. Med. 14, 2393–2403 (2010). 
90. Sitaru, C. Experimental models of epidermolysis bullosa acquisita. Exp. Dermatol. 16, 
520–531 (2007). 
91. Chen, M. et al. Development of an ELISA for rapid detection of anti-type VII collagen 
autoantibodies in epidermolysis bullosa acquisita. J. Invest. Dermatol. 108, 68–72 (1997). 
92. Saleh, M. A. et al. Development of NC1 and NC2 domains of type VII collagen ELISA 
for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita 
patients. J. Dermatol. Sci. 62, 169–175 (2011). 
93. Komorowski, L. et al. Sensitive and specific assays for routine serological diagnosis 
of epidermolysis bullosa acquisita. J. Am. Acad. Dermatol. 68, e89–95 (2013). 
94. Gammon, W. R. et al. Autoantibodies to type VII collagen recognize epitopes in a 
fibronectin-like region of the noncollagenous (NC1) domain. J. Invest. Dermatol. 100, 618–
622 (1993). 
  REFERENCES 120 
95. Engineer, L. & Ahmed, A. R. Emerging treatment for epidermolysis bullosa acquisita. 
J. Am. Acad. Dermatol. 44, 818–828 (2001). 
96. Kim, J. H. & Kim, S.-C. Epidermolysis bullosa acquisita. J. Eur. Acad. Dermatol. 
Venereol. JEADV 27, 1204–1213 (2013). 
97. Ishii, N. et al. Epidermolysis bullosa acquisita: what’s new? J. Dermatol. 37, 220–230 
(2010). 
98. Hellberg, L. et al. Methylprednisolone blocks autoantibody-induced tissue damage in 
experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through 
inhibition of neutrophil activation. J. Invest. Dermatol. 133, 2390–2399 (2013). 
99. Remington, J., Chen, M., Burnett, J. & Woodley, D. T. Autoimmunity to type VII 
collagen: epidermolysis bullosa acquisita. Curr. Dir. Autoimmun. 10, 195–205 (2008). 
100. Connolly, S. M. & Sander, H. M. Treatment of epidermolysis bullosa acquisita with 
cyclosporine. J. Am. Acad. Dermatol. 16, 890 (1987). 
101. Khatri, M. L., Benghazeil, M. & Shafi, M. Epidermolysis bullosa acquisita responsive 
to cyclosporin therapy. J. Eur. Acad. Dermatol. Venereol. JEADV 15, 182–184 (2001). 
102. Maize, J. C., Jr & Cohen, J. B. Cyclosporine controls epidermolysis bullosa acquisita 
co-occurring with acquired factor VIII deficiency. Int. J. Dermatol. 44, 692–694 (2005). 
103. Kim, J. H., Kim, Y. H. & Kim, S.-C. Epidermolysis bullosa acquisita: a retrospective 
clinical analysis of 30 cases. Acta Derm. Venereol. 91, 307–312 (2011). 
104. Bauer, J. W. et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br. J. 
Dermatol. 141, 887–892 (1999). 
105. Megahed, M. & Scharffetter-Kochanek, K. Epidermolysis bullosa acquisita--
successful treatment with colchicine. Arch. Dermatol. Res. 286, 35–46 (1994). 
106. Cunningham, B. B., Kirchmann, T. T. & Woodley, D. Colchicine for epidermolysis 
bullosa acquisita. J. Am. Acad. Dermatol. 34, 781–784 (1996). 
107. Arora, K. P., Sachdeva, B., Singh, N. & Bhattacharya, S. N. Remission of recalcitrant 
epidermolysis bullosa acquisita (EBA) with colchicine monotherapy. J. Dermatol. 32, 114–
119 (2005). 
108. Tanaka, N. et al. A case of epidermolysis bullosa acquisita with clinical features of 
Brunsting-Perry pemphigoid showing an excellent response to colchicine. J. Am. Acad. 
Dermatol. 61, 715–719 (2009). 
109. Kiniwa, Y. et al. A case of epidermolysis bullosa acquisita associated with laryngeal 
stenosis. Acta Derm. Venereol. 92, 93–94 (2012). 
110. Ishii, N., Hashimoto, T., Zillikens, D. & Ludwig, R. J. High-dose intravenous 
immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin. Rev. Allergy 
Immunol. 38, 186–195 (2010). 
111. Ahmed, A. R. & Gürcan, H. M. Treatment of epidermolysis bullosa acquisita with 
intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical 
outcome and post-treatment long-term follow-up. J. Eur. Acad. Dermatol. Venereol. 
JEADV 26, 1074–1083 (2012). 
  REFERENCES 121 
112. Sadler, E. et al. Treatment-resistant classical epidermolysis bullosa acquisita 
responding to rituximab. Br. J. Dermatol. 157, 417–419 (2007). 
113. Schmidt, E., Benoit, S., Bröcker, E.-B., Zillikens, D. & Goebeler, M. Successful 
adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody 
rituximab. Arch. Dermatol. 142, 147–150 (2006). 
114. Kim, J. H., Lee, S. E. & Kim, S.-C. Successful treatment of epidermolysis bullosa 
acquisita with rituximab therapy. J. Dermatol. 39, 477–479 (2012). 
115. Kirtschig, G., Murrell, D., Wojnarowska, F. & Khumalo, N. Interventions for mucous 
membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst. 
Rev. CD004056 (2003). doi:10.1002/14651858.CD004056 
116. Bieber, K. et al. Animal models for autoimmune bullous dermatoses. Exp. Dermatol. 
19, 2–11 (2010). 
117. Sitaru, C. et al. Induction of dermal-epidermal separation in mice by passive transfer 
of antibodies specific to type VII collagen. J. Clin. Invest. 115, 870–878 (2005). 
118. Woodley, D. T. et al. Evidence that anti-type VII collagen antibodies are pathogenic 
and responsible for the clinical, histological, and immunological features of epidermolysis 
bullosa acquisita. J. Invest. Dermatol. 124, 958–964 (2005). 
119. Woodley, D. T. et al. Induction of epidermolysis bullosa acquisita in mice by passive 
transfer of autoantibodies from patients. J. Invest. Dermatol. 126, 1323–1330 (2006). 
120. Sitaru, C. et al. Induction of complement-fixing autoantibodies against type VII 
collagen results in subepidermal blistering in mice. J. Immunol. Baltim. Md 1950 177, 
3461–3468 (2006). 
121. Liu, Z. et al. Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid. J. 
Exp. Med. 186, 777–783 (1997). 
122. Kobayashi, S. D., Voyich, J. M., Burlak, C. & DeLeo, F. R. Neutrophils in the innate 
immune response. Arch. Immunol. Ther. Exp. (Warsz.) 53, 505–517 (2005). 
123. Grassi, F. Purinergic control of neutrophil activation. J. Mol. Cell Biol. 2, 176–177 
(2010). 
124. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–
531 (2011). 
125. Pham, C. T. N. Neutrophil serine proteases fine-tune the inflammatory response. Int. 
J. Biochem. Cell Biol. 40, 1317–1333 (2008). 
126. Raptis, S. Z., Shapiro, S. D., Simmons, P. M., Cheng, A. M. & Pham, C. T. N. Serine 
protease cathepsin G regulates adhesion-dependent neutrophil effector functions by 
modulating integrin clustering. Immunity 22, 679–691 (2005). 
127. Borregaard, N. Neutrophils, from marrow to microbes. Immunity 33, 657–670 (2010). 
128. Korkmaz, B., Horwitz, M. S., Jenne, D. E. & Gauthier, F. Neutrophil elastase, 
proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol. Rev. 
62, 726–759 (2010). 
  REFERENCES 122 
129. Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. & Malik, A. B. Reactive oxygen 
species in inflammation and tissue injury. Antioxid. Redox Signal. 20, 1126–1167 (2014). 
130. Pham, C. T. N. Neutrophil serine proteases: specific regulators of inflammation. Nat. 
Rev. Immunol. 6, 541–550 (2006). 
131. Carden, D. L. & Korthuis, R. J. Protease inhibition attenuates microvascular 
dysfunction in postischemic skeletal muscle. Am. J. Physiol. 271, H1947–1952 (1996). 
132. Kawabata, K. et al. Delayed neutrophil elastase inhibition prevents subsequent 
progression of acute lung injury induced by endotoxin inhalation in hamsters. Am. J. 
Respir. Crit. Care Med. 161, 2013–2018 (2000). 
133. Kakimoto, K., Matsukawa, A., Yoshinaga, M. & Nakamura, H. Suppressive effect of a 
neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell. 
Immunol. 165, 26–32 (1995). 
134. Chen, M. et al. The cartilage matrix protein subdomain of type VII collagen is 
pathogenic for epidermolysis bullosa acquisita. Am. J. Pathol. 170, 2009–2018 (2007). 
135. Chen, M. & Woodley, D. T. Duplicating autoimmune bullous diseases by passively 
transferring autoantibodies into animals. J. Invest. Dermatol. 128, E25–27 (2008). 
136. Liu, Z. et al. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. 
Invest. 100, 1256–1263 (1997). 
137. Chiriac, M. T. et al. NADPH oxidase is required for neutrophil-dependent 
autoantibody-induced tissue damage. J. Pathol. 212, 56–65 (2007). 
138. Liu, Z., Zhao, M., Li, N., Diaz, L. A. & Mayadas, T. N. Differential roles for beta2 
integrins in experimental autoimmune bullous pemphigoid. Blood 107, 1063–1069 (2006). 
139. Shimanovich, I. et al. Granulocyte-derived elastase and gelatinase B are required for 
dermal-epidermal separation induced by autoantibodies from patients with epidermolysis 
bullosa acquisita and bullous pemphigoid. J. Pathol. 204, 519–527 (2004). 
140. Sitaru, C. et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-
epidermal separation in cryosections of human skin. J. Invest. Dermatol. 118, 664–671 
(2002). 
141. Yu, X. et al. EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced 
binding of immune complexes to neutrophils. PloS One 9, e85317 (2014). 
142. Kuhn, C., 3rd, Slodkowska, J., Smith, T. & Starcher, B. The tissue response to 
exogenous elastase. Bull. Eur. Physiopathol. Respir. 16 Suppl, 127–139 (1980). 
143. Garwicz, D., Lennartsson, A., Jacobsen, S. E. W., Gullberg, U. & Lindmark, A. 
Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived 
cellular myeloid differentiation model. Haematologica 90, 38–44 (2005). 
144. Borregaard, N. & Cowland, J. B. Granules of the human neutrophilic 
polymorphonuclear leukocyte. Blood 89, 3503–3521 (1997). 
145. Lominadze, G. et al. Proteomic analysis of human neutrophil granules. Mol. Cell. 
Proteomics MCP 4, 1503–1521 (2005). 
  REFERENCES 123 
146. Kalupov, T. et al. Structural characterization of mouse neutrophil serine proteases 
and identification of their substrate specificities: relevance to mouse models of human 
inflammatory diseases. J. Biol. Chem. 284, 34084–34091 (2009). 
147. Walsh, D. E. et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by 
MyD88/IRAK/TRAF-6 in human bronchial epithelium. J. Biol. Chem. 276, 35494–35499 
(2001). 
148. Devaney, J. M. et al. Neutrophil elastase up-regulates interleukin-8 via toll-like 
receptor 4. FEBS Lett. 544, 129–132 (2003). 
149. Liu, Z. et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. 
J. Clin. Invest. 105, 113–123 (2000). 
150. Oikarinen, A. I., Zone, J. J., Ahmed, A. R., Kiistala, U. & Uitto, J. Demonstration of 
collagenase and elastase activities in the blister fluids from bullous skin diseases. 
Comparison between dermatitis herpetiformis and bullous pemphigoid. J. Invest. 
Dermatol. 81, 261–266 (1983). 
151. Benabid, R. et al. Neutrophil elastase modulates cytokine expression: contribution to 
host defense against Pseudomonas aeruginosa-induced pneumonia. J. Biol. Chem. 287, 
34883–34894 (2012). 
152. Heussen, C. & Dowdle, E. B. Electrophoretic analysis of plasminogen activators in 
polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. 
Anal. Biochem. 102, 196–202 (1980). 
153. Nakajima, K., Powers, J. C., Ashe, B. M. & Zimmerman, M. Mapping the extended 
substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide 
substrates related to the alpha 1-protease inhibitor reactive site. J. Biol. Chem. 254, 4027–
4032 (1979). 
154. Castillo, M. J., Nakajima, K., Zimmerman, M. & Powers, J. C. Sensitive substrates for 
human leukocyte and porcine pancreatic elastase: a study of the merits of various 
chromophoric and fluorogenic leaving groups in assays for serine proteases. Anal. 
Biochem. 99, 53–64 (1979). 
155. Korkmaz, B. et al. Design and use of highly specific substrates of neutrophil elastase 
and proteinase 3. Am. J. Respir. Cell Mol. Biol. 30, 801–807 (2004). 
156. Wiesner, O. et al. Differences between human proteinase 3 and neutrophil elastase 
and their murine homologues are relevant for murine model experiments. FEBS Lett. 579, 
5305–5312 (2005). 
157. Lane, A. A. & Ley, T. J. Neutrophil elastase cleaves PML-RARalpha and is important 
for the development of acute promyelocytic leukemia in mice. Cell 115, 305–318 (2003). 
158. Ntziachristos, V., Ripoll, J., Wang, L. V. & Weissleder, R. Looking and listening to 
light: the evolution of whole-body photonic imaging. Nat. Biotechnol. 23, 313–320 (2005). 
159. McDonald, D. M. & Choyke, P. L. Imaging of angiogenesis: from microscope to clinic. 
Nat. Med. 9, 713–725 (2003). 
160. Contag, C. H. & Bachmann, M. H. Advances in in vivo bioluminescence imaging of 
gene expression. Annu. Rev. Biomed. Eng. 4, 235–260 (2002). 
  REFERENCES 124 
161. Wagnières, G. A., Star, W. M. & Wilson, B. C. In vivo fluorescence spectroscopy and 
imaging for oncological applications. Photochem. Photobiol. 68, 603–632 (1998). 
162. Jares-Erijman, E. A. & Jovin, T. M. FRET imaging. Nat. Biotechnol. 21, 1387–1395 
(2003). 
163. Förster, T. Zwischenmolekulare Energiewanderung und Fluoreszenz. Ann. Phys. 437, 
55–75 (1948). 
164. Cobos-Correa, A., Trojanek, J. B., Diemer, S., Mall, M. A. & Schultz, C. Membrane-
bound FRET probe visualizes MMP12 activity in pulmonary inflammation. Nat. Chem. Biol. 
5, 628–630 (2009). 
165. Gehrig, S., Mall, M. A. & Schultz, C. Spatially resolved monitoring of neutrophil 
elastase activity with ratiometric fluorescent reporters. Angew. Chem. Int. Ed Engl. 51, 
6258–6261 (2012). 
166. Gambin, Y. & Deniz, A. A. Multicolor single-molecule FRET to explore protein folding 
and binding. Mol. Biosyst. 6, 1540–1547 (2010). 
167. Lu, S. & Wang, Y. Fluorescence resonance energy transfer biosensors for cancer 
detection and evaluation of drug efficacy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer 
Res. 16, 3822–3824 (2010). 
168. Prasuhn, D. E. et al. Quantum dot peptide biosensors for monitoring caspase 3 
proteolysis and calcium ions. ACS Nano 4, 5487–5497 (2010). 
169. Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and 
cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97–
108 (2003). 
170. Adams, S. R., Harootunian, A. T., Buechler, Y. J., Taylor, S. S. & Tsien, R. Y. 
Fluorescence ratio imaging of cyclic AMP in single cells. Nature 349, 694–697 (1991). 
171. Miyawaki, A. et al. Fluorescent indicators for Ca2+ based on green fluorescent 
proteins and calmodulin. Nature 388, 882–887 (1997). 
172. Fonović, M. & Bogyo, M. Activity-based probes as a tool for functional proteomic 
analysis of proteases. Expert Rev. Proteomics 5, 721–730 (2008). 
173. Bachmann, M. F. & Kopf, M. On the role of the innate immunity in autoimmune 
disease. J. Exp. Med. 193, F47–50 (2001). 
174. Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what 
have we learned? Annu. Rev. Immunol. 19, 163–196 (2001). 
175. Foell, D., Wittkowski, H., Vogl, T. & Roth, J. S100 proteins expressed in phagocytes: 
a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81, 28–
37 (2007). 
176. Johnson, K. J. & Ward, P. A. Acute immunologic pulmonary alveolitis. J. Clin. Invest. 
54, 349–357 (1974). 
177. Guo, R.-F. & Ward, P. A. Mediators and regulation of neutrophil accumulation in 
inflammatory responses in lung: insights from the IgG immune complex model. Free 
Radic. Biol. Med. 33, 303–310 (2002). 
  REFERENCES 125 
178. Oppenheim, J. J. & Yang, D. Alarmins: chemotactic activators of immune responses. 
Curr. Opin. Immunol. 17, 359–365 (2005). 
179. Murao, S., Collart, F. R. & Huberman, E. A protein containing the cystic fibrosis 
antigen is an inhibitor of protein kinases. J. Biol. Chem. 264, 8356–8360 (1989). 
180. McNamara, M. P., Wiessner, J. H., Collins-Lech, C., Hahn, B. L. & Sohnle, P. G. 
Neutrophil death as a defence mechanism against Candida albicans infections. Lancet 2, 
1163–1165 (1988). 
181. Steinbakk, M. et al. Antimicrobial actions of calcium binding leucocyte L1 protein, 
calprotectin. Lancet 336, 763–765 (1990). 
182. Sohnle, P. G., Collins-Lech, C. & Wiessner, J. H. Antimicrobial activity of an abundant 
calcium-binding protein in the cytoplasm of human neutrophils. J. Infect. Dis. 163, 187–
192 (1991). 
183. Murthy, A. R., Lehrer, R. I., Harwig, S. S. & Miyasaki, K. T. In vitro candidastatic 
properties of the human neutrophil calprotectin complex. J. Immunol. Baltim. Md 1950 
151, 6291–6301 (1993). 
184. Hogg, N., Allen, C. & Edgeworth, J. Monoclonal antibody 5.5 reacts with p8,14, a 
myeloid molecule associated with some vascular endothelium. Eur. J. Immunol. 19, 1053–
1061 (1989). 
185. Berntzen, H. B., Olmez, U., Fagerhol, M. K. & Munthe, E. The leukocyte protein L1 in 
plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand. 
J. Rheumatol. 20, 74–82 (1991). 
186. Hessian, P. A., Edgeworth, J. & Hogg, N. MRP-8 and MRP-14, two abundant Ca(2+)-
binding proteins of neutrophils and monocytes. J. Leukoc. Biol. 53, 197–204 (1993). 
187. Kerkhoff, C., Eue, I. & Sorg, C. The regulatory role of MRP8 (S100A8) and MRP14 
(S100A9) in the transendothelial migration of human leukocytes. Pathobiol. J. 
Immunopathol. Mol. Cell. Biol. 67, 230–232 (1999). 
188. Edgeworth, J., Gorman, M., Bennett, R., Freemont, P. & Hogg, N. Identification of 
p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid 
cells. J. Biol. Chem. 266, 7706–7713 (1991). 
189. Lagasse, E. & Weissman, I. L. Mouse MRP8 and MRP14, two intracellular calcium-
binding proteins associated with the development of the myeloid lineage. Blood 79, 1907–
1915 (1992). 
190. Odink, K. et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid 
arthritis. Nature 330, 80–82 (1987). 
191. Roth, J., Vogl, T., Sorg, C. & Sunderkötter, C. Phagocyte-specific S100 proteins: a 
novel group of proinflammatory molecules. Trends Immunol. 24, 155–158 (2003). 
192. Heizmann, C. W., Fritz, G. & Schäfer, B. W. S100 proteins: structure, functions and 
pathology. Front. Biosci. J. Virtual Libr. 7, d1356–1368 (2002). 
193. Hunter, M. J. & Chazin, W. J. High level expression and dimer characterization of the 
S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J. Biol. 
Chem. 273, 12427–12435 (1998). 
  REFERENCES 126 
194. Vogl, T., Gharibyan, A. L. & Morozova-Roche, L. A. Pro-Inflammatory S100A8 and 
S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes. Int. 
J. Mol. Sci. 13, 2893–2917 (2012). 
195. Lackmann, M., Cornish, C. J., Simpson, R. J., Moritz, R. L. & Geczy, C. L. Purification 
and structural analysis of a murine chemotactic cytokine (CP-10) with sequence homology 
to S100 proteins. J. Biol. Chem. 267, 7499–7504 (1992). 
196. Raftery, M. J., Harrison, C. A., Alewood, P., Jones, A. & Geczy, C. L. Isolation of the 
murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from 
activated spleen cells: characterization of post-translational modifications and zinc binding. 
Biochem. J. 316 ( Pt 1), 285–293 (1996). 
197. Hobbs, J. A. R. et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol. Cell. 
Biol. 23, 2564–2576 (2003). 
198. Nacken, W., Sopalla, C., Pröpper, C., Sorg, C. & Kerkhoff, C. Biochemical 
characterization of the murine S100A9 (MRP14) protein suggests that it is functionally 
equivalent to its human counterpart despite its low degree of sequence homology. Eur. J. 
Biochem. FEBS 267, 560–565 (2000). 
199. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, 
promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042–1049 (2007). 
200. Sunahori, K. et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine 
production by macrophages via activation of nuclear factor kappa B and p38 mitogen-
activated protein kinase in rheumatoid arthritis. Arthritis Res. Ther. 8, R69 (2006). 
201. Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-
derived suppressor cells. J. Immunol. Baltim. Md 1950 181, 4666–4675 (2008). 
202. Nacken, W., Roth, J., Sorg, C. & Kerkhoff, C. S100A9/S100A8: Myeloid 
representatives of the S100 protein family as prominent players in innate immunity. 
Microsc. Res. Tech. 60, 569–580 (2003). 
203. Björk, P. et al. Identification of human S100A9 as a novel target for treatment of 
autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 7, e97 (2009). 
204. Van Zoelen, M. A. D. et al. Expression and role of myeloid-related protein-14 in 
clinical and experimental sepsis. Am. J. Respir. Crit. Care Med. 180, 1098–1106 (2009). 
205. Van Lent, P. L. E. M. et al. Myeloid-related proteins S100A8/S100A9 regulate joint 
inflammation and cartilage destruction during antigen-induced arthritis. Ann. Rheum. Dis. 
67, 1750–1758 (2008). 
206. Loser, K. et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the 
development of autoreactive CD8+ T cells. Nat. Med. 16, 713–717 (2010). 
207. Foell, D., Frosch, M., Sorg, C. & Roth, J. Phagocyte-specific calcium-binding S100 
proteins as clinical laboratory markers of inflammation. Clin. Chim. Acta Int. J. Clin. Chem. 
344, 37–51 (2004). 
208. Zenz, R. et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal 
deletion of Jun proteins. Nature 437, 369–375 (2005). 
  REFERENCES 127 
209. Rampersad, R. R. et al. S100A9 is not essential for disease expression in an acute 
(K/BxN) or chronic (CIA) model of inflammatory arthritis. Scand. J. Rheumatol. 38, 445–
449 (2009). 
210. Manitz, M.-P. et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced 
CD11b surface expression, a polarized microfilament system, and diminished 
responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23, 1034–1043 (2003). 
211. Faust, N., Varas, F., Kelly, L. M., Heck, S. & Graf, T. Insertion of enhanced green 
fluorescent protein into the lysozyme gene creates mice with green fluorescent 
granulocytes and macrophages. Blood 96, 719–726 (2000). 
212. Tkalcevic, J. et al. Impaired immunity and enhanced resistance to endotoxin in the 
absence of neutrophil elastase and cathepsin G. Immunity 12, 201–210 (2000). 
213. Chua, F. et al. Mice lacking neutrophil elastase are resistant to bleomycin-induced 
pulmonary fibrosis. Am. J. Pathol. 170, 65–74 (2007). 
214. Yu, X. et al. FcγRIIA and FcγRIIIB are required for autoantibody-induced tissue 
damage in experimental human models of bullous pemphigoid. J. Invest. Dermatol. 130, 
2841–2844 (2010). 
215. Kasprick, A. Die Beteiligung von Mastzellen in der Autoimmunerkrankung 
Epidermolysis bullosa acquisita. (Forschungszentrum Borstel-Universität zu lübeck, 
Deutschland, 2013). 
216. Kiernan, J. A. Histological and histochemical methods - Theory and practice. (2008). 
217. Zreiqat, H. et al. S100A8 and S100A9 in experimental osteoarthritis. Arthritis Res. 
Ther. 12, R16 (2010). 
218. Frosch, M. et al. Myeloid-related proteins 8 and 14 are specifically secreted during 
interaction of phagocytes and activated endothelium and are useful markers for monitoring 
disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43, 
628–637 (2000). 
219. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680–685 (1970). 
220. Mittendorf, E. A. et al. Breast cancer cell uptake of the inflammatory mediator 
neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 72, 
3153–3162 (2012). 
221. Brown, M. & Wittwer, C. Flow cytometry: principles and clinical applications in 
hematology. Clin. Chem. 46, 1221–1229 (2000). 
222. Döring, G. The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. 
Care Med. 150, S114–117 (1994). 
223. Agarwal, A., Allamaneni, S. S. R. & Said, T. M. Chemiluminescence technique for 
measuring reactive oxygen species. Reprod. Biomed. Online 9, 466–468 (2004). 
224. Pervushina, O. et al. Platelet factor 4/CXCL4 induces phagocytosis and the 
generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi 
protein activation or intracellular calcium transients. J. Immunol. Baltim. Md 1950 173, 
2060–2067 (2004). 
  REFERENCES 128 
225. Petersen, F., Van Damme, J., Flad, H. D. & Brandt, E. Neutrophil-activating 
polypeptides IL-8 and NAP-2 induce identical signal transduction pathways in the 
regulation of lysosomal enzyme release. Lymphokine Cytokine Res. 10, 35–41 (1991). 
226. Scrace, S., O’Neill, E., Hammond, E. M. & Pires, I. M. Use of the xCELLigence 
system for real-time analysis of changes in cellular motility and adhesion in physiological 
conditions. Methods Mol. Biol. Clifton NJ 1046, 295–306 (2013). 
227. Martinez-Serra, J. et al. xCELLigence system for real-time label-free monitoring of 
growth and viability of cell lines from hematological malignancies. OncoTargets Ther. 7, 
985–994 (2014). 
228. Kustermann, S. et al. A label-free, impedance-based real time assay to identify drug-
induced toxicities and differentiate cytostatic from cytotoxic effects. Toxicol. Vitro Int. J. 
Publ. Assoc. BIBRA 27, 1589–1595 (2013). 
229. Limame, R. et al. Comparative analysis of dynamic cell viability, migration and 
invasion assessments by novel real-time technology and classic endpoint assays. PloS 
One 7, e46536 (2012). 
230. Paddock, S. W. Principles and practices of laser scanning confocal microscopy. Mol. 
Biotechnol. 16, 127–149 (2000). 
231. Flaberg, E., Stuber, G. & Szekely, L. Multi-dimensional laser confocal microscopy on 
live cells in submicroliter volumes using glass capillaries. Acta Histochem. Cytochem. 39, 
103–106 (2006). 
232. Mochizuki, N. et al. Spatio-temporal images of growth-factor-induced activation of 
Ras and Rap1. Nature 411, 1065–1068 (2001). 
233. Sato, M., Ozawa, T., Inukai, K., Asano, T. & Umezawa, Y. Fluorescent indicators for 
imaging protein phosphorylation in single living cells. Nat. Biotechnol. 20, 287–294 (2002). 
234. Gu, Y., Di, W. L., Kelsell, D. P. & Zicha, D. Quantitative fluorescence resonance 
energy transfer (FRET) measurement with acceptor photobleaching and spectral 
unmixing. J. Microsc. 215, 162–173 (2004). 
235. Van Munster, E. B., Kremers, G. J., Adjobo-Hermans, M. J. W. & Gadella, T. W. J., Jr. 
Fluorescence resonance energy transfer (FRET) measurement by gradual acceptor 
photobleaching. J. Microsc. 218, 253–262 (2005). 
236. FRET acceptor photobleaching. Leica confocal application letter. (2007). 
237. Dunn, K. W. & Young, P. A. Principles of multiphoton microscopy. Nephron Exp. 
Nephrol. 103, e33–40 (2006). 
238. So, P. T., Dong, C. Y., Masters, B. R. & Berland, K. M. Two-photon excitation 
fluorescence microscopy. Annu. Rev. Biomed. Eng. 2, 399–429 (2000). 
239. Benninger, R. K. P. & Piston, D. W. Two-photon excitation microscopy for the study of 
living cells and tissues. Curr. Protoc. Cell Biol. Editor. Board Juan Bonifacino Al Chapter 
4, Unit 4.11.1–24 (2013). 
240. König, K. Multiphoton microscopy in life sciences. J. Microsc. 200, 83–104 (2000). 
  REFERENCES 129 
241. Li, J. L. et al. Intravital multiphoton imaging of immune responses in the mouse ear 
skin. Nat. Protoc. 7, 221–234 (2012). 
242. Lämmermann, T. et al. Neutrophil swarms require LTB4 and integrins at sites of cell 
death in vivo. Nature 498, 371–375 (2013). 
243. Ng, L. G. et al. Migratory dermal dendritic cells act as rapid sensors of protozoan 
parasites. PLoS Pathog. 4, e1000222 (2008). 
244. Ng, L. G. et al. Visualizing the neutrophil response to sterile tissue injury in mouse 
dermis reveals a three-phase cascade of events. J. Invest. Dermatol. 131, 2058–2068 
(2011). 
245. Celli, S., Albert, M. L. & Bousso, P. Visualizing the innate and adaptive immune 
responses underlying allograft rejection by two-photon microscopy. Nat. Med. 17, 744–749 
(2011). 
246. Dudeck, A. et al. Mast cells are key promoters of contact allergy that mediate the 
adjuvant effects of haptens. Immunity 34, 973–984 (2011). 
247. Matheu, M. P. et al. Imaging of effector memory T cells during a delayed-type 
hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29, 602–614 
(2008). 
248. Peters, N. C. et al. In vivo imaging reveals an essential role for neutrophils in 
leishmaniasis transmitted by sand flies. Science 321, 970–974 (2008). 
249. Gaiser, M. R. et al. Cancer-associated epithelial cell adhesion molecule (EpCAM; 
CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc. Natl. 
Acad. Sci. U. S. A. 109, E889–897 (2012). 
250. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. 
Nat. Neurosci. 8, 752–758 (2005). 
251. Kasperkiewicz, M. et al. Genetic identification and functional validation of FcγRIV as 
key molecule in autoantibody-induced tissue injury. J. Pathol. 228, 8–19 (2012). 
252. Chen, R. et al. Mast cells play a key role in neutrophil recruitment in experimental 
bullous pemphigoid. J. Clin. Invest. 108, 1151–1158 (2001). 
253. Lopez, A. F., Strath, M. & Sanderson, C. J. Differentiation antigens on mouse 
eosinophils and neutrophils identified by monoclonal antibodies. Br. J. Haematol. 57, 489–
494 (1984). 
254. Tang, T. et al. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated 
neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-
dependent neutrophil adhesion and complement-dependent proteinuria in acute 
glomerulonephritis. J. Exp. Med. 186, 1853–1863 (1997). 
255. Ottonello, L. et al. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils 
exposed to granulocyte-macrophage colony-stimulating factor: intervention of 
FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood 93, 3505–
3511 (1999). 
256. Soriano, S. G. et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to 
cerebral ischemia/reperfusion injury. Stroke J. Cereb. Circ. 30, 134–139 (1999). 
  REFERENCES 130 
257. Van Spriel, A. B. et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated 
neutrophil cytotoxicity and immunologic synapse formation. Blood 97, 2478–2486 (2001). 
258. Bastiaens, P. I., Majoul, I. V., Verveer, P. J., Söling, H. D. & Jovin, T. M. Imaging the 
intracellular trafficking and state of the AB5 quaternary structure of cholera toxin. EMBO J. 
15, 4246–4253 (1996). 
259. Bastiaens, P. I. & Jovin, T. M. Microspectroscopic imaging tracks the intracellular 
processing of a signal transduction protein: fluorescent-labeled protein kinase C beta I. 
Proc. Natl. Acad. Sci. U. S. A. 93, 8407–8412 (1996). 
260. Wouters, F. S., Bastiaens, P. I., Wirtz, K. W. & Jovin, T. M. FRET microscopy 
demonstrates molecular association of non-specific lipid transfer protein (nsL-TP) with 
fatty acid oxidation enzymes in peroxisomes. EMBO J. 17, 7179–7189 (1998). 
261. Liu, Z. et al. The role of complement in experimental bullous pemphigoid. J. Clin. 
Invest. 95, 1539–1544 (1995). 
262. Liu, Z. et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase 
B/MMP-9 in vivo. Cell 102, 647–655 (2000). 
263. Cross, M., Mangelsdorf, I., Wedel, A. & Renkawitz, R. Mouse lysozyme M gene: 
isolation, characterization, and expression studies. Proc. Natl. Acad. Sci. U. S. A. 85, 
6232–6236 (1988). 
264. Brady, G. et al. Analysis of gene expression in a complex differentiation hierarchy by 
global amplification of cDNA from single cells. Curr. Biol. CB 5, 909–922 (1995). 
265. Chen, R. et al. Macrophages, but not T and B lymphocytes, are critical for 
subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated 
neutrophil infiltration depends on mast cell activation. J. Immunol. Baltim. Md 1950 169, 
3987–3992 (2002). 
266. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: 
the multistep paradigm. Cell 76, 301–314 (1994). 
267. Németh, T. & Mócsai, A. The role of neutrophils in autoimmune diseases. Immunol. 
Lett. 143, 9–19 (2012). 
268. Belaaouaj, A. et al. Mice lacking neutrophil elastase reveal impaired host defense 
against gram negative bacterial sepsis. Nat. Med. 4, 615–618 (1998). 
269. Lee, W. L. & Downey, G. P. Leukocyte elastase: physiological functions and role in 
acute lung injury. Am. J. Respir. Crit. Care Med. 164, 896–904 (2001). 
270. Shapiro, S. D. Neutrophil elastase: path clearer, pathogen killer, or just pathologic? 
Am. J. Respir. Cell Mol. Biol. 26, 266–268 (2002). 
271. Weiss, S. J. Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365–376 (1989). 
272. Yoshimura, K., Nakagawa, S., Koyama, S., Kobayashi, T. & Homma, T. Roles of 
neutrophil elastase and superoxide anion in leukotriene B4-induced lung injury in rabbit. J. 
Appl. Physiol. Bethesda Md 1985 76, 91–96 (1994). 
273. Hoenderdos, K. & Condliffe, A. The neutrophil in chronic obstructive pulmonary 
disease. Am. J. Respir. Cell Mol. Biol. 48, 531–539 (2013). 
  REFERENCES 131 
274. Voynow, J. A., Fischer, B. M. & Zheng, S. Proteases and cystic fibrosis. Int. J. 
Biochem. Cell Biol. 40, 1238–1245 (2008). 
275. Wiedow, O., Wiese, F., Streit, V., Kalm, C. & Christophers, E. Lesional elastase 
activity in psoriasis, contact dermatitis, and atopic dermatitis. J. Invest. Dermatol. 99, 306–
309 (1992). 
276. Liu, Z. et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. 
J. Clin. Invest. 105, 113–123 (2000). 
277. Korkmaz, B., Attucci, S., Jourdan, M.-L., Juliano, L. & Gauthier, F. Inhibition of 
neutrophil elastase by alpha1-protease inhibitor at the surface of human 
polymorphonuclear neutrophils. J. Immunol. Baltim. Md 1950 175, 3329–3338 (2005). 
278. Kessenbrock, K., Dau, T. & Jenne, D. E. Tailor-made inflammation: how neutrophil 
serine proteases modulate the inflammatory response. J. Mol. Med. Berl. Ger. 89, 23–28 
(2011). 
279. Travis, J. & Salvesen, G. S. Human plasma proteinase inhibitors. Annu. Rev. 
Biochem. 52, 655–709 (1983). 
280. Ye, S. & Goldsmith, E. J. Serpins and other covalent protease inhibitors. Curr. Opin. 
Struct. Biol. 11, 740–745 (2001). 
281. Huntington, J. A., Read, R. J. & Carrell, R. W. Structure of a serpin-protease complex 
shows inhibition by deformation. Nature 407, 923–926 (2000). 
282. Carrell, R. W. alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue 
damage. J. Clin. Invest. 78, 1427–1431 (1986). 
283. Owen, C. A., Campbell, M. A., Sannes, P. L., Boukedes, S. S. & Campbell, E. J. Cell 
surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative 
mechanism by which neutrophils focus and preserve catalytic activity of serine 
proteinases. J. Cell Biol. 131, 775–789 (1995). 
284. Campbell, E. J., Campbell, M. A. & Owen, C. A. Bioactive proteinase 3 on the cell 
surface of human neutrophils: quantification, catalytic activity, and susceptibility to 
inhibition. J. Immunol. Baltim. Md 1950 165, 3366–3374 (2000). 
285. Owen, C. A. & Campbell, E. J. The cell biology of leukocyte-mediated proteolysis. J. 
Leukoc. Biol. 65, 137–150 (1999). 
286. Zemans, R. L., Colgan, S. P. & Downey, G. P. Transepithelial migration of 
neutrophils: mechanisms and implications for acute lung injury. Am. J. Respir. Cell Mol. 
Biol. 40, 519–535 (2009). 
287. Downey, G. P., Dong, Q., Kruger, J., Dedhar, S. & Cherapanov, V. Regulation of 
neutrophil activation in acute lung injury. Chest 116, 46S–54S (1999). 
288. Winn, R. K. et al. Role of protein synthesis and CD11/CD18 adhesion complex in 
neutrophil emigration into the lung. Exp. Lung Res. 19, 221–235 (1993). 
289. Campbell, E. J., Senior, R. M., McDonald, J. A. & Cox, D. L. Proteolysis by 
neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of 
proteinase inhibitors in vitro. J. Clin. Invest. 70, 845–852 (1982). 
  REFERENCES 132 
290. Campbell, E. J. & Owen, C. A. The sulfate groups of chondroitin sulfate- and heparan 
sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites 
for human leukocyte elastase and cathepsin G. J. Biol. Chem. 282, 14645–14654 (2007). 
291. Cahalan, M. D. & Parker, I. Choreography of cell motility and interaction dynamics 
imaged by two-photon microscopy in lymphoid organs. Annu. Rev. Immunol. 26, 585–626 
(2008). 
292. Coombes, J. L. & Robey, E. A. Dynamic imaging of host-pathogen interactions in 
vivo. Nat. Rev. Immunol. 10, 353–364 (2010). 
293. Germain, R. N., Miller, M. J., Dustin, M. L. & Nussenzweig, M. C. Dynamic imaging of 
the immune system: progress, pitfalls and promise. Nat. Rev. Immunol. 6, 497–507 
(2006). 
294. Hickman, H. D., Bennink, J. R. & Yewdell, J. W. Caught in the act: intravital 
multiphoton microscopy of host-pathogen interactions. Cell Host Microbe 5, 13–21 (2009). 
295. Ng, L. G., Mrass, P., Kinjyo, I., Reiner, S. L. & Weninger, W. Two-photon imaging of 
effector T-cell behavior: lessons from a tumor model. Immunol. Rev. 221, 147–162 (2008). 
296. Roediger, B., Ng, L. G., Smith, A. L., Fazekas de St Groth, B. & Weninger, W. 
Visualizing dendritic cell migration within the skin. Histochem. Cell Biol. 130, 1131–1146 
(2008). 
297. Frizzell, R. A. & Pilewski, J. M. Finally, mice with CF lung disease. Nat. Med. 10, 452–
454 (2004). 
298. Kossodo, S. et al. Noninvasive in vivo quantification of neutrophil elastase activity in 
acute experimental mouse lung injury. Int. J. Mol. Imaging 2011, 581406 (2011). 
299. Mitra, S., Modi, K. D. & Foster, T. H. Enzyme-activatable imaging probe reveals 
enhanced neutrophil elastase activity in tumors following photodynamic therapy. J. 
Biomed. Opt. 18, 101314 (2013). 
300. Zhao, Z., Raftery, M. J., Niu, X. M., Daja, M. M. & Russell, P. J. Application of in-gel 
protease assay in a biological sample: characterization and identification of urokinase-type 
plasminogen activator (uPA) in secreted proteins from a prostate cancer cell line PC-3. 
Electrophoresis 25, 1142–1148 (2004). 
301. Lucas, S. D., Costa, E., Guedes, R. C. & Moreira, R. Targeting COPD: advances on 
low-molecular-weight inhibitors of human neutrophil elastase. Med. Res. Rev. 33 Suppl 1, 
E73–101 (2013). 
302. Chen, M., Kim, G. H., Prakash, L. & Woodley, D. T. Epidermolysis bullosa acquisita: 
autoimmunity to anchoring fibril collagen. Autoimmunity 45, 91–101 (2012). 
303. Grevers, L. C. et al. S100A8 enhances osteoclastic bone resorption in vitro through 
activation of Toll-like receptor 4: implications for bone destruction in murine antigen-
induced arthritis. Arthritis Rheum. 63, 1365–1375 (2011). 
304. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation 
of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. 
Cell Biol. 8, 1369–1375 (2006). 
  REFERENCES 133 
305. Hoyaux, D. et al. S100 proteins in Corpora amylacea from normal human brain. Brain 
Res. 867, 280–288 (2000). 
306. Salama, I., Malone, P. S., Mihaimeed, F. & Jones, J. L. A review of the S100 proteins 
in cancer. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 34, 357–
364 (2008). 
307. Zwadlo, G., Brüggen, J., Gerhards, G., Schlegel, R. & Sorg, C. Two calcium-binding 
proteins associated with specific stages of myeloid cell differentiation are expressed by 
subsets of macrophages in inflammatory tissues. Clin. Exp. Immunol. 72, 510–515 (1988). 
308. Foell, D. & Roth, J. Proinflammatory S100 proteins in arthritis and autoimmune 
disease. Arthritis Rheum. 50, 3762–3771 (2004). 
309. Foell, D. et al. Early recruitment of phagocytes contributes to the vascular 
inflammation of giant cell arteritis. J. Pathol. 204, 311–316 (2004). 
310. Foell, D. et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right 
time to stop? Ann. Rheum. Dis. 63, 206–208 (2004). 
311. Haga, H. J. et al. Calprotectin in patients with systemic lupus erythematosus: relation 
to clinical and laboratory parameters of disease activity. Lupus 2, 47–50 (1993). 
312. Rugtveit, J. et al. Cytokine profiles differ in newly recruited and resident subsets of 
mucosal macrophages from inflammatory bowel disease. Gastroenterology 112, 1493–
1505 (1997). 
313. Lügering, N. et al. Immunohistochemical distribution and serum levels of the Ca(2+)-
binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn’s disease. 
Digestion 56, 406–414 (1995). 
314. Gammon, W. R. & Briggaman, R. A. Functional heterogeneity of immune complexes 
in epidermolysis bullosa acquisita. J. Invest. Dermatol. 89, 478–483 (1987). 
315. Delabie, J., de Wolf-Peeters, C., van den Oord, J. J. & Desmet, V. J. Differential 
expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous 
conditions: an immunohistochemical study. Clin. Exp. Immunol. 81, 123–126 (1990). 
316. Strupat, K., Rogniaux, H., Van Dorsselaer, A., Roth, J. & Vogl, T. Calcium-induced 
noncovalently linked tetramers of MRP8 and MRP14 are confirmed by electrospray 
ionization-mass analysis. J. Am. Soc. Mass Spectrom. 11, 780–788 (2000). 
317. Vogl, T., Roth, J., Sorg, C., Hillenkamp, F. & Strupat, K. Calcium-induced 
noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-
assisted laser desorption/ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 10, 
1124–1130 (1999). 
318. Donato, R. S100: a multigenic family of calcium-modulated proteins of the EF-hand 
type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33, 637–
668 (2001). 
319. Leukert, N. et al. Calcium-dependent tetramer formation of S100A8 and S100A9 is 
essential for biological activity. J. Mol. Biol. 359, 961–972 (2006). 
320. Teigelkamp, S. et al. Calcium-dependent complex assembly of the myeloic 
differentiation proteins MRP-8 and MRP-14. J. Biol. Chem. 266, 13462–13467 (1991). 
  REFERENCES 134 
321. Longbottom, D., Sallenave, J. M. & van Heyningen, V. Subunit structure of 
calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial 
cells. Biochim. Biophys. Acta 1120, 215–222 (1992). 
322. Passey, R. J. et al. A null mutation in the inflammation-associated S100 protein 
S100A8 causes early resorption of the mouse embryo. J. Immunol. Baltim. Md 1950 163, 
2209–2216 (1999). 
323. Gebhardt, C., Németh, J., Angel, P. & Hess, J. S100A8 and S100A9 in inflammation 
and cancer. Biochem. Pharmacol. 72, 1622–1631 (2006). 
324. Lim, S. Y., Raftery, M. J., Goyette, J., Hsu, K. & Geczy, C. L. Oxidative modifications 
of S100 proteins: functional regulation by redox. J. Leukoc. Biol. 86, 577–587 (2009). 
325. Petersen, B. et al. The alarmin Mrp8/14 as regulator of the adaptive immune 
response during allergic contact dermatitis. EMBO J. 32, 100–111 (2013). 
326. Brun, J. G., Håland, G., Haga, H. J., Fagerhol, M. K. & Jonsson, R. Effects of 
calprotectin in avridine-induced arthritis. APMIS Acta Pathol. Microbiol. Immunol. Scand. 
103, 233–240 (1995). 
327. Otsuka, K. et al. Suppression of inflammation in rat autoimmune myocarditis by 
S100A8/A9 through modulation of the proinflammatory cytokine network. Eur. J. Heart 
Fail. 11, 229–237 (2009). 
328. Ikemoto, M., Murayama, H., Itoh, H., Totani, M. & Fujita, M. Intrinsic function of 
S100A8/A9 complex as an anti-inflammatory protein in liver injury induced by 
lipopolysaccharide in rats. Clin. Chim. Acta Int. J. Clin. Chem. 376, 197–204 (2007). 
329. Wu, N. & Davidson, J. M. Migration inhibitory factor-related protein (MRP)8 and 
MRP14 are differentially expressed in free-electron laser and scalpel incisions. Wound 
Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc. 12, 327–336 (2004). 
330. Champaiboon, C., Sappington, K. J., Guenther, B. D., Ross, K. F. & Herzberg, M. C. 
Calprotectin S100A9 calcium-binding loops I and II are essential for keratinocyte 
resistance to bacterial invasion. J. Biol. Chem. 284, 7078–7090 (2009). 
331. Grimbaldeston, M. A., Geczy, C. L., Tedla, N., Finlay-Jones, J. J. & Hart, P. H. 
S100A8 induction in keratinocytes by ultraviolet A irradiation is dependent on reactive 
oxygen intermediates. J. Invest. Dermatol. 121, 1168–1174 (2003). 
332. Paccola, C. C. et al. Antinociceptive effect of the C-terminus of murine S100A9 
protein on experimental neuropathic pain. Peptides 29, 1806–1814 (2008). 
333. Greenlee, K. J. et al. Proteomic identification of in vivo substrates for matrix 
metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. 
Immunol. Baltim. Md 1950 177, 7312–7321 (2006). 
334. Foell, D. et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in 
rheumatoid and psoriatic arthritis. Rheumatol. Oxf. Engl. 42, 1383–1389 (2003). 
335. Stair, J. L., Watkinson, M. & Krause, S. Sensor materials for the detection of 
proteases. Biosens. Bioelectron. 24, 2113–2118 (2009). 
336. Liu, Z. et al. Gelatinase B-deficient mice are resistant to experimental bullous 
pemphigoid. J. Exp. Med. 188, 475–482 (1998). 
      APPENDIX 135 
APPENDIX 
 
Buffer and Media 
Buffer Composition 
Anesthetic materials (short term anesthesia) 
4.313 ml NaCl (0.9%) 
625 μl Ketamin (10%) 
62.5 μl Xylazin (2%) 
Anesthetic materials (long term anesthesia, for 
in vivo microscopy) 
3.5 ml NaCl (0.9%) 
400 µl Fentanyl (0.1 mg/ml)  
400 µl Midazolam (5 mg/ml) 
200 µl Medetomidine (1 mg /ml) 
Blotting buffer 
25 mM Tris 
150 mM Glycin 
Methanol 100% (20% v/v) 
CL-Medium RPMI 1640, modified (without Phenol Red) 
Electrophoresis buffer 
25 mM Tris 
200 mM Glycin 
3.5 mM SDS, in Aqua dest 
FACS buffer 
PBS-D without Ca
2+
 and Mg
2+
 
0.1% BSA 
HBSS-Prep 
HBSS without Ca
2+
 and Mg
2+  
20 mM HEPES 
0.5% FCS, in Aqua dest 
Imaging medium (IM) 
20 mM HEPES 
1.2 mM MgCl2 
1.2 mM K2HPO4 
115 mM NaCl 
1.2 mM CaCl2 
2 g/L D-glucose, in Aqua dest 
Lysis buffer (for erythrocytes, pH 7.2) 
155 mM NH4Cl  
10 mM KHCO3  
0.1 mM EDTA in, Aqua dest 
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Buffer Composition 
PBS (pH 7.2) 
10 mM NaH2PO4 
0.15 M NaCl, in Aqua dest 
PBS-Dulbecco (PBS-D, pH 7.2 - 7.3)  
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.5 mM KH2PO4, in Aqua dest 
Trypan blue 
0.9 % NaCl 
0.5 % Trypan blue, in H2O  
 
 
Video legends 
Video 1 Elastase-mediated cleavage of NEmo-2 FRET reporter on Jurkat T cells. Jurkat T 
cells were incubated with the reporter for 5 min and bound reporter was determined by confocal 
microscopy. NEmo-2 localized exclusively on the cell membrane. Donor fluorescence and sensitized 
acceptor emission was imaged and D/A ratio images were calculated. NE was added after 4 min of 
incubation. Representative confocal videos of donor (D) and acceptor (A) fluorescence intensities and 
the corresponding D/A ratios are shown in absence (A-C) and in presence (D-F) of neutrophil 
elastase. Video consists of 20 images collected every one second by photomultiplier tube (PMT) of 
confocal microscopy. Cleavage of reporter was observed is shown in D/A ratio video after addition of 
neutrophil elastase. Look up table (LUT): blue = low D/A ratio, intact NEmo-2; red = high D/A ratio, 
indicative for cleaved NEmo-2. 
 
Video 2 Elastase enzyme activities on IC-activated neutrophils in presence of protease 
inhibitors. Neutrophils were preincubated with NEmo-2 in presence of A1AT and allowed to adhere to 
immobilized IC or irrelevant antibodies of the same isotype. Cells were analyzed by confocal 
microscopy and representative videos of fluorescence intensities of the donor and acceptor as well as 
the ratio of the intensities of D/A are shown. (A-F) Cells were able to spread on immobilized IC (but 
not unrelated antibodies) and as a consequence, cleavage of reporter was observed even in the 
presence of inhibitors which became visible after 5 min and significant after 10 min of incubation as 
compared to the controls. Video consists of 30 images collected every one second by photomultiplier 
tube (PMT) of confocal microscopy. LUT: blue = low D/A ratio, intact NEmo-2; red = high D/A ratio, 
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indicative of cleaved NEmo-2. Scale bars: 5 µm for IC-stimulated and 20 µm for unstimulated 
neutrophils. 
 
Video 3 Migration of intrinsic neutrophils to the site of pathogenic antibodies. Local antibody 
transfer model of EBA was induced by a single dose injection of anti-mCOLVII labeled with DyLight 
649 intradermally into the ventral ear skin of lys-eGFP mice. Neutrophil migration towards pathogenic 
antibody was monitored by two-photon microscopy. Results indicate the recruitment of neutrophils in 
close proximity of the antibody. Top video (A) as well as a side view generated by stack analysis 
demonstrate the close proximity of neutrophils to the pathogenic IgG (B). EGFP appears as green 
color while deposition of anti-mCOLVII is shown in red. Results of one representative experiment are 
shown. Video is shown as a time-lapse over 15 min taken by multi-photon intravital microscopy. 
 
Video 4 Response of adoptively transferred neutrophils to focal tissue damage. BM-derived 
neutrophils from Balb/c mice were labeled with cell tracker and injected intradermally into the ventral 
ear skin 2 h before laser-induced focal tissue damage was set. Neutrophil recruitment towards focal 
damage (white arrow; green spot) was recorded by multi-photon microscopy over a 30 min time-lapse 
(A). Neutrophils (red dots) were identified and cell migration was followed by track analyses (B). 
Tracks are indicated by colored lines. Migration areas of neutrophils are shown by direction lines 
which their color shifts from blue to red reflecting from the early step to the final area, respectively. 
Results of one representative experiment out of three experiments are shown. Video is shown as a 
time-lapse over 30 min taken by multi-photon intravital microscopy. 
 
Video 5 Damage-induced neutrophil migrations in presence of IC. NEmo-2-labeled 
neutrophils (small bright dots) as well as anti-mCOLVII antibody conjugated to DyLight 649 (blue 
color) were simultaneously injected in presence of A1AT into the ear of wildtype Balb/c mice. After 2h, 
focal tissue injury was applied (arrow) and the dynamics of administrated neutrophils was 
subsequently monitored over 90 min. D/A ratio together with donor signal are shown. Results of one 
representative experiment out of three are shown. Video is shown as a time-lapse over 1 h and 38 min 
taken by multi-photon intravital microscopy. 
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Video 6 NE activities at the adhesion site of activated neutrophils in vivo. Local EBA was 
induced by single injection of anti-mCOLVII to the ventral side of ear. Thereafter, neutrophils were 
labeled with NEmo-2 reporter in presence of A1AT. Video represents NE activities on single neutrophil 
at different time-points over a 15 min time-lapse by multi-photon microscopy. D/A ratio (violet color) 
together with donor signal (green color) are shown.  
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